

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

A systematic analysis and quality assessment of COVID-19 treatment and prevention information on the Internet

| | |
|-------------------------------|--|
| Journal: | <i>BMJ Open</i> |
| Manuscript ID | bmjopen-2020-040487 |
| Article Type: | Original research |
| Date Submitted by the Author: | 15-May-2020 |
| Complete List of Authors: | Fan, Ka Siu; St George's University Hospitals NHS Foundation Trust, Ghani, Shahi; St George's University Hospitals NHS Foundation Trust Machairas, Nikolaos ; Royal Free Hospital, Department of HPB Surgery and Liver Transplant Lenti, Lorenzo; St George's University Hospitals NHS Foundation Trust Fan, Ka Hay; Imperial College London Richardson, Daniel; St George's University Hospitals NHS Foundation Trust Scott, Aneya; St George's University Hospitals NHS Foundation Trust Raptis, Dimitri; Royal Free Hospital, Department of HPB Surgery and Liver Transplant |
| Keywords: | World Wide Web technology < BIOTECHNOLOGY & BIOINFORMATICS, Health informatics < BIOTECHNOLOGY & BIOINFORMATICS, JOURNALISM (see Medical Journalism) |
| | |

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

Cover Letter

Dear Editor,

We would like to submit to you the manuscript under the title of “A systematic analysis and quality assessment of COVID-19 treatment and prevention information on the Internet”.

Our work sets out to evaluate the quality of information available to the public regarding both the treatment and prevention of COVID-19 using validated assessment tools. These tools, which have been used in the past to assess quality, include the Ensuring Quality Information for Patients (EQIP) tool, JAMA benchmark and the DISCERN tool, all of which have been proven to be robust and effective at assessing online health information.

To the best of our knowledge this is the first study to evaluate the nature and quality of information regarding COVID-19 currently available to the public. Our findings indicate that most websites were unable to provide adequate information on both treatment and preventative methods and were generally of poor quality. Without interventions to improve these websites, they will likely impact the awareness and actions of the wider public and, by extension, affect the efficacy of public health measures. Our study reflects the ongoing need for high quality information while it is still possible to influence its dissemination, especially for countries that are now entering the growth phase.

We believe that this report as well as the subtopics it addresses will be of interest for the readers of your respectable journal.

We hereby certify that the authors of the above manuscript have all: 1) Conceived, planned, and performed the work leading to this article, 2) Written the article or reviewed successive versions and shared in their revisions, 3) Approved the final version. Further, we certify that this work has neither been published in whole or in part elsewhere nor is under consideration elsewhere, and we accept full responsibility for the design and conduct of the study.

Yours sincerely,

Ka Siu Fan, BSc and Shahi Abdul Ghani, MSc, DHMSA

On behalf of Dimitri Aristotle Raptis, MD, MSc, PhD and the authors

1
2
3 **A systematic analysis and quality assessment of COVID-19 treatment and prevention information**
4
5 **on the Internet**

6
7 Ka Siu Fan, BSc*¹, Shahi Abdul Ghani, MSc, DHMSA*¹, Nikolaos Machairas, MD, PhD², Lorenzo
8 Lenti, BSc¹, Ka Hay Fan³, Daniel Richardson, BSc¹, Aneya Scott, MChem¹, Dimitri Aristotle Raptis
9 MD, MSc, PhD²

10
11
12
13 *Ka Siu Fan and Shahi Abdul Ghani contributed equally to this paper.

- 14
15
16 1. St. Georges University of London, UK
17
18 2. Department of HPB Surgery and Liver Transplant, Royal Free Hospital, London, UK
19
20 3. Imperial College London, UK
21
22

23
24 **Corresponding author:**

25
26 Dr Dimitri Aristotle Raptis MD, MSc, PhD

27
28 Department of HPB Surgery and Liver Transplant

29
30 Royal Free Hospital, London, UK

31
32 Dimitri.Raptis@NHS.net
33
34
35
36

37 **Conflict of interest:** The authors have no conflicts of interests or funding sources to disclose
38
39
40

41 **Acknowledgements:** None
42
43
44

45 **Patient and Public Involvement:** There were no patient or public involvement in the conception,
46 design or data collection of the study or in the production of the manuscript.
47
48
49
50

51 **Statement of Author Contribution:**

52
53 Study conception and design: DAR, NM, SAG, KSF

54
55 Acquisition of data: SAG, KSF, LL, KHF, DR, AS

56
57 Analysis and interpretation of data: KSF, SAG, NM, DAR

58
59 Drafting of manuscript: KSF, SAG, NM, KHF
60

1
2
3 Critical revision: KSF, SAG, NM, DAR
4
5
6

7 **Word count:** 4482
8

9 **Keywords:** Coronavirus, Internet, Patient Education Handout, Public Health Informatics, Search
10
11 Engine
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Abstract

Objective: To evaluate the quality of information regarding the treatment and prevention of COVID-19 available to the general public from all countries.

Design: Systematic analysis using the 'Ensuring Quality Information for Patients' (EQIP) tool (score 0-36), JAMA benchmark (score 0-4) and the DISCERN tool (score 16-80) to analyse websites containing information targeted at the general public.

Data Sources: Twelve popular search terms, including 'Coronavirus', 'COVID 19', 'Wuhan virus', 'How to treat coronavirus' and 'COVID 19 Prevention' were identified by 'Google Trends'. The first 100 websites for each term were identified and evaluated on its quality of information.

Eligibility Criteria for selecting studies: All websites written in English language, and provides information on prevention or treatment of COVID-19 intended for the general public were considered eligible. Any websites intended for professionals, or specific isolated populations, such as students from one particular school, were excluded, as well as websites with only video content, marketing content, daily caseload update or news dashboard pages with no health-related information.

Results: Of the 1275 identified websites, 321 (25%) were eligible for analysis. The overall EQIP, JAMA and DISCERN scores were 17.8, 2.7 and 38.0. Websites originated from 34 countries, with the majority from the USA (55%). News Services (50%) and Government/Health Departments (27%) were the most common sources of information and their information quality varied significantly. Majority of websites discuss prevention alone despite popular search trends of COVID-19 treatment. Websites discussing both treatment and prevention (n=73, 22%) score significantly higher across all tools (P<0.001).

Conclusion: This comprehensive assessment of online COVID-19 information using EQIP, JAMA and DISCERN tools indicate that most websites were inadequate. This necessitates improvements in online resources to facilitate public health measures during the pandemic.

Strengths and Limitations of this study

- This study evaluated 321 websites, significantly improving our data coverage and representativeness over currently available studies.
- Top indexed websites from 12 different search terms were used, including both synonyms to COVID-19 and 'open' phrases, to capture the bulk of the available online resources.
- Quality of information on each website was evaluated using three validated tools, EQIP, DISCERN and JAMA, and were also evaluated by a second assessor to increase accuracy and minimise bias.
- The utility of each evaluation tool may be limited as they were not originally designed to assess online information during pandemics, however, their combinational use may offer enhanced accuracy and improved assessments as shown in other studies.
- The website database is obtained based on the popularity of different search terms on the Google Search Engine and, hence, results may be subject to change throughout the pandemic and serves as an indirect indicator for which websites the public uses.

view only

Introduction

With the increasing popularity of the Internet, both the accessibility and availability of health information has increased drastically and is now a primary source of information for many.[1,2] It is known that health information-seeking behaviour also applies to the use of online resources and has become ever more important during the current Coronavirus disease 2019 (COVID-19) pandemic[3] Information on such widely-discussed topic will inevitably be produced in quantity and vary in production quality, potentially adversely affecting patient awareness and health-seeking behaviour.[4] Many of these resources read by the public may be unreliable or produced from non-peer-reviewed sources and affect behaviours such as recognition of symptoms, taking appropriate preventative precautions or seeking timely treatment.[3,5,6] Furthermore, inaccurate online information may contradict healthcare professionals and potentially compromise the trusting relationship with patients, worsening outcomes.[7]

Since the declaration of COVID-19 as a pandemic on 12th March 2020, its prevalence and mortality has continued to rise[8,9] and lead to the introduction of various measures such as social distancing, quarantine procedures and lockdown protocols.[10] As evidenced from previous outbreaks, effective public education and public health intervention relies on access to health information[11,12], which is now primarily delivered through the Internet. Many countries have since introduced lockdown and quarantine protocols as their mainstay preventative measures[13] but public health continues to be threatened by certain populations.[14] Due to both the novelty and rapid developments of COVID-19, there is a significant barrier for individuals to critically appraise online resources and, hence, necessitates a quantitative evaluation of the popular information sources available to the wider public.

Many instruments have been developed to evaluate patient information and may also be applied to online COVID-19 information.[15] The modified Ensuring Quality of Information for Patients (EQIP) tool is a reproducible modality used in previous studies to evaluate the reliability and quality of online patient information[16–18]. Previously, our group evaluated online information using the modified EQIP tool in a variety of conditions and procedures including bariatric surgery[19], Dupuytren's

1
2
3 disease[20], carpal tunnel disease[21], breast augmentation[22], liposuction[16] and liver
4 transplantation[23]. Tools such as the Journal of American Medical Association (JAMA) benchmark
5 and the DISCERN tool (no acronym) have also been used to evaluate online health information and
6 their combinational use can provide a more comprehensive evaluation.[18,24] Given that the Internet
7 has become an ever-important source of information and can determine health-seeking behaviour,
8 which by extension can affect the progression of COVID-19. Hence, our study aims to assess the quality
9 of information of top indexed websites that discuss information, prevention, or treatment of COVID-19
10 using the modified EQIP tool, JAMA benchmark and DISCERN tool.
11
12
13
14
15
16
17
18
19
20
21

22 **Methods**

23 **Eligibility criteria, information sources and data selection**

24
25
26 On 27th March 2020, 12 search terms and phrases were queried on the most used search engine,
27 Google[25–27], to obtain a database of websites. Only Google was used as previous studies have shown
28 that the use of multiple search engines will only provide duplicate results. To increase the number of
29 results, more search terms were used: ‘Coronavirus’, ‘COVID 19’, ‘Stop getting Coronavirus’, ‘Corona
30 Virus’, ‘How to treat coronavirus’, ‘Coronavirus safety tips’, ‘Drugs for coronavirus’, ‘What is self
31 isolation coronavirus’, ‘China virus’, ‘Wuhan virus’, ‘Coronavirus Medicine’ and ‘COVID 19
32 prevention’. These were commonly searched phrases identified using the ‘Google Adwords Keyword
33 Planner’[28]. Only the first 100 websites were identified and recorded as previous work suggest patients
34 tend to stay within the first 100 returned webpages[17,23]. Various search terms and their relative
35 popularity were also collected directly from Google Trends[29] for further comparative analysis.
36
37
38
39
40
41
42
43
44
45
46

47 All websites written in English language and providing information on prevention, treatment or
48 management of COVID-19 intended for the general public or COVID-19 patients were considered
49 eligible for inclusion. Any subsidiary pages or subdirectories of a website that contained information
50 for the public and were easily accessible are also assessed. Websites or articles intended for
51 professionals or specific population subsets, such as students alone, were excluded. Weblinks to purely
52 video content, marketing content, daily caseload update or news dashboard pages with no educational
53
54
55
56
57
58
59
60

1
2
3 purposes were also excluded. The creation of the website database, eligibility assessment, website
4 assessment and statistical analysis were performed within 4 weeks between March and April 2020.
5
6
7
8

9 **Website Scraping**

10 A website scraping tool was developed to identify and record the first 100 web links from Google. The
11 tool utilises custom PHP to make HTTP requests to the search engine to mimic the requests made by
12 the public. The queries were made from a server located in Texas, USA but no preferences were made
13 to limit searches by geographical region. The tool makes repeated requests and logs the first 100 unique
14 URLs. Duplicates were then removed from the database. A minority of websites were restricted by
15 General Data Protection Regulation (GDPR) and were accessed through the use of virtual private
16 networks (VPN) as any websites that could reasonably be accessed by the general public were included.
17
18
19
20
21
22
23
24
25
26
27

28 **Data entry**

29 Six assessors, (SAG, KSF, KHF, LL, AS and DR), all of whom fluent in English, independently
30 assessed the websites between 30 March and 13 April 2020. Evaluation included 36 EQIP items and
31 four items on JAMA benchmark, all assessed through 'Yes, No or N/A' questions. DISCERN tool adds
32 a further 16 items to assess reliability and quality of information on treatment using scales of 1 to 5.
33 Assessors also recorded the country of origin, and type of source: Academic centre, Charity/Non-
34 Governmental Organisation, Encyclopaedia, Government/Health Department, Hospital, Industry, News
35 service, Patient group, Practitioner, and Professional Society. Qualitative information about
36 preventative methods and treatment was also recorded. After the initial round of data entry, each website
37 was evaluated by a second assessor between 14 April and 21 April and any contradictory results were
38 resolved by consensus.
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53

54 **EQIP Tool**

55 The modified EQIP tool includes 36 criteria for a comprehensive assessment of patient information.
56 This tool sets out to satisfy both the guidelines of British Medical Association (BMA)[30] and
57 International Patient Decision Aids Standards (IPDAS) collaboration[31] on ideal information for
58
59
60

1
2
3 patients and have been utilised in a variety of specialities previously.[16–18] 36 items across three
4 domains were included: Content (items 1-18), Identification (items 19-24) and Structure (items 25-36).
5
6 Similar to previous uses, ‘Yes/No’ questions reduce assessor subjectivity in partial answers. ‘N/A’
7
8 option was also included if items were not relevant for the type of source. A cut-off point of 75th
9
10 percentile was set for EQIP score to discriminate between high-scoring from low-scoring websites as
11
12 was done in previous studies.
13
14
15

16 17 18 **JAMA benchmark criteria**

19
20 Critical appraisals of Internet-based resources are also assessed by the core standards identified by
21
22 JAMA in 1997.[32] This checklist was proposed by Silberg *et al.* to assist the appraisal and evaluation
23
24 of the credibility of unregulated Internet resources and have been used in various studies
25
26 previously[33,34]. This is evaluated by four items: Authorship, Attribution, Disclosure and Currency:
27
28 Authorship requires identification of authors, credentials and their affiliations; Attribution requires
29
30 appropriate citations on written information; Disclosure requires transparency of the website owner and
31
32 conflicts of interests; Currency requires a clear indication of the date of publication and updates.
33
34 Similarly, ‘Yes/No’ criterion is implemented to reduce the subjectivity of partial answers.
35
36
37
38

39 **DISCERN Tool**

40
41 The DISCERN evaluation tool was first developed in 1998 at Oxford to judge the quality of information
42
43 regarding treatment choices.[35] This tool has been validated and used across various specialities to
44
45 assess treatment information.[33,36] This consisted of 16 items, of which the first 15 assesses the
46
47 reliability of and level of details provided on treatments and the last rates the overall quality of the
48
49 information. A score between 1 and 5 can be assigned to each item, with 1 being ‘No’, 3 being ‘Partial’
50
51 and 5 being ‘Yes’. To improve assessment accuracy, overall quality of information will be scored in
52
53 proportion to the mean scores calculated from the answers to items 1-15, with 1 being the lowest and 5
54
55 being the highest.
56
57
58
59

60 **Additional Items**

1
2
3 Additional items were included to further assess the websites, including whether a website discussed
4 prevention methods, current treatments and the role of empirical evidence in the prevention or treatment
5 for COVID-19. Data collected were in the form of 'Yes/No' to reduce ambiguity of partial answers
6 again. Additionally, details provided by the website on these items were recorded if the item scores
7 'Yes'. Websites were further analysed by whether their purpose is prevention, treatment, or both.
8
9
10
11
12
13
14
15

16 **Statistical Analysis**

17
18 The dataset consisted of both continuous and categorical variables, which are reported as median and
19 interquartile range (IQR) as well as numbers and percentages respectively. Scores above the 75th
20 percentile are considered as high-scoring. Mann-Whitney and Kruskal-Wallis tests were used for
21 analysis of continuous variables where appropriate. Fisher's or χ^2 tests were used to analyse proportions
22 where appropriate. All P values were two-tailed and considered significant when $P < 0.05$. R version
23 3.3.2 (R Core Team, GNU GPL v2 License), R Studio version 1.0.44 (RStudio, Inc. GNU Affero
24 General Public License v3, Boston, MA, 2016) and their respective graphical user interface (GUI)
25 rBiostatistics.com (rBiostatistics.com, London, Switzerland, 2017)[37] was used to perform the
26 statistical analysis.
27
28
29
30
31
32
33
34
35
36
37
38

39 **Results**

40 **Gathering of websites with information on COVID-19, its prevention and its management**

41
42 A database of websites was gathered from the first 100 unique URLs returned using the 12 search terms.
43 Additional hits on the last page of each search were also gathered if unique. The final dataset included
44 1275 URLs. After filtering out duplicate results and websites that failed to meet our inclusion criteria,
45 321 remained eligible for analysis. The workflow of dataset creation is shown in **Figure 1**. List of
46 websites were obtained on a single day, 27th March 2020, and website evaluation was completed within
47 two weeks.
48
49
50
51
52
53
54
55
56
57

58 **Website demographics and search trends**

1
2
3 The most popular search terms were 'Coronavirus', followed by 'COVID' and 'Corona Virus', while
4 search popularity peaked in mid- and late-March 2020 respectively. COVID-19-specific searches
5 regarding treatment and masks were significantly more popular ($P<0.001$) than prevention and peaked
6 in mid-March and early-April respectively. **Figure 2** summarises the most popular search trends. The
7 returned websites originated from 34 different countries (**Figure 3**): the USA produced the most
8 websites ($n=178$), followed by the United Kingdom ($n=52$), Australia ($n=18$) and Canada ($n=18$). The
9 source of information and website category is shown in **Table 1**. News Services were the most common
10 source of information ($n=163$), followed by Health Departments/Government ($n=87$).

11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Forty-six websites (14.3%) described treatment methods alone, 202 websites (62.9%) mentioned
treatment methods alone and 73 websites (22.7%) discussed both prevention and treatment. Of the
mentioned prevention methods, 205 (63.9%) described social isolation, 169 (52.7%) physical
distancing, 157 (48.9%) advised staying home and 136 (42.4%) described the benefits of disinfecting
or cleaning surfaces. With regards to mentioned treatment methods, 55 (17.1%) described the use of
antiviral medications, 31 (9.7%) described hydroxychloroquine or chloroquine and 26 (8.1%) described
the use of non-steroidal anti-inflammatory drugs such as paracetamol and ibuprofen. Only 31 (9.7%)
websites discussed the use of oxygen, ventilation or fluids as a possible treatment method.

Overall performance

The mean Total score for EQIP, JAMA and DISCERN is 17.78, 2.69 and 38.00 respectively and their
respective 75th percentile high-score cut-offs were 21, 4 and 43 (**Figure 4**). No website achieved the
maximum score for EQIP Content (out of 18) or Structure (out of 6) domain but one website did attain
maximum for EQIP Identification (out of 12). Seventy-four websites fulfilled all the JAMA criteria (out
of 4). Four websites achieved the maximum for DISCERN Reliability (out of 40) but none scored fully
in DISCERN Treatment (out of 40). 74 high-scoring websites were identified for EQIP and JAMA and
76 for DISCERN tool. The mean scores for each tool and domain are as follows: EQIP Content (9.99
vs 6.07; $P<0.001$), EQIP Identification (4.03 vs 3.34; $P<0.001$), EQIP Structure (8.45 vs 6.96; $P<0.001$),
Total EQIP (22.46 vs 16.37; $P<0.001$), Total JAMA (4.00 vs 2.30; $P<0.001$), DISCERN Reliability
(31.72 vs 25.44; $P<0.001$), DISCERN Treatment (13.49 vs 10.31; $P=0.002$) and Total DISCERN (45.21
vs 35.76; $P<0.001$).

1
2
3 All tools and subsequent domains, except DISCERN Reliability and Total DISCERN scores, varied
4 significantly between websites of different sources, notably with the Encyclopaedia (n=5) cohort
5 holding the highest score for all domains. All tools and domains varied between website cohorts, with
6 websites that include both Treatment and Prevention scoring above the mean values. **Table 2** and **Table**
7
8
9
10
11 **3** summarises the variation of information quality with the source of information and website category
12 respectively.
13

14 15 16 **Subset analysis of Government/Health Department and News Services**

17
18 Collectively, 250 (77.9%) of all web links were either Government/Health Departments and News
19 Services websites, of which 121 (37.7%) were based in the USA. Globally, there is significant variation
20 between Government/Health Departments and News Services in EQIP Content (mean 8.11 vs 6.22;
21 P<0.001), Total EQIP (mean 18.90 vs 17.06; P<0.001), Total JAMA (mean 2.16 vs 2.98; P<0.001) and
22 DISCERN Treatment (mean 9.02 vs 11.72; P=0.001). Variations in US websites were similar except
23 for EQIP structure (P=0.148). The US-based cohort scored lower in Total EQIP than the global cohort
24 but USA News Services specifically scored better in Total JAMA (3.17 vs 2.98) and Total DISCERN
25 (39.25 vs 38.04). Breakdowns of comparison between the cohorts are shown in **Table 4**.
26
27
28
29
30
31
32
33

34 35 **High-scoring websites**

36
37 Sixteen websites scored above 75th percentile across all three evaluation tools, 13 were from the USA,
38 2 from the UK and 1 from Canada. Most were from News Services (n=10), followed by industry (n=4),
39 Encyclopaedia (n=1) and Government/Health Departments (n=1). The 4 websites with the highest Total
40 EQIP and Total DISCERN scores are shown in **Table 5** with their respective breakdowns.
41
42
43
44

45 46 **Discussion**

47
48 Our search terms included various synonyms to COVID-19 to capture the bulk of the available material
49 as well as 'open' search terms to capture websites that specifically intend to display prevention and
50 treatment information. Our analysis identified that the overall quality of information was low across all
51 assessment tools, as indicated by the low 75th percentile cut-offs for EQIP and DISCERN, at 21 and 43
52 respectively, which are only at 58.3% and 53.8% of their respective full scores. Regarding EQIP,
53 websites generally scored poorly, with a mean and median approximately 18 (IQR 15-20) out of a total
54 of 36. Despite having less marks allocated for EQIP Structure, websites generally outperform the EQIP
55
56
57
58
59
60

1
2
3 Content domain (7.30 vs 6.97), indicating that while their information may not be of high quality, the
4 design and the ease-of-use of these websites are adequate. However, as these websites can be easily
5 used and navigated irrespective of background, it may present a potential pitfall where low-quality
6 information can appear credible as user-friendly designs alone have been shown to improve information
7 credibility.[38] The indicators assessing website referencing quality, such as JAMA benchmark and
8 DISCERN Reliability, scored similarly, 2.69 (67.3% of maximum) and 26.93 (67.3% of maximum)
9 respectively, but is lower in EQIP Identification domain 3.50 (58.3% of maximum), likely attributable
10 to its additional assessment of whether there is patient involvement in the production of the material.

11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Most sources scored poorly due to several possible reasons. First and foremost, the lack of primary
scientific research limits our knowledge on COVID, an emergent disease COVID only identified in
early December 2019[39] and recognised as a pandemic in March 2020.[40] While research efforts
have since gained traction and shifted to COVID, both the production of quality research and its
subsequent peer-review process takes a considerable amount of time. This may limit the amount and
speed of research output in comparison to the rapid progression of the COVID from local clusters to
epidemic to pandemic. However, many journals have since implemented the fast-tracking of COVID
research as well as making them freely accessible.[41–43] Similarly, efforts from Governments and
Health Departments have also cooperated to help support and fast-track COVID studies in response to
the growing pandemic.[44] Together, these efforts have facilitated the publication of COVID research
where the WHO database alone has already indexed an excess of 5,000 articles.[45] However, it is also
important to note the role of preprint servers on publications during the pandemic. Preprints are
accessible to the public through various databases and while they have helped facilitate the peer-review
process through improved accessibility, non-peer-reviewed articles can potentially be used, or cherry-
picked, by non-professionals and cause potentially profound and unhelpful effects on public perception
and awareness of COVID.[46–49]

Upon publication, research articles have to be reviewed and summarised by journalists who act as a
bridge of information between scientists and the wider public. This often allows for efficient
dissemination of critical research information to the public who often lack the scientific or medical
background to be able to critically appraise and evaluate the latest developments. This is particularly

1
2
3 important as 52% (n=169) of all sources were classified as 'News Services'. As only 12 (7.4%) News
4 Services website scored highly in all three tools respectively, it was clear that very few websites
5 provided a comprehensive account of all current and relevant information on COVID, reflecting both
6 the difficulty in matching the pace of rapid developments as well as the having the technical knowledge
7 and expertise required to deliver concise and relevant information to readers. In such trying times, the
8 health information-seeking behaviour of citizens will inevitably lead them to obtain information from
9 news services[50] which can often be of variable quality.

10
11 Previous studies have already identified that many health journalists lacked the knowledge and training
12 required for accurate and reliable dissemination of health news and can have profound, or even harmful,
13 impact on the health of readers.[51,52] This is reflected by the low scores across the various tools,
14 indicating the overall inadequacy in both reliability and accuracy of these online resources. Potential
15 causes and pitfalls in health journalism was highlighted by a survey of medical journalists in 37
16 countries and revealed three most common constraints: the lack of time, space and knowledge, impairs
17 their ability to deliver quality articles.[53] While their work stresses the ability to work quickly and
18 summarise content concisely, many of the experienced journalists self-reported the lack of knowledge
19 as a barrier. As they noted the importance of accumulating such knowledge throughout their career, the
20 lack of expert knowledge in a rapidly progressing scientific field such as COVID can likely impact
21 journalists' understanding and quality of conveyed information significantly. Furthermore, journalists
22 reported difficulty in finding experts to explain scientific jargon, further limiting the information they
23 produce. This potentially presents a large barrier towards disseminating quality COVID information as
24 many countries and institutions have been re-directing their research efforts towards COVID, which in
25 turn likely reduces the availability of experts to assist with medical journalism.[54,55] This is also
26 demonstrated from one of the highest-scoring entries, an article whose author holds a PhD. in molecular
27 genetics, which scored 22 in Total EQIP, 4 in JAMA and 74 in DISCERN.[56] When compared against
28 the majority of the other sources, this underlines the importance of a relevant academic background in
29 being able to disseminate novel scientific developments both reliably and accurately.

30
31 Based on our analysis, Governments or health departments constitute another major source of
32 information. We identified that the majority of these websites belonged to the local Governments of
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 various states in the USA, many of whom have based their information and advice on CDC. As both
4 the nature and purpose of these information sources vary, they may be visited by different subsets of
5 the population according to demographics and their information-seeking behaviour. A recent study has
6 identified the importance of awareness and trust in information originating from the Government such
7 as those of the Centers for Disease Control and Prevention (CDC), revealing that while up to 83.6% of
8 American adults are aware of the CDC, only 64.6% of them report that they trust this source.[57]
9 American adolescents were, however, less aware of the CDC (55.8%), but were more trusting of their
10 information (72.2%). As previously established, the importance of trust in a government is a predictor
11 of various health behaviours and outcomes such as use of health services and intention to vaccinate.[58–
12 60] Similarly, as access and usage of online health information is known to vary between different
13 demographic populations, it is paramount to create and provide targeted and effective educational
14 material for public use.[61,62]

15
16 A comparison between the global Government/Health Department against News Services websites
17 revealed significant differences between EQIP Content, Total EQIP, Total and DISCERN Treatment.
18 The EQIP Content scores likely reflect the differences in how new information is obtained as
19 Government/Health Departments are directly involved in primary research, allowing more in-depth and
20 accurate information dissemination compared to journalists who take on the role of secondary research.
21 However, News Services scored higher in DISCERN Treatment and this may be due to the reluctance
22 of the Government to prematurely disclose information on treatment at such an early stage of discovery,
23 whereas journalists may be less limited by such constraints and willing to report the results of all
24 potential studies. Interestingly, the majority of USA Government websites had some form of copy-
25 pasted information from the Centre for Disease Control and Prevention (CDC), likely with the aim of
26 maintaining consistency as well as to centralise their source of information. This contrasts with the
27 majority of other sources where information may be re-written based on a variety of sources. However,
28 while American sources display a similar pattern of variation, the EQIP Identification scores of
29 Government/Health Departments had statistically significant differences and also scored lower than
30 News Services (mean 3.34 vs 3.78; $P=0.011$). This verbatim use of CDC information may have
31 neglected the importance of clarity and transparency in displaying the source of information as these
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Government websites primarily serve to disseminate information instead of justifying or providing a
4 critical appraisal of available literature.
5

6
7 Google Trends also identified that search popularity of treatment has increased rapidly and outgrown
8 prevention searches since early-March. The increased interests suggest that the demand for preventative
9 measures may have been sufficiently met and that the public interests may be shifting towards treatment
10 methods. However, while 275 (85%) websites addressed prevention methods to some degree, the cohort
11 scored below the mean Total EQIP score (17.12 vs 17.78; $P<0.001$), Total JAMA score (2.53 vs 2.69;
12 $P=0.001$) and Total DISCERN score (34.64 vs 38.00; $P<0.001$). This suggests that while numerous, the
13 quality of websites that focus on preventative methods remain subpar across all quality indicators.
14 Similarly, of the 46% of websites that focussed on treatment alone, they scored below the mean in Total
15 EQIP score (16.89 vs 17.78; $P<0.001$) despite scoring the highest in EQIP Identification domain (3.87
16 vs 3.50; $P<0.001$), suggesting that treatment websites tend to be better referenced and adept at sourcing
17 evidence. This is also reflected by its above-average JAMA score (3.13 vs 2.69; $P=0.001$) and Total
18 DISCERN (45.07 vs 38.00; $P<0.001$) scores. Contrarily, the 73 websites that discussed both treatment
19 and prevention of COVID-19 consistently scored higher than the mean across all indicators, Total EQIP
20 (20.15 vs 17.78; $P<0.001$), Total JAMA (2.85 vs 2.69; $P=0.001$) and Total DISCERN (42.84 vs 38.00;
21 $P<0.001$). As these are websites that explore multiple aspects of the virus, its production likely requires
22 processing information from multiple sources. This likely necessitates better understanding on the
23 writer's behalf, leading to both the production of substantially higher quality articles as well as the
24 tendency to reference its numerous resources clearly and appropriately. It is nonetheless important to
25 maintain and improve the quality of such online resources in order to combat the increasingly dangerous
26 COVID-19 myths, of which one of the latest suggests injection of disinfectants as treatment.[63,64]

27
28 Similar to the tools used in this study, the Minervation validation instrument (LIDA)[65], Flesch
29 Reading Ease (FRE) Score and the Flesch-Kincaid Grade (FKG) have also been used to evaluate the
30 quality of online health information.[66] However, LIDA was not considered as an appropriate
31 assessment tool here as it does not provide a quantitative or qualitative assessment of either benefits or
32 risks to interventions. Additionally, the majority of its items in 'Accessibility' and 'Usability' sections
33 assess the design and ease-of-access of a website which is already adequately covered by the modified
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 EQIP tool. Similarly, the use of FRE and FKG only provides an assessment of total sentences, words
4 and syllables and does not evaluate the content itself.[67]
5

6
7 This study has several limitations. Only the most popular search engine, 'Google', was used and may
8 not be reflective of those who use other search engines. The searches may also be affected by the
9 geographical location of the requesting computer, which means results could still be centred around a
10 particular continent despite disabling the geolocation features. Similarly, the search terms were obtained
11 using 'Google Adwords Keyword Planner' and 'Google Trends', which provided commonly searched
12 phrases but may not be truly indicative of search patterns of the wider public when seeking for COVID-
13 related information. Hence, we opted to use 12 different search terms, containing both variations of
14 'COVID-19' names as well as different phrases that patients may search for. Another limitation is the
15 exclusion of non-English language websites, which reduces the representativeness of all the available
16 information, especially given the international nature of the pandemic. A minority of URLs, particularly
17 of News Services, updated their content regularly or modified to redirect visitors, which may affect the
18 second round of evaluation and subsequent statistical analysis. Additionally, as modified EQIP tool,
19 JAMA benchmark and DISCERN tool were not originally designed for the specific purpose of assessing
20 the highly variable information produced during pandemics, it may be considered as a limitation.
21 However, the EQIP tool was designed to assess any type of patient information and demonstrated high
22 inter-rater reliability.[16] Similarly, JAMA benchmark was designed to evaluate website reliability
23 alone and DISCERN examines both reliability and content accuracy, thus, the combinational use of
24 tools enhances the accuracy and objective assessment of websites. Finally, the extracted websites were
25 limited temporally as the results might no longer be representative of online information at time of
26 publication due to the fast-paced developments of COVID as many websites found during our search
27 in March 2020 may inevitably be updated or removed since our search.
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50

51 52 53 **Conclusion**

54 In short, the abundance of Internet resources providing COVID-19 information is exemplified by the
55 numerous identified websites during our search. The information available to the public may affect their
56 health decisions, which, subsequently, affects the efficacy and outcome of public health measures
57
58
59
60

1
2
3 implemented by the state. As effective treatments and vaccines research are underway, COVID-19 is
4 primarily addressed with preventative measures, hence necessitating a critical review of the quality and
5 nature of information accessible to the public. Our results demonstrated that the websites were chiefly
6 produced by News Services and Government/Health Departments but were nonetheless of low quality.
7 While the majority of websites addressed prevention, and likely met the information needs of the public
8 as reflected by search trends, there is a relative deficit in websites that discuss treatment methods. A
9 minority of websites discussed both prevention methods and treatment and were generally good
10 resources but the majority websites were of inadequate quality. Thus, there is a need for higher quality
11 for online COVID-19 resources to facilitate public education and enable better cooperation and
12 outcomes of public health measures.
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Bibliography

- 1 Clarke MA, Moore JL, Steege LM, *et al.* Health information needs, sources, and barriers of
2 primary care patients to achieve patient-centered care: A literature review. *Health Informatics*
3 *J* 2016;**22**:992–1016. doi:10.1177/1460458215602939
- 4 Tan SS-L, Goonawardene N. Internet Health Information Seeking and the Patient-Physician
5 Relationship: A Systematic Review. *J Med Internet Res* 2017;**19**. doi:10.2196/jmir.5729
- 6 Semigran HL, Linder JA, Gidengil C, *et al.* Evaluation of symptom checkers for self diagnosis
7 and triage: audit study. *BMJ* 2015;**351**:h3480–h3480. doi:10.1136/bmj.h3480
- 8 Alduraywish SA, Altamimi LA, Aldhuwayhi RA, *et al.* Sources of Health Information and
9 Their Impacts on Medical Knowledge Perception Among the Saudi Arabian Population:
10 Cross-Sectional Study. *J Med Internet Res* 2020;**22**. doi:10.2196/14414
- 11 Vogel L. Viral misinformation threatens public health. *Can Med Assoc J* 2017;**189**:E1567–
12 E1567. doi:10.1503/cmaj.109-5536
- 13 British Medical Journal. Health information on internet is often unreliable. *BMJ Br Med J*
14 2000;**321**:136.
- 15 Silver MP. Patient perspectives on online health information and communication with doctors:
16 a qualitative study of patients 50 years old and over. *J Med Internet Res* 2015;**17**:e19–e19.
17 doi:10.2196/jmir.3588
- 18 World Health Organization. Coronavirus disease 2019.
19 <https://www.who.int/emergencies/diseases/novel-coronavirus-2019> (accessed 30 Apr 2020).
- 20 World Health Organization. WHO announces COVID-19 outbreak a pandemic.
21 2020.<http://www.euro.who.int/en/health-topics/health-emergencies/coronavirus-covid-19/news/news/2020/3/who-announces-covid-19-outbreak-a-pandemic> (accessed 30 Apr 2020).
- 22 World Health Organization. COVID-19 Strategy Update. 2020.
23 https://www.who.int/docs/default-source/coronaviruse/covid-strategy-update-14april2020.pdf?sfvrsn=29da3ba0_19 (accessed 30 Apr 2020).
- 24 Feldmann H. Ebola — A Growing Threat? *N Engl J Med* 2014;**371**:1375–8.
25 doi:10.1056/NEJMp1405314

- 1
2
3 12 Odium M, Yoon S. Health Information Needs and Health Seeking Behavior During the 2014-
4 2016 Ebola Outbreak: A Twitter Content Analysis. *PLoS Curr* 2018;**10**.
5 doi:10.1371/currents.outbreaks.fa814fb2bec36e29b718ab6af66124fa
6
7
8
9 13 Gilbert D. Which countries are under lockdown - and is it working?
10
11 2020. <https://www.telegraph.co.uk/news/2020/04/16/countries-in-lockdown-denmark-germany/>
12 (accessed 30 Apr 2020).
13
14
15 14 British Broadcasting Company. Coronavirus lockdown protest: What's behind the US
16 demonstrations? - BBC News. 2020. <https://www.bbc.co.uk/news/world-us-canada-52359100>
17 (accessed 30 Apr 2020).
18
19
20
21 15 Elwyn G, O'Connor A, Stacey D, *et al*. Developing a quality criteria framework for patient
22 decision aids: online international Delphi consensus process. *Bmj-British Med J*
23 2006;**333**:417–9. doi:10.1136/bmj.38926.629329.AE
24
25
26
27 16 Zuk G, Palma AF, Eylert G, *et al*. Systematic Review of Quality of Patient Information on
28 Liposuction in the Internet. *Plast Reconstr Surgery-Global Open* 2016;**4**.
29 doi:10.1097/gox.0000000000000798
30
31
32
33 17 Raptis DA, Sinanyan M, Ghani S, *et al*. Quality assessment of patient information on the
34 management of gallstone disease in the internet – A systematic analysis using the modified
35 ensuring quality information for patients tool. *HPB* 2019;**21**:1632–40.
36 doi:10.1016/j.hpb.2019.03.355
37
38
39
40
41
42 18 McCool ME, Wahl J, Schlecht I, *et al*. Evaluating written patient information for eczema in
43 German: Comparing the reliability of two instruments, DISCERN and EQIP. *PLoS One*
44 2015;**10**. doi:10.1371/journal.pone.0139895
45
46
47
48 19 Vetter D, Ruhwinkel H, Raptis DA, *et al*. Quality Assessment of Information on Bariatric
49 Surgery Websites. *Obes Surg* 2018;:1–8.
50
51
52
53 20 Zuk G, Reinisch KB, Raptis DA, *et al*. Dupuytren Disease: Is There Enough Comprehensive
54 Patient Information on the Internet? *Interact J Med Res* 2017;**6**:e7. doi:10.2196/ijmr.7822
55
56
57
58 21 Frueh FS, Palma AF, Raptis DA, *et al*. Carpal tunnel syndrome: Analysis of online patient
59 information with the EQIP tool. *Chir Main* 2015;**34**:113–21. doi:10.1016/j.main.2015.04.003
60

- 1
2
3 22 Palma AF, Zuk G, Raptis DA, *et al.* Quality of information for women seeking breast
4 augmentation in the Internet. *J Plast Surg Hand Surg* 2016;**50**:262–71.
5
6
7 doi:10.3109/2000656X.2016.1154469
8
- 9 23 Melloul E, Raptis DA, Oberkofler CE, *et al.* Donor information for living donor liver
10 transplantation: Where can comprehensive information be found? *Liver Transplant*
11
12 2012;**18**:892–900. doi:10.1002/lt.23442
13
14
15 24 Corcelles R, Daigle CR, Talamas HR, *et al.* Assessment of the quality of Internet information
16 on sleeve gastrectomy. *Surg Obes Relat Dis* 2015;**11**:539–44. doi:10.1016/j.soard.2014.08.014
17
18
19 25 The eBusiness. Top 15 Best Search Engines | February 2020.
20
21
22 <http://www.ebizmba.com/articles/search-engines> (accessed 30 Apr 2020).
23
24 26 Search Engine Watch. Google Hits the Billion Monthly Unique Visitors Mark.
25
26 2011;**2020**.[https://www.searchenginewatch.com/2011/06/23/google-hits-the-billion-monthly-](https://www.searchenginewatch.com/2011/06/23/google-hits-the-billion-monthly-unique-visitors-mark/)
27
28 [unique-visitors-mark/](https://www.searchenginewatch.com/2011/06/23/google-hits-the-billion-monthly-unique-visitors-mark/)
29
30 27 Google. <https://www.google.com/> (accessed 30 Apr 2020).
31
32 28 Google. Google Ads - Get More Customers With Easy Online Advertising.
33
34 https://ads.google.com/intl/en_GB/home/ (accessed 30 Apr 2020).
35
36 29 Google. Google Trends. <https://trends.google.com/trends>
37
38 30 British Medical Association. BMA Patient Information Awards, .
39
40 2018;**2018**.<https://www.bma.org.uk/library/patient-information-awards>
41
42
43 31 International Patient Decision Aid Standards Collaboration. IPDAS Collaboration Background
44
45 Document. 2005;**2018**.http://ipdas.ohri.ca/IPDAS_Background.pdf
46
47 32 Silberg WM, Lundberg GD, Musacchio RA. Assessing, controlling, and assuring the quality of
48
49 medical information on the Internet: Caveant lector et viewer—Let the reader and viewer
50
51 beware. *JAMA* 1997;**277**:1244–5.
52
53 33 Janssen S, Fahlbusch FB, Kaesmann L, *et al.* Radiotherapy for prostate cancer: DISCERN
54
55 quality assessment of patient-oriented websites in 2018. *Bmc Urol* 2019;**19**.
56
57
58 doi:10.1186/s12894-019-0474-4
59
60 34 Borgmann H, Wölm J-H, Vallo S, *et al.* Prostate Cancer on the Web—Expedient Tool for

- 1
2
3 Patients' Decision-Making? *J Cancer Educ* 2017;**32**:135–40.
4
5 35 Charnock D, Shepperd S, Needham G, *et al.* DISCERN: an instrument for judging the quality
6 of written consumer health information on treatment choices. *J Epidemiol Community Heal*
7 1999;**53**:105–11.
8
9
10
11 36 Nghiem AZ, Mahmoud Y, Som R. Evaluating the quality of internet information for breast
12 cancer. *Breast* 2016;**25**:34–7. doi:10.1016/j.breast.2015.10.001
13
14
15 37 Raptis DA. rBiostatistics.com (alpha version) | rBiostatistics.com.
16 <https://www.rbiostatistics.com/> (accessed 30 Apr 2020).
17
18
19 38 Sbaffi L, Rowley J. Trust and Credibility in Web-Based Health Information: A Review and
20 Agenda for Future Research. *J Med Internet Res* 2017;**19**. doi:10.2196/jmir.7579
21
22
23 39 World Health Organization. WHO | Novel Coronavirus – China.
24 2020.<https://www.who.int/csr/don/12-january-2020-novel-coronavirus-china/en/> (accessed 30
25 Apr 2020).
26
27
28
29 40 World Health Organization. Statement on the second meeting of the International Health
30 Regulations (2005) Emergency Committee regarding the outbreak of novel coronavirus (2019-
31 nCoV). 2020.[https://www.who.int/news-room/detail/30-01-2020-statement-on-the-second-
32 meeting-of-the-international-health-regulations-\(2005\)-emergency-committee-regarding-the-
33 outbreak-of-novel-coronavirus-\(2019-ncov\)](https://www.who.int/news-room/detail/30-01-2020-statement-on-the-second-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-(2019-ncov)) (accessed 30 Apr 2020).
34
35
36 41 COVID-19 Updates. <https://plos.org/covid-19/> (accessed 30 Apr 2020).
37
38
39 42 Elsevier. COVID-19 Update - Elsevier. [https://www.journals.elsevier.com/journal-of-critical-
40 care/covid-19](https://www.journals.elsevier.com/journal-of-critical-care/covid-19) (accessed 30 Apr 2020).
41
42
43 43 Anesthesia & Analgesia. Call for Papers: Coronavirus Disease 2019 (COVID-19).
44 <https://journals.lww.com/anesthesia-analgesia/Pages/CFPCOVID19.aspx> (accessed 30 Apr
45 2020).
46
47
48 44 National Health Service Health Research Authority. COVID-19 research - Health Research
49 Authority. <https://www.hra.nhs.uk/covid-19-research/> (accessed 30 Apr 2020).
50
51
52 45 World Health Organization. COVID-19: Global literature on coronavirus disease.
53 <https://search.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/> (accessed 30 Apr
54
55
56
57
58
59
60

- 2020).
- 46 Majumder MS, Mandl KD. Early in the epidemic: impact of preprints on global discourse about COVID-19 transmissibility. *Lancet Glob Heal* 2020.
- 47 Pradhan P, Pandey AK, Mishra A, *et al*. Uncanny similarity of unique inserts in the 2019-nCoV spike protein to HIV-1 gp120 and Gag. *BioRxiv* 2020.
- 48 Liu DWC. Science Denial and the Science Classroom. *Cbe-Life Sci Educ* 2012;**11**:129–34. doi:10.1187/cbe.12-03-0029
- 49 Altmetric – Uncanny similarity of unique inserts in the 2019-nCoV spike protein to HIV-1 gp120 and Gag. <https://www.altmetric.com/details/74957328> (accessed 30 Apr 2020).
- 50 Longo DR. Understanding health information, communication, and information seeking of patients and consumers: a comprehensive and integrated model. *Heal Expect* 2005;**8**:189–94.
- 51 Keshvari M, Yamani N, Adibi P, *et al*. Health journalism: Health reporting status and challenges. *Iran J Nurs Midwifery Res* 2018;**23**:14.
- 52 Schwitzer G. How do US journalists cover treatments, tests, products, and procedures? An evaluation of 500 stories. *PLoS Med* 2008;**5**.
- 53 Larsson A, Oxman AD, Carling C, *et al*. Medical messages in the media—barriers and solutions to improving medical journalism. *Heal Expect* 2003;**6**:323–31.
- 54 Cattani M. Global coalition to accelerate COVID-19 clinical research in resource-limited settings. *Lancet* 2020.
- 55 ST. George’s University of London. 3 April: 2020 Covid-19 response — our role in tackling the pandemic. <https://www.sgul.ac.uk/news/alerts/bulletins/3-april-2020> (accessed 30 Apr 2020).
- 56 Saey Tina Hesman. Repurposed drugs may help scientists fight the new coronavirus. 2020. doi:10.1101/2020.01.28.922922V2
- 57 Kowitt SD, Schmidt AM, Hannan A, *et al*. Awareness and trust of the FDA and CDC: Results from a national sample of US adults and adolescents. *PLoS One* 2017;**12**.
- 58 Bish A, Yardley L, Nicoll A, *et al*. Factors associated with uptake of vaccination against pandemic influenza: a systematic review. *Vaccine* 2011;**29**:6472–84.

- 1
2
3 59 Whetten K, Leserman J, Whetten R, *et al.* Exploring lack of trust in care providers and the
4 government as a barrier to health service use. *Am J Public Health* 2006;**96**:716–21.
5
6
7 60 Quinn SC, Parmer J, Freimuth VS, *et al.* Exploring communication, trust in government, and
8 vaccination intention later in the 2009 H1N1 pandemic: results of a national survey.
9
10
11 *Biosecurity bioterrorism biodefense Strateg Pract Sci* 2013;**11**:96–106.
12
13 61 Sadah SA, Shahbazi M, Wiley MT, *et al.* Demographic-based content analysis of web-based
14 health-related social media. *J Med Internet Res* 2016;**18**:e148.
15
16 62 Sadah SA, Shahbazi M, Wiley MT, *et al.* A study of the demographics of web-based health-
17 related social media users. *J Med Internet Res* 2015;**17**:e194.
18
19
20 63 World Health Organization. Myth busters. [https://www.who.int/emergencies/diseases/novel-](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/advice-for-public/myth-busters)
21 coronavirus-2019/advice-for-public/myth-busters (accessed 30 Apr 2020).
22
23 64 Smith D. Coronavirus: medical experts denounce Trump’s theory of ‘disinfectant injection’ |
24 World news | The Guardian. 2020.[https://www.theguardian.com/world/2020/apr/23/trump-](https://www.theguardian.com/world/2020/apr/23/trump-coronavirus-treatment-disinfectant)
25 coronavirus-treatment-disinfectant (accessed 30 Apr 2020).
26
27 65 Minervation. The LIDA Instrument Minervation validation instrument for health care web
28 sites Full Version (1.2) containing instructions. 2007. www.minervation.com/validation
29 (accessed 30 Apr 2020).
30
31 66 Coughler C, M Burke S, Cardy JO. Analysis of the quality of online resources for parents of
32 children who are late to talk. *Autism Dev Lang Impair* 2020;**5**:239694152091794.
33
34 doi:10.1177/2396941520917940
35
36 67 Kher A, Johnson S, Griffith R. Readability assessment of online patient education material on
37 congestive heart failure. *Adv Prev Med* 2017;**2017**.
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1. Website demographic and background information

| Type | Total (n,%) | Treatment (n,%) | Prevention (n,%) | Treatment and Prevention (n,%) |
|------------------------------|--------------|-----------------|------------------|--------------------------------|
| Academic Centre | 10 (3.12%) | 1 (0.31%) | 4 (1.25%) | 5 (1.56%) |
| Charity/NGO | 12 (3.74%) | 1 (0.31%) | 9 (2.8%) | 2 (0.62%) |
| Encyclopaedia | 5 (1.56%) | 0 (0%) | 1 (0.31%) | 4 (1.25%) |
| Government/Health Department | 87 (27.10%) | 1 (0.31%) | 65 (20.25%) | 21 (6.54%) |
| Hospital | 7 (2.18%) | 0 (0%) | 5 (1.56%) | 2 (0.62%) |
| Industry | 30 (9.35%) | 8 (2.49%) | 10 (3.12%) | 12 (3.74%) |
| Military | 1 (0.31%) | 0 (0%) | 1 (0.31%) | 0 (0%) |
| News Service | 163 (50.78%) | 34 (10.59%) | 102 (31.78%) | 27 (8.41%) |
| Patient group | 1 (0.10%) | 1 (0.31%) | 0 (0%) | 0 (0%) |
| Professional society | 4 (1.25%) | 0 (0%) | 4 (1.25%) | 0 (0%) |
| Research Centre | 1 (0.31%) | 0 (0%) | 1 (0.31%) | 0 (0%) |
| Total | 321 | 46 (14.33%) | 202 (62.93%) | 73 (22.74%) |

Table 2. Overall quality of information of all sources of information

| Indicator/ (Mean, SD) | Academic centre | Charity/N GO | Encyclopa edia | Governme nt/Health Departmen t | Hospital | Industry | Military | News Service | Patient group | Profession al society | Research Centre | P Value |
|-----------------------------|--------------------|-----------------|-------------------|---|-------------|-------------|----------|-----------------|------------------|--------------------------|--------------------|---------|
| EQIP Content | 7.70 (2.50) | 6.75 (3.33) | 10.80 (3.11) | 8.11 (2.49) | 7.14 (2.19) | 7.13 (2.60) | 5.00 (0) | 6.22 (2.11) | 10.00 (0) | 5.50 (3) | 5.00 (0) | <0.001 |

| | | | | | | | | | | | | |
|---------------------|---------------|--------------|--------------|--------------|--------------|---------------|-----------|---------------|-----------|-------------|-----------|--------|
| EQIP Identification | 2.90 (1.20) | 3.08 (0.90) | 4.80 (0.45) | 3.44 (1.03) | 2.71 (1.38) | 3.4 (1.13) | 1.00 (0) | 3.62 (0.73) | 3.00 (0) | 4.00 (0) | 4.00 (0) | 0.003 |
| EQIP Structure | 7.90 (1.85) | 7.67 (1.30) | 8.60 (1.67) | 7.34 (1.45) | 7.43 (0.98) | 6.97 (1.83) | 9.00 (0) | 7.22 (1.39) | 10.00 (0) | 7.25 (0.5) | 5.00 (0) | 0.08 |
| EQIP Total | 18.50 (3.66) | 17.50 (4.32) | 24.20 (3.56) | 18.9 (3.79) | 17.29 (3.50) | 17.5 (4.48) | 15.00 (0) | 17.06 (3.19) | 23.00 (0) | 16.75 (3.4) | 14.00 (0) | <0.001 |
| JAMA Total | 2.50 (0.97) | 2.50 (1.00) | 3.40 (0.55) | 2.16 (0.86) | 2.14 (1.57) | 2.73 (1.23) | 1.00 (0) | 2.98 (0.85) | 3.00 (0) | 3.50 (0.58) | 3.00 (0) | <0.001 |
| DISCERN Reliability | 27.20 (6.78) | 26.25 (6.51) | 35.60 (4.77) | 27.47 (5.96) | 29.86 (5.58) | 26.6 (7.46) | 23.00 (0) | 26.31 (6.3) | 27.00 (0) | 29.50 (4.2) | 26.00 (0) | 0.128 |
| DISCERN Treatment | 13.00 (6.70) | 9.42 (2.39) | 16.00 (9.30) | 9.02 (3.14) | 8.71 (1.89) | 13.33 (6.39) | 8.00 (0) | 11.72 (6.22) | 13.00 (0) | 8.50 (1) | 17.00 (0) | 0.001 |
| DISCERN Total | 40.20 (10.38) | 35.67 (7.67) | 51.60 (12.3) | 36.49 (7.50) | 38.57 (5.47) | 39.93 (10.45) | 31.00 (0) | 38.04 (10.44) | 40.00 (0) | 38.00 (5.1) | 43.00 (0) | 0.167 |

Table 3. Overall quality of information of all websites subsets

| Indicator/(Mean, SD) | Overall | Treatment | Prevention | Treatment and Prevention | P Value |
|----------------------|-------------|-------------|-------------|--------------------------|---------|
| EQIP Content | 6.97 (2.52) | 6.26 (1.81) | 6.55 (2.30) | 8.58 (2.84) | <0.001 |

| | | | | | |
|---------------------|--------------|---------------|--------------|---------------|--------|
| EQIP Identification | 3.50 (0.93) | 3.87 (0.72) | 3.32 (0.97) | 3.78 (0.80) | <0.001 |
| EQIP Structure | 7.30 (1.47) | 6.76 (1.46) | 7.25 (1.46) | 7.79 (1.37) | <0.001 |
| EQIP Total | 17.78 (3.71) | 16.89 (2.84) | 17.12 (3.45) | 20.15 (3.95) | <0.001 |
| JAMA Total | 2.69 (0.98) | 3.13 (0.72) | 2.53 (1.05) | 2.85 (0.84) | 0.001 |
| DISCERN Reliability | 26.93 (6.35) | 26.98 (6.92) | 26.04 (5.72) | 29.37 (7.04) | <0.001 |
| DISCERN Treatment | 11.07 (5.60) | 18.09 (6.04) | 8.60 (2.45) | 13.47 (6.73) | <0.001 |
| DISCERN Total | 38.00 (9.61) | 45.07 (11.67) | 34.64 (6.52) | 42.84 (10.93) | <0.001 |

Table 4. Comparison between Government and News Services

| Indicator | Global (USA inclusive) (n=250) | | | | | USA (n=121) | | | | |
|-----------|--------------------------------|----------------------|-----------------|----------------|---------|-----------------------|----------------------|-----------------|----------------|---------|
| | Government Mean Score | Government Mean Rank | News Mean Score | News Mean Rank | P Value | Government Mean Score | Government Mean Rank | News Mean Score | News Mean Rank | P Value |
| | | | | | | | | | | |

| | | | | | | | | | | |
|---------------------|-------|--------|-------|--------|--------|-------|-------|-------|-------|--------|
| EQIP Content | 8.11 | 161.34 | 6.22 | 106.37 | <0.001 | 7.66 | 75.80 | 6.17 | 54.22 | 0.002 |
| EQIP Identification | 3.44 | 118.28 | 3.62 | 129.35 | 0.207 | 3.34 | 50.29 | 3.78 | 65.90 | 0.011 |
| EQIP Structure | 7.34 | 129.90 | 7.22 | 123.15 | 0.464 | 7.55 | 67.54 | 7.08 | 58.01 | 0.148 |
| EQIP Total | 18.90 | 151.52 | 17.06 | 111.61 | <0.001 | 18.55 | 71.21 | 17.04 | 56.33 | 0.029 |
| JAMA Total | 2.16 | 85.72 | 2.98 | 146.73 | <0.001 | 2.03 | 34.28 | 3.17 | 73.23 | <0.001 |
| DISCERN Reliability | 27.47 | 137.15 | 26.31 | 119.28 | 0.062 | 26.53 | 60.26 | 26.66 | 61.34 | 0.876 |
| DISCERN Treatment | 9.02 | 110.95 | 11.72 | 133.27 | 0.001 | 8.84 | 47.99 | 12.59 | 66.96 | 0.001 |
| DISCERN Total | 36.49 | 105.32 | 38.04 | 136.27 | 0.963 | 35.37 | 54.72 | 39.25 | 63.87 | 0.182 |

Table 5. Websites with the highest EQIP and DISCERN scores

| URL | Country | Treatment Prevention | or | Total EQIP | Total JAMA | Total DISCERN |
|---|---------|-------------------------|----|------------|------------|---------------|
| https://www.cnet.com/how-to/coronavirus-explained-all-your-questions-about-covid-19-answered/ | USA | Both | | 27 | 4 | 52 |
| https://www.wikihow.com/Prevent-Coronavirus | USA | Prevention | | 27 | 4 | 46 |
| https://www.sciencenews.org/article/coronavirus-covid19-repurposed-treatments-drugs | USA | Treatment | | 22 | 4 | 75 |
| https://www.vox.com/science-and-health/2020/3/4/21154590/coronavirus-vaccine-treatment-covid-19-drug-cure | USA | Both | | 22 | 4 | 74 |

Figure 4. Scores of all websites for EQIP tool, JAMA benchmark and DISCERN tool, with scores above 75th percentile marked as high

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1. Workflow of webscraping and exclusion

70x55mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 2. Popular search terms

99x123mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 3. Country of origin of websites

132x79mm (300 x 300 DPI)




Figure 4. High-score distribution of websites

60x94mm (300 x 300 DPI)



PRISMA 2009 Checklist

| Section/topic | # | Checklist item | Reported on page # |
|------------------------------------|----|---|--------------------|
| TITLE | | | |
| Title | 1 | Identify the report as a systematic review, meta-analysis, or both. | 2 |
| ABSTRACT | | | |
| Structured summary | 2 | Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number. | 4 |
| INTRODUCTION | | | |
| Rationale | 3 | Describe the rationale for the review in the context of what is already known. | 6-7 |
| Objectives | 4 | Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS). | 6-7 |
| METHODS | | | |
| Protocol and registration | 5 | Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number. | 8 |
| Eligibility criteria | 6 | Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale. | 7-8 |
| Information sources | 7 | Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched. | 7-8 |
| Search | 8 | Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated. | 7-8 |
| Study selection | 9 | State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis). | 6-8 |
| Data collection process | 10 | Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators. | 8-10 |
| Data items | 11 | List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made. | 8-10 |
| Risk of bias in individual studies | 12 | Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis. | 8-10 |
| Summary measures | 13 | State the principal summary measures (e.g., risk ratio, difference in means). | 8-10 |
| Synthesis of results | 14 | Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I^2) for each meta-analysis. | 10 |



PRISMA 2009 Checklist

Page 1 of 2

| Section/topic | # | Checklist item | Reported on page # |
|-------------------------------|----|--|--------------------|
| Risk of bias across studies | 15 | Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies). | N/A |
| Additional analyses | 16 | Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified. | N/A |
| RESULTS | | | |
| Study selection | 17 | Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram. | 10, Figure 1 |
| Study characteristics | 18 | For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations. | 10-11 |
| Risk of bias within studies | 19 | Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12). | N/A |
| Results of individual studies | 20 | For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot. | N/A |
| Synthesis of results | 21 | Present results of each meta-analysis done, including confidence intervals and measures of consistency. | N/A |
| Risk of bias across studies | 22 | Present results of any assessment of risk of bias across studies (see Item 15). | N/A |
| Additional analysis | 23 | Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]). | 10-12 |
| DISCUSSION | | | |
| Summary of evidence | 24 | Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers). | 12-17 |
| Limitations | 25 | Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias). | 17 |
| Conclusions | 26 | Provide a general interpretation of the results in the context of other evidence, and implications for future research. | 17-18 |
| FUNDING | | | |
| Funding | 27 | Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review. | 2 |

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit: www.prisma-statement.org.

Page 2 of 2
For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

BMJ Open

A systematic analysis and quality assessment of COVID-19 treatment and prevention information on the Internet

| | |
|---------------------------------|--|
| Journal: | <i>BMJ Open</i> |
| Manuscript ID | bmjopen-2020-040487.R1 |
| Article Type: | Original research |
| Date Submitted by the Author: | 21-Jul-2020 |
| Complete List of Authors: | Fan, Ka Siu; St George's University Hospitals NHS Foundation Trust, Ghani, Shahi; St George's University Hospitals NHS Foundation Trust Machairas, Nikolaos ; Royal Free Hospital, Department of HPB Surgery and Liver Transplant Lenti, Lorenzo; St George's University Hospitals NHS Foundation Trust Fan, Ka Hay; Imperial College London Richardson, Daniel; St George's University Hospitals NHS Foundation Trust Scott, Aneya; St George's University Hospitals NHS Foundation Trust Raptis, Dimitri; Royal Free Hospital, Department of HPB Surgery and Liver Transplant |
| Primary Subject Heading: | Health informatics |
| Secondary Subject Heading: | Infectious diseases, Patient-centred medicine, Public health |
| Keywords: | World Wide Web technology < BIOTECHNOLOGY & BIOINFORMATICS, Health informatics < BIOTECHNOLOGY & BIOINFORMATICS, JOURNALISM (see Medical Journalism) |
| | |

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

Cover Letter

Dear Editor,

We would like to submit to you the manuscript under the title of “A systematic analysis and quality assessment of COVID-19 treatment and prevention information on the Internet”.

Our work sets out to evaluate the quality of information available to the public regarding both the treatment and prevention of COVID-19 using validated assessment tools. These tools, which have been used in the past to assess quality, include the Ensuring Quality Information for Patients (EQIP) tool, JAMA benchmark and the DISCERN tool, all of which have been proven to be robust and effective at assessing online health information.

To the best of our knowledge, this is the first study to evaluate the nature and quality of information regarding COVID-19 currently available to the public. Our findings indicate that most websites were unable to provide adequate information on both treatment and preventative methods and were generally of poor quality. Without interventions to improve these websites, they will likely impact the awareness and actions of the wider public and, by extension, affect the efficacy of public health measures. Our study reflects the ongoing need for high-quality information while it is still possible to influence its dissemination, especially for countries that are now entering the growth phase.

We believe that this report, as well as the subtopics it addresses, will be of interest for the readers of your respectable journal.

We hereby certify that the authors of the above manuscript have all: 1) Conceived, planned, and performed the work leading to this article, 2) Written the article or reviewed successive versions and shared in their revisions, 3) Approved the final version. Further, we certify that this work has neither been published in whole or in part elsewhere nor is under consideration elsewhere, and we accept full responsibility for the design and conduct of the study.

Yours sincerely,

Ka Siu Fan, BSc and Shahi Abdul Ghani, MSc, DHMSA

On behalf of Dimitri Aristotle Raptis, MD, MSc, PhD and the authors

1
2
3 **A systematic analysis and quality assessment of COVID-19 treatment and prevention**
4 **information on the Internet**
5

6
7 Ka Siu Fan, BSc*¹, Shahi Abdul Ghani, MSc, DHMSA*¹, Nikolaos Machairas, MD, PhD²,
8
9 Lorenzo Lenti, BSc¹, Ka Hay Fan³, Daniel Richardson, BSc¹, Aneya Scott, MChem¹, Dimitri
10
11 Aristotle Raptis MD, MSc, PhD²
12

13
14 *Ka Siu Fan and Shahi Abdul Ghani contributed equally to this paper.

- 15
16 1. St. Georges University of London, UK
17
18 2. Department of HPB Surgery and Liver Transplant, Royal Free Hospital, London, UK
19
20 3. Imperial College London, UK
21
22

23
24 **Corresponding author:**
25

26 Dr Dimitri Aristotle Raptis MD, MSc, PhD
27
28 Department of HPB Surgery and Liver Transplant
29
30 Royal Free Hospital, London, UK
31
32 Dimitri.Raptis@NHS.net
33

34
35
36
37 **Conflict of interest:** The authors have no conflicts of interests or funding sources to
38
39 disclose
40
41

42
43 **Acknowledgements:** None
44
45

46
47 **Statement of Author Contribution:**
48

49 Study conception and design: DAR, NM, SAG, KSF

50 Acquisition of data: SAG, KSF, LL, KHF, DR, AS

51 Analysis and interpretation of data: KSF, SAG, NM, DAR

52 Drafting of manuscript: KSF, SAG, NM, KHF

53
54
55
56
57
58
59
60
60 Critical revision: KSF, SAG, NM, DAR

1
2
3 **Word count:** 6264
4

5 **Keywords:** Coronavirus, Internet, Patient Education Handout, Public Health Informatics,
6
7 Search Engine
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Abstract

Objective: To evaluate the quality of information regarding the treatment and prevention of COVID-19 available to the general public from all countries.

Design: Systematic analysis using the 'Ensuring Quality Information for Patients' (EQIP) tool (score 0-36), JAMA benchmark (score 0-4) and the DISCERN tool (score 16-80) to analyse websites containing information targeted at the general public.

Data Sources: Twelve popular search-terms, including 'Coronavirus', 'COVID 19', 'Wuhan virus', 'How to treat coronavirus' and 'COVID 19 Prevention' were identified by 'Google AdWords' and 'Google Trends'. Unique links from the first 10 pages for each search-term were identified and evaluated on its quality of information.

Eligibility Criteria for selecting studies: All websites written in the English language, and provides information on prevention or treatment of COVID-19 intended for the general public were considered eligible. Any websites intended for professionals, or specific isolated populations, such as students from one particular school, were excluded, as well as websites with only video content, marketing content, daily caseload update or news dashboard pages with no health information.

Results: Of the 1275 identified websites, 321 (25%) were eligible for analysis. The overall EQIP, JAMA and DISCERN scores were 17.8, 2.7 and 38.0. Websites originated from 34 countries, with the majority from the USA (55%). News Services (50%) and Government/Health Departments (27%) were the most common sources of information and their information quality varied significantly. Majority of websites discuss prevention alone despite popular search trends of COVID-19 treatment. Websites discussing both treatment and prevention (n=73, 23%) score significantly higher across all tools ($P<0.001$).

Conclusion: This comprehensive assessment of online COVID-19 information using EQIP, JAMA and DISCERN tools indicate that most websites were inadequate. This necessitates improvements in online resources to facilitate public health measures during the pandemic.

Section 1: What is already known on this topic

- Since the declaration of COVID-19 as a pandemic on 12th March, the WHO, UN and EU have reported that unreliable information, or worse, disinformation has reduced the impact of their efforts in informing the public on matters related to the pandemic; leading to poor uptake of public health advice amongst certain communities.
- Research from previous outbreaks such as the Ebola outbreak from 2013-16 has identified that effective public education and public health intervention relies on public access to high-quality health information.
- As governments are relying heavily on a widespread concordance to public health advice during the COVID-19 pandemic, it is important to characterise the health information seeking habits of the public, the quality of the information that is available, and whether the information meets the needs identified through search habits at this time.

Section 2: What this study adds

- For this study, we identified 12 search-terms used by those seeking information related to COVID-19, 321 of the 1275 obtained websites met our eligibility criteria for analysis.
- An analysis with three widely respected tools (EQIP, DISCERN and JAMA benchmark) identified that the majority of websites poorly referenced sources of information or provided inadequate information, reflecting the ongoing need for better quality information regarding COVID-19 aimed at the public.

Introduction

With the increasing popularity of the Internet, both the accessibility and availability of health information has increased drastically and is now a primary source of information for many.[1,2] It is known that health information-seeking behaviour also applies to the use of online resources and has become ever more important during the current Coronavirus disease 2019 (COVID-19) pandemic[3] Information on such a widely-discussed topic will inevitably be vast and vary in production quality, potentially adversely affecting patient awareness and health-seeking behaviour.[4] Many of these resources read by the public may be unreliable or produced from non-peer-reviewed sources and affect behaviours such as recognition of symptoms, taking appropriate preventative precautions or seeking timely treatment.[3,5,6] Furthermore, inaccurate online information may contradict healthcare professionals and potentially compromise the trusting relationship with patients, worsening outcomes.[7]

Since the declaration of COVID-19 as a pandemic on 12th March 2020, its prevalence and mortality have continued to rise[8,9] and lead to the introduction of various measures such as social distancing, quarantine procedures and lockdown protocols.[10] As evidenced by previous outbreaks, effective public education and public health intervention rely on access to health information[11,12], which is now primarily delivered through the Internet. Many countries have since introduced lockdown and quarantine protocols as their mainstay preventative measures[13] but public health continues to be threatened by certain populations.[14] Due to both the novelty and rapid developments of COVID-19, there is a significant barrier for individuals to critically appraise online resources and, hence, necessitates a quantitative evaluation of the popular information sources available to the wider public.

Many instruments have been developed to evaluate patient information and may also be applied to online COVID-19 information.[15] The modified Ensuring Quality of Information for

1
2
3 Patients (EQIP) tool is a reproducible modality used in previous studies to evaluate the
4 reliability and quality of all information types, providing a robust assessment of quality,
5 readability and design aspects of any written information[16–18]. Previously, our group
6
7 evaluated online information using the modified EQIP tool in a variety of conditions and
8
9 procedures including bariatric surgery[19], Dupuytren's disease[20], carpal tunnel
10
11 disease[21], breast augmentation[22], liposuction[16] and liver transplantation[23]. The
12
13 Minervation validation instrument (LIDA)[24], Flesch Reading Ease (FRE) Score and the
14
15 Flesch-Kincaid Grade (FKG) have also been used to evaluate the quality of online health
16
17 information.[25] However, they are not considered appropriate here as only assesses
18
19 readability and website design, which is adequately covered by EQIP.[26] Tools such as the
20
21 Journal of American Medical Association (JAMA) benchmark and the DISCERN tool (no
22
23 acronym) have also been used to evaluate online health information and their combinational
24
25 use can provide a more comprehensive evaluation.[18,27,28] Given that the Internet has
26
27 become an ever-important source of information and can determine health-seeking
28
29 behaviour, which by extension can affect the progression of COVID-19. Hence, our study
30
31 aims to assess the quality of information of top indexed websites that discuss information,
32
33 prevention, or treatment of COVID-19 using the modified EQIP tool, JAMA benchmark and
34
35 DISCERN tool.
36
37
38
39
40
41
42

43 **Methods**

44 **Eligibility criteria, information sources and data selection**

45
46 On 27th March 2020, 12 search-terms and phrases were queried on the most used search
47
48 engine, Google[29–31], to obtain a database of websites. Only Google was used as previous
49
50 studies have shown that the use of multiple search engines will only provide duplicate
51
52 results. To increase the number of results, more search-terms were used: 'Coronavirus',
53
54 'COVID 19', 'Stop getting Coronavirus', 'Corona Virus', 'How to treat coronavirus',
55
56 'Coronavirus safety tips', 'Drugs for coronavirus', 'What is self isolation coronavirus', 'China
57
58 virus', 'Wuhan virus', 'Coronavirus Medicine' and 'COVID 19 prevention'. These were
59
60

1
2
3 commonly searched phrases identified using the 'Google Adwords Keyword Planner'[32].
4
5 Google AdWords allows the input of a term (in this case coronavirus) which then provides
6
7 popular related keyword suggestions. The most popular search-terms were 'Coronavirus',
8
9 followed by 'COVID' and 'Corona Virus' and their respective search popularity peaked in
10
11 mid- and late-March 2020 respectively. **Figure 1** summarises the most popular search
12
13 trends. Only the first 10 pages of unique websites were identified and recorded as previous
14
15 work suggests patients tend to stay within the first 100 returned webpages[17,23]. Various
16
17 search-terms and their relative popularity were also collected directly from Google
18
19 Trends[33] for further comparative analysis.
20
21
22
23

24 All websites written in the English language and providing information on prevention or
25
26 treatment of COVID-19 intended for the general public or COVID-19 patients were
27
28 considered eligible for inclusion. Any subsidiary pages or subdirectories of a website that
29
30 contained information for the public and were easily accessible are also assessed. Websites
31
32 or articles intended for professionals or specific population subsets, such as students alone,
33
34 were excluded. Weblinks to purely video content, marketing content, daily caseload update
35
36 or news dashboard pages with no educational purposes were excluded. The creation of the
37
38 website database, eligibility assessment, website assessment and statistical analysis was
39
40 performed within 4 weeks between March and April 2020.
41
42
43
44

45 **Website Scraping**

46
47 A website scraping tool was developed to identify and record all unique websites from the
48
49 first 10 pages of Google results. The tool utilises custom PHP to make HTTP requests to the
50
51 search engine to mimic the requests made by the public. The queries were made from a
52
53 server located in Texas, USA but no preferences were made to limit searches by
54
55 geographical region. The tool makes repeated requests, logs the first 10 pages of unique
56
57 URLs and outputs the dataset after excluding all duplicate links within each search-term A
58
59 minority of websites were restricted by General Data Protection Regulation (GDPR) and
60

1
2
3 were accessed through the use of virtual private networks (VPN) as any websites that could
4 reasonably be accessed by the general public were included.
5
6
7
8

9 **Data entry**

10
11 Six assessors, (SAG, KSF, KHF, LL, AS and DR), all of whom fluent in English,
12 independently assessed the websites between 30 March and 13 April 2020. The evaluation
13 included 36 EQIP items and four items on JAMA benchmark, all assessed through 'Yes, No
14 or N/A' questions. DISCERN tool adds a further 16 items to assess reliability and quality of
15 information on treatment using scales of 1 to 5. Assessors also recorded the country of
16 origin, and type of source: Academic Centre, Charity/Non-Governmental Organisation,
17 Encyclopaedia, Government/Health Department, Hospital, Industry, News Service, Patient
18 Group, Practitioner, and Professional Society. Organisations that primarily serves patients,
19 such as Patient.info, is considered a 'Patient Group' whereas non-governmental
20 organisations that oversee a broader demographic, like Red Cross and World Health
21 Organization (WHO), are classified as 'Charity/Non-Governmental Organisation'. News
22 service includes both primary and secondary news articles that are not written for
23 professionals. 'Practitioner' considers the for-profit webpages of individual medical
24 practitioners, whereas 'Industry' considers organisations within the medical industry.
25 'Academic Centres' consider all sources from academic institutions, while 'Professional
26 Society' refer to non-profit groups of healthcare professionals. Qualitative information about
27 preventative methods and treatment was also recorded. After the initial round of data entry,
28 each website was verified on a second-round between 14 April and 21 April by a verifier who
29 has had previous experience performing data entry for evaluation of patient health
30 information.
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55

56 **EQIP Tool**

57
58 The Ensuring Quality Information for Patients (EQIP) tool consists of 20 items, acting as a
59 checklist for criteria such as quality of written work, design and coherence.[34] More
60

1
2
3 recently, modifications were made to the EQIP tool, expanding the criteria to 36 items[35], to
4 satisfy both the guidelines of British Medical Association (BMA)[36] and International Patient
5 Decision Aids Standards (IPDAS) collaboration[37] on ideal information for patients and
6 have been utilised in a variety of specialities previously.[16–18] A decision was made to use
7 the modified EQIP tool as the inclusion of 'partly yes' in the original EQIP introduces
8 subjectiveness into the responses and has been shown to lower its reliability.[23,34] 36
9 items across three domains were included: Content (items 1-18), Identification (items 19-24)
10 and Structure (items 25-36). Similar to previous uses, 'Yes/No' binary questions reduce
11 assessor subjectivity in partial answers. 'N/A' option was also included if items were not
12 relevant for the type of source. The Content domain assesses whether an adequate amount
13 of information is included in an article, ranging from a description of the medical problem
14 itself (items 1-3,11,14) to details of its management and complications (items 4-11).
15 Identification domain assesses how well a website displays its production details, including
16 date of issue, author, finance sources and bibliography (items 19-24). Structure domain
17 evaluates the readability of a website and how well it accommodates to its audience, such as
18 delivering the information through short, non-contradictory statements arranged in a logical
19 layout (items 25-36). As COVID-19 is an emergent disease, certain items are tailored to
20 accommodate for the limited evidence: describing treatment (item 3) include articles that
21 address the lack of proven treatment, and alert signs (item 14) include recognised COVID-19
22 symptoms such as fever, cough and changes in taste or smell. A cut-off point of 75th
23 percentile was set for EQIP score to discriminate between high-scoring from low-scoring
24 websites as was done in previous studies.
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51

52 **JAMA Benchmark**

53
54 Critical appraisals of Internet-based resources are also assessed by one of the earliest core
55 standards identified by JAMA in 1997.[38] This checklist was proposed by Silberg *et al.* to
56 assist the appraisal and evaluation of the credibility of unregulated Internet resources and
57
58
59
60

1
2
3 have been used in various studies previously[39,40]. This is evaluated by four items:
4 Authorship, Attribution, Disclosure and Currency: Authorship requires identification of
5 authors, credentials and their affiliations; Attribution requires appropriate citations on written
6 information; Disclosure requires transparency of the website owner and conflicts of interests;
7 Currency requires a clear indication of the date of publication and updates. Similarly, the
8 'Yes/No' criterion is implemented to reduce the subjectivity of partial answers.
9
10
11
12
13
14
15
16
17

18 **DISCERN Tool**

19
20 The DISCERN evaluation tool was first developed in 1998 at Oxford to judge the quality of
21 information regarding treatment choices.[41] This tool has been validated and used across
22 various specialities to assess treatment information.[28,39,42] This consisted of 16 items to
23 assesses both the reliability and level of detail on treatments as well as the overall quality of
24 the information. The reliability section (items 1-8) evaluates the ability of a website to
25 achieve its aims while remaining unbiased and providing its sources of information. Quality
26 section (items 9-15) evaluates the content specifically for describing the rationale, methods
27 and alternatives to the current management of a disease. Criteria for treatment section was
28 adjusted to accommodate the treatment uncertainty and items are considered fulfilled as
29 long as the website discusses the relevant information with regards to potential drugs or
30 interventions such as assisted ventilation. A score between 1 and 5 can be assigned to each
31 item, with 1 being 'No', 3 being 'Partial' and 5 being 'Yes'. To improve assessment accuracy,
32 overall quality of information will be scored in proportion to the mean scores calculated from
33 the answers to items 1-15, with 1 being the lowest and 5 being the highest.
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50

51 **Additional Items**

52
53 Additional items were included to further assess the websites, including whether a website
54 discussed prevention methods, current treatments and the role of empirical evidence in the
55 prevention or treatment for COVID-19. Data collected were in the form of 'Yes/No' to reduce
56 the ambiguity of partial answers again. Additionally, details provided by the website on these
57
58
59
60

1
2
3 items were recorded if the item scores 'Yes'. Websites were further analysed by whether
4
5 their purpose is prevention, treatment, or both.
6
7
8

9 **Statistical Analysis**

10
11 The dataset consisted of both continuous and categorical variables, which are reported as
12
13 the mean, median and interquartile range (IQR) as well as numbers and percentages
14
15 respectively. High-scoring websites are identified as those with scores above the 75th
16
17 percentile for all three tools. Kruskal-Wallis tests were used for the analysis of continuous
18
19 variables where appropriate and intraclass correlation coefficient (ICC) was calculated to
20
21 identify the correlation between website analysis test methods. Fisher's or χ^2 tests were
22
23 used to analyse proportions where appropriate. Inter-rater reliability of each assessor was
24
25 evaluated using Bland-Altman plots. All P values were two-tailed and considered significant
26
27 when $P < 0.05$. R version 3.3.2 (R Core Team, GNU GPL v2 License), R Studio version
28
29 1.0.44 (RStudio, Inc. GNU Affero General Public License v3, Boston, MA, 2016) and their
30
31 respective graphical user interface (GUI) rBiostatistics.com (rBiostatistics.com, London,
32
33 Switzerland, 2017)[43] was used to perform the statistical analysis.
34
35
36
37
38

39 **Patient and Public Involvement**

40
41 There were no patient or public involvement in the conception, design or data collection of
42
43 the study or the production of the manuscript.
44
45
46
47
48

49 **Results**

50 51 **Gathering of websites with information on COVID-19, its prevention and its** 52 53 **management** 54

55
56 A database of websites was gathered from the first 10 pages of unique URLs returned using
57
58 the 12 search-terms. The final dataset included 1275 URLs. After filtering out duplicate
59
60 results and websites that failed to meet our inclusion criteria, 321 remained eligible for

1
2
3 analysis. The workflow of dataset creation is shown in **Figure 2**. List of websites was
4 obtained on a single day, 27th March 2020, and website evaluation was completed within two
5 weeks.
6
7
8
9

10 11 **Website demographics and search trends**

12 COVID-19-specific searches regarding treatment and masks were significantly more popular
13 (P<0.001) than prevention and peaked in mid-March and early-April respectively. The
14 returned websites originated from 34 different countries (**Figure 3 and 4**): the USA produced
15 the most websites (n=178), followed by the United Kingdom (n=52), Australia (n=18) and
16 Canada (n=18). However, no statistically significant differences were observed between the
17 four countries across all tools. The source of information and website category is shown in
18 **Table 1**. News Services were the most common source of information (n=163), followed by
19 Health Departments/Government (n=87).
20
21
22
23
24
25
26
27
28
29
30

31
32 Forty-six websites (14.3%) described treatment methods alone, 202 websites (62.9%)
33 mentioned treatment methods alone and 73 websites (22.7%) discussed both prevention
34 and treatment. Of the mentioned prevention methods, 205 (63.9%) described social
35 isolation, 169 (52.7%) physical distancing, 157 (48.9%) advised staying home and 136
36 (42.4%) described the benefits of disinfecting or cleaning surfaces. With regards to
37 mentioned treatment methods, 55 (17.1%) described the use of antiviral medications, 31
38 (9.7%) described hydroxychloroquine or chloroquine and 26 (8.1%) described the use of
39 non-steroidal anti-inflammatory drugs such as paracetamol and ibuprofen. Only 31 (9.7%)
40 websites discussed the use of oxygen, ventilation or fluids as a possible treatment method.
41
42
43
44
45
46
47
48
49
50
51

52 53 **Overall performance**

54 The mean total score for EQIP, JAMA and DISCERN are 17.78, 2.69 and 38.00 respectively
55 and their respective 75th percentile high-score cut-offs were 21, 4 and 43. No website
56 achieved the maximum score for EQIP Content (out of 18) or Structure (out of 6) domain but
57
58
59
60

1
2
3 one website did attain maximum for EQIP Identification (out of 12). Seventy-four websites
4 fulfilled all four JAMA criteria. Four websites achieved the maximum for DISCERN Reliability
5 (out of 40) but none scored fully in DISCERN Treatment (out of 40). 74 high-scoring
6 websites were identified for EQIP and JAMA and 76 for DISCERN tool. The mean scores for
7 each tool and domain are as follows: EQIP Content (9.99 vs 6.07; $P<0.001$), EQIP
8 Identification (4.03 vs 3.34; $P<0.001$), EQIP Structure (8.45 vs 6.96; $P<0.001$), Total EQIP
9 (22.46 vs 16.37; $P<0.001$), Total JAMA (4.00 vs 2.30; $P<0.001$), DISCERN Reliability (31.72
10 vs 25.44; $P<0.001$), DISCERN Treatment (13.49 vs 10.31; $P=0.002$) and Total DISCERN
11 (45.21 vs 35.76; $P<0.001$).

12
13
14 All tools and subsequent domains, except DISCERN Reliability and Total DISCERN scores,
15 varied significantly between websites of different sources, notably with the Encyclopaedia
16 (n=5) cohort holding the highest score for all domains. All tools and domains varied between
17 website cohorts, with websites that include both Treatment and Prevention scoring above
18 the mean values. **Table 2** and **Table 3** summarises the variation of information quality with
19 the source of information and website category respectively. A detailed breakdown of the
20 performance of each item and each tool is displayed in **Supplementary Table 1, 2 and 3**.

21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 **Subset analysis of Government/Health Department and News Services**

42 Collectively, 250 (77.9%) of all web links were either Government/Health Departments and
43 News Services websites, of which 121 (37.7%) were based in the USA. Globally, there is
44 significant variation between Government/Health Departments and News Services in EQIP
45 Content (mean 8.11 vs 6.22; $P<0.001$), Total EQIP (mean 18.90 vs 17.06; $P<0.001$), Total
46 JAMA (mean 2.16 vs 2.98; $P<0.001$) and DISCERN Treatment (mean 9.02 vs 11.72;
47 $P=0.001$). Variations in US websites were similar except for EQIP structure ($P=0.148$). The
48 US-based cohort scored lower in Total EQIP than the global cohort but USA News Services
49 specifically scored better in Total JAMA (3.17 vs 2.98) and Total DISCERN (39.25 vs 38.04).
50 Breakdowns of comparison between the cohorts are provided in **Table 4**.

High-scoring websites

Sixteen websites scored above 75th percentile across all three evaluation tools, 13 were from the USA, 2 from the UK and 1 from Canada. Most were from News Services (n=10), followed by industry (n=4), Encyclopaedia (n=1) and Government/Health Departments (n=1). The top 5 websites with the highest Total EQIP and Total DISCERN scores are shown in **Table 5** with their respective breakdowns. Top JAMA websites were not shown as there were 74 that scored the full four points.

Intraclass correlation between tools

Intraclass correlation (ICC) between the 3 analysis tools is provided in **Supplementary Figure 1**. The ICC between all three tools was moderate to high 0.48 (95% CI 0.37-0.56). Furthermore, as the JAMA benchmark only offers four scoring variations, the Kruskal-Wallis analysis is used to correlate JAMA with EQIP and DISCERN. The results are shown in **Supplementary Figure 2** and demonstrate statistically significant moderate-high correlation for both JAMA-EQIP and JAMA-DISCERN.

Inter-rater reliability

Kappa coefficients, ranges and outliers. Mean kappa and SD for each tool. Supplementary Data. Intraclass correlation, 95% CI intervals. Bland-Altman plots. The biases of each tool and assessor are within 95% CI interval limits. The Bland-Altman plots and individual degree of bias have been provided in **Supplementary Figure 3**. The mean degree of bias and 95% confidence intervals for each assessor is identified. Mean bias for EQIP, JAMA and DISCERN were -0.36, +0.29 and +0.51 respectively. Bias for each assessor, within each tool, was minimal and falls within their respective 95% CI.

Discussion

1
2
3 To our knowledge, this is the first study to evaluate the content intended for the public
4 seeking information for preventing or treating of COVID-19. Our search-terms included
5 various synonyms of COVID-19 and “open” search-terms to capture the majority of materials
6 related to our study. While no tools are validated to assess information specifically during
7 pandemics; this study used a combination of EQIP, JAMA and DISCERN. The combined
8 scope and efficacy of these tools enable a comprehensive evaluation of all important
9 aspects for a layperson seeking health information from articles; namely readability,
10 coherence, design and quality of information.
11
12
13
14
15
16
17
18
19
20
21

22 **Evaluation of the websites**

23
24 We determined the quality of information to be low, as indicated by the low 75th percentile
25 cut-offs for EQIP and DISCERN, at 21 and 43 respectively, or 58.3% and 53.8% of their
26 respective full scores. Abundant COVID-19 content is being produced, as evident in **Figure**
27 **1**, with the majority being excluded due to its nature rather than inter-term duplications. Most
28 frequently excluded websites were either daily caseload updates or general news articles
29 lacking information on prevention and treatment.
30
31
32
33
34
35
36
37
38

39 Websites generally scored poorly, with an EQIP mean and median of 18 (IQR 15-20).
40 Despite fewer marks allocated to Structure, websites generally outperform the Content
41 domain (7.30 vs 6.97), suggesting information quality is less adequate than usability. The
42 indicators assessing referencing quality, such as JAMA benchmark and DISCERN
43 Reliability, scored similarly at 2.69 (67.3% of maximum) and 26.93 (67.3% of maximum)
44 respectively but scored lower in the EQIP Identification domain 3.50 (58.3% of maximum),
45 likely due to more items (i.e. whether patients were involved in the material’s production).
46 Generally, high-scoring websites performed better in the Content domain, with odds ratios
47 (OR) between 3-7. The OR was significantly higher for item 4 (defining the purpose of
48 interventions) (OR 27.78; 95% CI 4.695-1000; P<0.001), suggesting that high-scoring
49 websites provided greater reasoning behind preventative and treatment measures. While
50
51
52
53
54
55
56
57
58
59
60

1
2
3 high-scoring websites scored significantly higher across 23 of the 36 EQIP items,
4 quantitative benefits (item 8) is a notable exception where both cohorts performed poorly
5 (4.1% vs 2.4%; OR 1.695; 95% CI 0.267-8.197; P=0.436), significantly lower than available
6 literature.[17,22,23] This likely reflects the general lack of COVID-19 knowledge compared to
7 previously explored diseases and treatments. High-scoring websites similarly performed
8 better in Identification (OR ranged between 1.312 and 5.376), with the inclusion of
9 bibliography (item 23) differing most (41.89% vs 11.74%; OR 5.376; 95% CI 1.727-7.407;
10 P<0.001) as the majority of said websites seem to lack bibliographies, potentially due to
11 subpar production quality in a high turnover topic. Structure revealed both high- and low-
12 scoring websites to provide clear information (item 30; 98.65% vs 89.88%; OR 8.197; 95%
13 CI 1.294-333.3; P=0.013). High scoring websites provided poor benefit-risk balancing(item
14 31; 39.19% vs 10.93%; 5.208; 95% CI 2.703-10.101; P<0.001), as did most other websites
15 assessed (17.5% overall), comparable to existing studies ranging 11% to 44%. As shown in
16 **Figure 5**, EQIP scores were relatively homogeneous, ranging from 6 to 29, with the majority
17 between 14-22. Overall performance agreed with available literature that information is
18 inadequate, as median EQIP scores ranged between 15-19 and IQR ranged 12-20 and 16-
19 22.[17,19,21,22,44] Furthermore, scores for describing intervention sequence (item 6) and
20 quantitative risks (item 10) were much lower (15.9% and 0.9% respectively) when compared
21 against the study on gallstone disease (27% and 21% respectively) or liver transplantation
22 (66% and 53% respectively). This likely reflects the prioritisation of discussing prevention
23 and treatment method efficacy over treatment sequences and risks. Item 23 also scored
24 poorly, both in itself and against literature: only 18.7% of websites provided a short
25 bibliography whereas studies ranged from 19% in liver transplantation to 47% in
26 orthognathic surgery. Interestingly, COVID-19 websites scored well in dating (item 19;
27 87.2%) compared literature, likely reflecting the demanding and time-sensitive nature to
28 understand how the COVID-19 pandemic affect individuals. Unsurprisingly, encyclopaedias
29 (n= 5) scored the highest in content (10.80), identification (4.80) domains and overall EQIP
30 (24.20), holding the highest proportion of websites discussing both prevention and treatment
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 (n=4; 80%). Encyclopaedias' high scores are attained through their endeavours to provide
4 neutral summaries meeting the majority of the EQIP criterion.[45] Nonetheless, while overall
5 EQIP scores do not differ substantially from existing literature, it is important to recognise
6 that the quality of information assessed is significantly influenced by the rapid turnover of
7 information, a phenomenon not present in other comparable studies.
8
9
10
11
12

13
14
15 JAMA benchmark scores, unlike EQIP and DISCERN, were more consistent as only four
16 points are available. Hence, high-scoring websites often fulfilled all four criteria while the
17 majority of remaining entries scored two or three. Low-scoring websites scored significantly
18 lower ($P<0.001$) in Authorship and Attribution, with only 44.13% and 17.81% fulfilling the
19 criteria, reflecting congruence with the findings from EQIP regarding bibliography inclusion.
20 Contrarily, website ownership and funding assessment, under Disclosure, (86.23%) and
21 assessments of publishing and updating dates, under Currency (81.78%), varied to a lesser
22 degree, albeit still scoring significantly lower ($P<0.001$). Comparative to the related EQIP
23 sections, Disclosure and Currency likely scored better by assessing attributes separate to
24 the content itself. Professional societies (n= 4; 3.50), closely followed by encyclopaedias
25 (n=5; 3.40), scored the highest (scored highest what?), whereas the mean JAMA scores
26 were only 2.69, with four websites scoring zero. This is likely attributable to the lack of
27 additional assessment criteria by the JAMA benchmark due to JAMA's development during a
28 time of rudimentary online resources. Regardless, the tool is still effective at identifying high-
29 quality content as high-scoring websites scored significantly better across each item
30 ($P<0.001$).
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50

51 DISCERN's mean score of 38.0 across 16 items averaged 2.38 out of five per item. The
52 DISCERN handbook details a rating of one when the information does not provide the
53 appropriate information, three where it addresses it partially and five for a complete and
54 adequate inclusion. Based on these guidelines, the majority of websites meet the listed
55 criteria to a minimal extent. Similar to EQIP, DISCERN scores vary significantly, ranging 19
56
57
58
59
60

1
2
3 to 75 with a majority distributed within 25 to 47. Of the 16 items, 12 presented statistically
4 significant differences between high- and low-scoring websites. Interestingly, the Reliability
5 section provided the greatest difference in scoring, seen between item 4, clear display of
6 information sources (mean 4.16 vs 2.55; $P=0.019$), and item 5, a clear indication of where
7 sources were used (mean 3.54 vs 2.28; $P=0.007$). This corroborates with results from EQIP
8 and JAMA assessments, highlighting the inadequacies of informative material production.

9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Quality of treatment information scores varied less, albeit all statistically significant, with
largest differences observed between item 9, describing how each treatment works (1.76 vs
1.43; $P=0.005$) and item 10, detailing treatment benefits (1.78 vs 1.43; $P<0.001$). Despite
accommodating for the treatment uncertainty during the assessment, almost all items
evaluating treatment scored poorly, including high-scoring websites, and may be reflective of
its lower journalistic priority or demand as we also found the majority of websites tailored
towards discussing prevention. As a whole, DISCERN scores specifically addressing
treatment options were poor, scoring 45.07 (SD 11.68) for websites that only discuss
treatment as well as 42.84 (SD 10.93) for websites that discuss both prevention and
treatment. These scores are also lower than those of other DISCERN studies, which have
mean scores between 45.8 and 56.1, with SD between 8.76 and 13.6.[46–48] While the
majority of websites DISCERN scores were low, they scored similarly in Reliability section.
The mean scores for items 1,2 and 3 were the highest of all indicators, averaging 4.37, 4.29
and 4.33, whereas treatment section scored between 1 and 2, with a maximum of 1.66. The
treatment section of DISCERN shows much more variation, with prevention alone (8.60;
 $n=202$) scoring lowest, treatment alone (18.09; $n=46$) scoring highest and websites
discussing both (13.47; $n=73$) in between. This suggests that many websites do not include
treatment information and, of those that do, websites tend to avoid discussion rather than
provide the limited information available.

In short, all three tools utilised here are validated based on international recommendations
and provides a comprehensive assessment of online information: EQIP delivers an all-

1
2
3 rounded evaluation of health information, DISCERN excels at scrutinising treatment and
4 JAMA benchmark assesses all of a website's content as a whole. Additionally, as design
5 alone is known to improv perception of information credibility[49], the higher emphasis on
6 quality of content in EQIP and DISCERN will likely prevent well-presented and user-friendly
7 websites with poor content from attaining high scores over poorly-presented websites with
8 good content. Altogether the tools suggest that the majority of COVID-19 websites are
9 generally of poor quality and that quality fluctuates highly. The need to improve public
10 awareness and education exist and through these tools, expectations can be held across
11 different sources of information. This may subsequently impair the ability of the public to filter
12 out websites of low validity and reliability and, hence, increase their risk of unsafe health
13 behaviours during the pandemic.
14
15
16
17
18
19
20
21
22
23
24
25
26
27

28 **Reasons for poor quality information**

29
30 Most sources scored poorly due to several possible reasons. Firstly, as COVID-19 was only
31 identified in early December 2019[50] and recognised as a pandemic in March 2020[51], the
32 general lack of information from which to produce patient information prevents accurate and
33 reliable conclusions to be drawn. While research efforts have since gained traction,
34 production of research, reviewing and publication is a lengthy process comparative to the
35 rapid spread of COVID-19. Journals have since implemented fast-tracking of COVID-19
36 research.[52–54] Similarly, Governments and Health Departments have also cooperated to
37 support and fast-track COVID-19 studies.[55] The combined efforts have facilitated the
38 publication of over 5,000 COVID-19 articles in the WHO database alone.[56] It is also
39 important to note the role of preprint servers during the pandemic as they are accessible to
40 the public. While improving accessibility helps facilitate peer-reviewing; non-peer-reviewed
41 articles can potentially be used, or cherry-picked, by non-professionals which can adversely
42 affect public understanding.[57–60]
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Health literacy plays a crucial role in how COVID-19 information influences health behaviour.
4
5 The associations between health literacy and health behaviour are well documented, with
6
7 low literacy common among older adults with poor health behaviour ($P < 0.005$) ranging from
8
9 lifestyles, such as physical activity, dietary habits and obesity, to social factors, such as
10
11 loneliness and social isolation.[61–63] The effects of primary preventative measures, such
12
13 as social distancing, self-isolation and other hygiene recommendations, may become
14
15 impaired by the abundance of poorly written and incorrect information online. In particular,
16
17 the elderly, most vulnerable population, suffer from even higher risks due to their lower
18
19 health literacy.[64] Although health literacy, and by extension, health behaviours, can be
20
21 improved through education[65], effective dissemination of credible information is critical
22
23 during the pandemic. The public, and journalists, need to exercise caution when accessing
24
25 research and pre-prints during this period as inadequate health literacy may lead to
26
27 counterproductive effects. Similarly, mass production of online information greatly increases
28
29 the difficulty in distinguishing reliable information from the sea of misinformation, and hence,
30
31 a greater emphasis must be placed on authors and journalists to deliver unbiased, credible
32
33 and accurate information to the public.[66,67]
34
35
36
37
38

39 Upon publication, articles are reviewed and summarised by journalists who bridges the
40
41 knowledge gap between scientists and the wider public. This allows efficient dissemination
42
43 of critical research to those who lack the scientific background to critically appraise and
44
45 evaluate research. Notably, while 52% ($n=169$) of websites were 'News Services', only 12
46
47 (7.1%) were considered high-scoring, reflecting that very few provide a comprehensive
48
49 account of COVID-19 information, possibly explained by the difficulty in matching the pace of
50
51 COVID-19 research and technical inadequacies in delivering accurate and concise scientific
52
53 information. As health information-seeking behaviour of the public will likely be based on
54
55 news services[68], the highly variable and generally poor content is problematic.
56
57
58
59
60

1
2
3 Previous studies have identified many health journalists lack the training required to
4 accurately disseminate health news, leading to potentially harmful health effects.[69,70] The
5 low scores across all tools indicate overall inadequacy of both reliability and accuracy. A
6 survey of medical journalists across 37 countries highlighted the 3 most common barriers
7 against quality content: lack of time, space and knowledge.[71] While journalism stresses the
8 ability to summarise content quickly and concisely, experienced journalists often report the
9 lack of knowledge as a barrier. The lack of expert knowledge in a rapidly progressing
10 scientific field can impact the quality of conveyed information significantly. Furthermore,
11 journalists reported difficulty in finding experts to explain jargon, further impacting quality.
12 This presents a large barrier towards disseminating quality COVID-19 information as the
13 redirected efforts of many countries and institutions' scientists into research reduces
14 availability to assist with medical journalism. [72,73] Expertise in a relevant academic
15 background likely helps improve the content, as indicated by the highest-scoring entry,
16 whose author holds a PhD in molecular genetics which scoring 22 in EQIP, 4 in JAMA and
17 74 in DISCERN.[74] In short, our findings highlight the importance of addressing health
18 outcomes through health literacy of both the public and authors.

19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39 Our analysis identified the majority of websites as sources from Governments or health
40 departments across various states of the USA, many of which have based information and
41 advice from the Centers for Disease Control and Prevention (CDC). As both the nature and
42 purpose of these sources vary, the visiting population and demographics would similarly vary
43 due to different information-seeking behaviours. A recent study has identified a deficit of
44 awareness and trust in information originating from the Government such as those of the
45 CDC, revealing that while up to 83.6% of American adults are aware of the CDC, only 64.6%
46 trust this source.[75] American adolescents were, however, less aware of the CDC (55.8%),
47 but were more trusting of their information (72.2%). As previously established, the trust in a
48 government is a predictor of health outcome as it affects behaviours such as service usage
49 and vaccination rates. [76–78] Similarly, as access and usage of online health information
50
51
52
53
54
55
56
57
58
59
60

1
2
3 vary between different demographic populations, it is paramount we create and provide
4 targeted and effective educational material for public use.[79,80]
5
6
7
8

9
10 A comparison between the global Government/Health Department and News Services
11 websites revealed significant differences between EQIP Content, Total EQIP, Total and
12 DISCERN Treatment. The EQIP Content scores reflect differences in information retrieval
13 methods between Government/Health Departments' using primary research for more in-
14 depth accurate information dissemination, and journalists utilising secondary research.
15
16 However, News Services scored higher in DISCERN Treatment, potentially due to the
17 Government's reluctance to prematurely disclose treatment information at early stages of
18 discovery, whereas journalists may freely report results of all potential studies. Interestingly,
19 the majority of USA Government websites had some form of copy-pasted information from
20 the Centre for Disease Control and Prevention (CDC), likely with the aim of maintaining
21 consistency and centralisation information sources. In contrast, the majority of other sources
22 rewrite information based on a variety of sources. American sources display a similar pattern
23 of variation but the EQIP Identification scores of Government/Health Departments show
24 statistically significant differences, scoring lower than News Services (mean 3.34 vs 3.78;
25 P=0.011). Verbatim use of CDC information on these Government websites may have
26 neglected the importance of clarity and transparency, discarding justification and critical
27 appraisal of available literature and focusing on information dissemination instead.
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

48 **Is the current information online adequate?**

49 Google Trends identified search popularity of treatment to have increased rapidly,
50 outgrowing prevention searches since early-March. This suggests that initial demands for
51 preventative information have been sufficiently met and interests now shift towards
52 treatment. The 275 websites addressing prevention scored below the mean EQIP (17.12 vs
53 17.78; P<0.001), JAMA (2.53 vs 2.69; P=0.001) and DISCERN scores (34.64 vs 38.00;
54 P<0.001), showing that quality of preventative information remains subpar across all quality
55
56
57
58
59
60

1
2
3 indicators. Similarly, websites demonstrated their efficacy in sourcing over discussing
4 information, excelling in Identification (3.87 vs 3.50; $P<0.001$), as a treatment alone (46%)
5 scored below the mean in EQIP (16.89 vs 17.78; $P<0.001$). This is also reflected by its
6 above-average JAMA (3.13 vs 2.69; $P=0.001$) and DISCERN (45.07 vs 38.00; $P<0.001$)
7 scores. Contrarily, the 73 websites that discussed both treatment and prevention of COVID-
8 19 consistently scored higher than the mean across all indicators: EQIP (20.15 vs 17.78;
9 $P<0.001$), JAMA (2.85 vs 2.69; $P=0.001$) and DISCERN (42.84 vs 38.00; $P<0.001$). These
10 websites explored multiple aspects of the virus, likely utilising a variety of sources, thus
11 producing a higher quality article through a better understanding of the topic. To combat
12 increasingly dangerous COVID-19 myths, such as injection of disinfectants as treatment,
13 continued maintenance and improvement to online available resources is paramount.[81,82]
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

29 **Limitations**

30 Although our utilised search engine, 'Google', is the most commonly used, it is not wholly
31 representative as searches are often affected by the location of the requesting server and
32 previous Internet usage. While querying from every country is not practical, the utilised
33 server has not conducted any other COVID-19 searches, thus impact should be minimised.
34 A further search was conducted on 10th July 2020 on the top 10 scoring EQIP and DISCERN
35 websites through VPN servers in Texas, London, Toronto and Sydney. Only three of the
36 websites were found within the first 10 pages of results using the same search-terms on the
37 original server, with London and Sydney returning two of the results, Toronto returning none
38 (**Supplementary Table 4**) and the remaining URL redirecting to another page. The search
39 also confirms differences in results between the location of the search, however, all three
40 results from the Texas server were covered by London and Sydney. As websites can be
41 updated or removed any time, our results are representative only at the time of the search,
42 demonstrated by the distinct lack of the original websites in July. Similarly, search-terms
43 obtained using 'Google Adwords Keyword Planner' and 'Google Trends', may not truly be
44 indicative of search patterns of the wider public. Hence, 12 different variations of 'COVID-19'
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 names and phrases potentially used by patients were utilised as search-terms. As
4
5 popularised social media is in sharing health information, our study focused on search
6
7 engines because previous studies have identified a lacking trust in social media information
8
9 responsible, developing subsequent barriers towards public engagement.[83] Similarly, while
10
11 video-based information constitutes a valuable source of information, no tools have been
12
13 validated in assessing video-based information, particularly for COVID-19, to the best of our
14
15 knowledge. Forced inclusion of video content would likely yield inaccurately low scores
16
17 across current tools as videos typically do not include as much written information. Another
18
19 limitation is the exclusion of non-English language websites, especially reducing the
20
21 representation of publicly available information given the international nature of the
22
23 pandemic. A minority of URLs, particularly of News Services, regularly update their content
24
25 or redirect visitors, potentially affecting the second round of evaluation and subsequent
26
27 statistical analysis. Additionally, modified EQIP tool, JAMA benchmark and DISCERN tool
28
29 were limited as they were not designed to specifically assess the highly variable information
30
31 produced during pandemics. However, the EQIP tool was designed to assess any type of
32
33 patient information and demonstrated high inter-rater reliability.[16] Similarly, JAMA
34
35 benchmark was designed to evaluate website reliability alone and DISCERN examines both
36
37 reliability and content accuracy, thus, the combinational use of tools enhances the accuracy
38
39 and objective assessment of websites.
40
41
42
43
44

45 **Conclusion**

46
47 In short, the abundance of Internet resources providing COVID-19 information is exemplified
48
49 by the numerous identified websites during our search. The information available to the
50
51 public may affect their health decisions, which, subsequently, affects the efficacy and
52
53 outcome of public health measures implemented by the state. As effective treatments and
54
55 vaccines research is underway, COVID-19 is primarily addressed with preventative
56
57 measures, hence necessitating a critical review of the quality and nature of the information
58
59 accessible to the public. Our results demonstrated that the websites were chiefly produced
60

1
2
3 by News Services and Government/Health Departments but were nonetheless of low quality.
4
5 While the majority of websites addressed prevention, and likely met the information needs of
6
7 the public as reflected by search trends, there is a relative deficit in websites that discuss
8
9 treatment methods. A minority of websites discussed both prevention methods and
10
11 treatment and were generally good resources but the majority websites were of inadequate
12
13 quality. Thus, there is a need for higher quality for online COVID-19 resources to facilitate
14
15 public education and enable better cooperation and outcomes of public health measures.
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Contributorship statement

Study conception and design: DAR, NM, SAG, KSF

Acquisition of data: SAG, KSF, LL, KHF, DR, AS

Analysis and interpretation of data: KSF, SAG, NM, DAR

Drafting of manuscript: KSF, SAG, NM, KHF

Critical revision: KSF, SAG, NM, DAR

Competing interests

Authors have declared that no competing interests exist.

Funding

Authors received no specific funding for this work.

Data sharing statement

All relevant data are within this manuscript and supplementary files.

Bibliography

- 1 Clarke MA, Moore JL, Steege LM, *et al.* Health information needs, sources, and
2 barriers of primary care patients to achieve patient-centered care: A literature review.
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- 1 Clarke MA, Moore JL, Steege LM, *et al.* Health information needs, sources, and
barriers of primary care patients to achieve patient-centered care: A literature review.
Health Informatics J 2016;**22**:992–1016. doi:10.1177/1460458215602939
- 2 Tan SS-L, Goonawardene N. Internet Health Information Seeking and the Patient-
Physician Relationship: A Systematic Review. *J Med Internet Res* 2017;**19**.
doi:10.2196/jmir.5729
- 3 Semigran HL, Linder JA, Gidengil C, *et al.* Evaluation of symptom checkers for self
diagnosis and triage: audit study. *BMJ* 2015;**351**:h3480–h3480.
doi:10.1136/bmj.h3480
- 4 Alduraywish SA, Altamimi LA, Aldhuwayhi RA, *et al.* Sources of Health Information
and Their Impacts on Medical Knowledge Perception Among the Saudi Arabian
Population: Cross-Sectional Study. *J Med Internet Res* 2020;**22**. doi:10.2196/14414
- 5 Vogel L. Viral misinformation threatens public health. *Can Med Assoc J*
2017;**189**:E1567–E1567. doi:10.1503/cmaj.109-5536
- 6 British Medical Journal. Health information on internet is often unreliable. *BMJ Br
Med J* 2000;**321**:136.
- 7 Silver MP. Patient perspectives on online health information and communication with
doctors: a qualitative study of patients 50 years old and over. *J Med Internet Res*
2015;**17**:e19–e19. doi:10.2196/jmir.3588
- 8 World Health Organization. Coronavirus disease 2019.
<https://www.who.int/emergencies/diseases/novel-coronavirus-2019> (accessed 30 Apr
2020).
- 9 World Health Organization. WHO announces COVID-19 outbreak a pandemic.
2020.<http://www.euro.who.int/en/health-topics/health-emergencies/coronavirus-covid-19/news/news/2020/3/who-announces-covid-19-outbreak-a-pandemic> (accessed 30
Apr 2020).
- 10 World Health Organization. COVID-19 Strategy Update. 2020.

- 1
2
3 [https://www.who.int/docs/default-source/coronaviruse/covid-strategy-update-](https://www.who.int/docs/default-source/coronaviruse/covid-strategy-update-14april2020.pdf?sfvrsn=29da3ba0_19)
4 [14april2020.pdf?sfvrsn=29da3ba0_19](https://www.who.int/docs/default-source/coronaviruse/covid-strategy-update-14april2020.pdf?sfvrsn=29da3ba0_19) (accessed 30 Apr 2020).
5
6
7
8 11 Feldmann H. Ebola — A Growing Threat? *N Engl J Med* 2014;**371**:1375–8.
9
10 doi:10.1056/NEJMp1405314
11
12 12 Odlum M, Yoon S. Health Information Needs and Health Seeking Behavior During the
13 2014-2016 Ebola Outbreak: A Twitter Content Analysis. *PLoS Curr* 2018;**10**.
14
15 doi:10.1371/currents.outbreaks.fa814fb2bec36e29b718ab6af66124fa
16
17
18 13 Gilbert D. Which countries are under lockdown - and is it working?
19
20 2020.[https://www.telegraph.co.uk/news/2020/04/16/countries-in-lockdown-denmark-](https://www.telegraph.co.uk/news/2020/04/16/countries-in-lockdown-denmark-germany/)
21 [germany/](https://www.telegraph.co.uk/news/2020/04/16/countries-in-lockdown-denmark-germany/) (accessed 30 Apr 2020).
22
23
24 14 British Broadcasting Company. Coronavirus lockdown protest: What's behind the US
25 demonstrations? - BBC News. 2020.[https://www.bbc.co.uk/news/world-us-canada-](https://www.bbc.co.uk/news/world-us-canada-52359100)
26 [52359100](https://www.bbc.co.uk/news/world-us-canada-52359100) (accessed 30 Apr 2020).
27
28
29
30 15 Elwyn G, O'Connor A, Stacey D, *et al*. Developing a quality criteria framework for
31 patient decision aids: online international Delphi consensus process. *Bmj-British Med*
32 *J* 2006;**333**:417–9. doi:10.1136/bmj.38926.629329.AE
33
34
35
36 16 Zuk G, Palma AF, Eylert G, *et al*. Systematic Review of Quality of Patient Information
37 on Liposuction in the Internet. *Plast Reconstr Surgery-Global Open* 2016;**4**.
38
39 doi:10.1097/gox.0000000000000798
40
41
42
43 17 Raptis DA, Sinanyan M, Ghani S, *et al*. Quality assessment of patient information on
44 the management of gallstone disease in the internet – A systematic analysis using the
45 modified ensuring quality information for patients tool. *HPB* 2019;**21**:1632–40.
46
47
48
49
50
51
52 18 McCool ME, Wahl J, Schlecht I, *et al*. Evaluating written patient information for
53 eczema in German: Comparing the reliability of two instruments, DISCERN and EQIP.
54
55 *PLoS One* 2015;**10**. doi:10.1371/journal.pone.0139895
56
57
58 19 Vetter D, Ruhwinkel H, Raptis DA, *et al*. Quality Assessment of Information on
59 Bariatric Surgery Websites. *Obes Surg* 2018;:1–8.
60

- 1
2
3 20 Zuk G, Reinisch KB, Raptis DA, *et al.* Dupuytren Disease: Is There Enough
4 Comprehensive Patient Information on the Internet? *Interact J Med Res* 2017;**6**:e7.
5
6 doi:10.2196/ijmr.7822
7
8
9 21 Frueh FS, Palma AF, Raptis DA, *et al.* Carpal tunnel syndrome: Analysis of online
10 patient information with the EQIP tool. *Chir Main* 2015;**34**:113–21.
11
12 doi:10.1016/j.main.2015.04.003
13
14
15 22 Palma AF, Zuk G, Raptis DA, *et al.* Quality of information for women seeking breast
16 augmentation in the Internet. *J Plast Surg Hand Surg* 2016;**50**:262–71.
17
18 doi:10.3109/2000656X.2016.1154469
19
20
21 23 Melloul E, Raptis DA, Oberkofler CE, *et al.* Donor information for living donor liver
22 transplantation: Where can comprehensive information be found? *Liver Transplant*
23 2012;**18**:892–900. doi:10.1002/lt.23442
24
25
26
27 24 Minervation. The LIDA Instrument Minervation validation instrument for health care
28 web sites Full Version (1.2) containing instructions. 2007.
29
30 www.minervation.com/validation (accessed 30 Apr 2020).
31
32
33 25 Coughler C, M Burke S, Cardy JO. Analysis of the quality of online resources for
34 parents of children who are late to talk. *Autism Dev Lang Impair*
35 2020;**5**:239694152091794. doi:10.1177/2396941520917940
36
37
38
39 26 Kher A, Johnson S, Griffith R. Readability assessment of online patient education
40 material on congestive heart failure. *Adv Prev Med* 2017;**2017**.
41
42
43
44 27 Corcelles R, Daigle CR, Talamas HR, *et al.* Assessment of the quality of Internet
45 information on sleeve gastrectomy. *Surg Obes Relat Dis* 2015;**11**:539–44.
46
47 doi:10.1016/j.soard.2014.08.014
48
49
50 28 Sobota A, Ozakinci G. The quality and readability of online consumer information
51 about gynecologic cancer. *Int J Gynecol Cancer* 2015;**25**:537–41.
52
53 doi:10.1097/IGC.0000000000000362
54
55
56 29 The eBusiness. Top 15 Best Search Engines | February 2020.
57
58
59
60 <http://www.ebizmba.com/articles/search-engines> (accessed 30 Apr 2020).

- 1
2
3 30 Search Engine Watch. Google Hits the Billion Monthly Unique Visitors Mark.
4
5 2011;**2020**.[https://www.searchenginewatch.com/2011/06/23/google-hits-the-billion-](https://www.searchenginewatch.com/2011/06/23/google-hits-the-billion-monthly-unique-visitors-mark/)
6
7 monthly-unique-visitors-mark/
8
9
10 31 Google. <https://www.google.com/> (accessed 30 Apr 2020).
11
12 32 Google. Google Ads - Get More Customers With Easy Online Advertising.
13
14 https://ads.google.com/intl/en_GB/home/ (accessed 30 Apr 2020).
15
16 33 Google. Google Trends. <https://trends.google.com/trends>
17
18 34 Moulton B, Franck LS, Brady H. Ensuring quality information for patients: development
19 and preliminary validation of a new instrument to improve the quality of written health
20 care information. *Health Expect* 2004;**7**:165–75. doi:10.1111/j.1369-
21 7625.2004.00273.x
22
23
24
25
26 35 Charvet-Berard AI, Chopard P, Perneger T V. Measuring quality of patient information
27 documents with an expanded EQIP scale. *Patient Educ Couns* 2008;**70**:407–11.
28 doi:10.1016/j.pec.2007.11.018
29
30
31
32 36 British Medical Association. BMA Patient Information Awards, .
33
34 2018;**2018**.<https://www.bma.org.uk/library/patient-information-awards>
35
36
37 37 International Patient Decision Aid Standards Collaboration. IPDAS Collaboration
38 Background Document. 2005;**2018**.http://ipdas.ohri.ca/IPDAS_Background.pdf
39
40
41 38 Silberg WM, Lundberg GD, Musacchio RA. Assessing, controlling, and assuring the
42 quality of medical information on the Internet: Caveant lector et viewer—Let the
43 reader and viewer beware. *JAMA* 1997;**277**:1244–5.
44
45
46
47 39 Janssen S, Fahlbusch FB, Kaesmann L, *et al*. Radiotherapy for prostate cancer:
48 DISCERN quality assessment of patient-oriented websites in 2018. *Bmc Urol*
49 2019;**19**. doi:10.1186/s12894-019-0474-4
50
51
52
53 40 Borgmann H, Wölm J-H, Vallo S, *et al*. Prostate Cancer on the Web—Expedient Tool
54 for Patients' Decision-Making? *J Cancer Educ* 2017;**32**:135–40.
55
56
57 41 Charnock D, Shepperd S, Needham G, *et al*. DISCERN: an instrument for judging the
58 quality of written consumer health information on treatment choices. 1998.
59
60

- 1
2
3 42 Nghiem AZ, Mahmoud Y, Som R. Evaluating the quality of internet information for
4 breast cancer. *Breast* 2016;**25**:34–7. doi:10.1016/j.breast.2015.10.001
5
6
7 43 Raptis DA. rBiostatistics.com (alpha version) | rBiostatistics.com.
8
9
10 https://www.rbiostatistics.com/ (accessed 30 Apr 2020).
11
12 44 Karamitros GA, Kitsos NA. Clefts of the lip and palate: is the Internet a trustworthy
13 source of information for patients? *Int J Oral Maxillofac Surg* 2018;**47**:1114–20.
14
15
16 doi:10.1016/j.ijom.2018.03.003
17
18 45 Sanger L. Wikipedia Policy.
19
20 2001.http://en.wikipedia.org/w/index.php?title=Wikipedia_policy&direction=next&oldid
21
22 =68263 (accessed 10 Jul 2020).
23
24 46 Som R, Gunawardana NP. Internet chemotherapy information is of good quality:
25 Assessment with the DISCERN tool. *Br J Cancer* 2012;**107**:403.
26
27
28 doi:10.1038/bjc.2012.223
29
30 47 Kaicker J, Debono VB, Dang W, *et al.* Assessment of the quality and variability of
31 health information on chronic pain websites using the DISCERN instrument. *BMC*
32
33
34 *Med* 2010;**8**:59. doi:10.1186/1741-7015-8-59
35
36
37 48 Jaffe J, Tonick S, Angell N. Quality of Web-Based Information on Epidural
38 Anesthesia. *Obstet Gynecol* 2014;**123**:115S.
39
40
41 doi:10.1097/01.aog.0000447063.32706.46
42
43 49 Sbaffi L, Rowley J. Trust and Credibility in Web-Based Health Information: A Review
44 and Agenda for Future Research. *J Med Internet Res* 2017;**19**. doi:10.2196/jmir.7579
45
46
47 50 World Health Organization. WHO | Novel Coronavirus – China.
48 2020.https://www.who.int/csr/don/12-january-2020-novel-coronavirus-china/en/
49
50
51 (accessed 30 Apr 2020).
52
53 51 World Health Organization. Statement on the second meeting of the International
54 Health Regulations (2005) Emergency Committee regarding the outbreak of novel
55 coronavirus (2019-nCoV). 2020.https://www.who.int/news-room/detail/30-01-2020-
56
57
58 statement-on-the-second-meeting-of-the-international-health-regulations-(2005)-
59
60

- 1
2
3 emergency-committee-regarding-the-outbreak-of-novel-coronavirus-(2019-ncov)
4
5 (accessed 30 Apr 2020).
6
7
8 52 COVID-19 Updates. <https://plos.org/covid-19/> (accessed 30 Apr 2020).
9
10 53 Elsevier. COVID-19 Update - Elsevier. [https://www.journals.elsevier.com/journal-of-](https://www.journals.elsevier.com/journal-of-critical-care/covid-19)
11 [critical-care/covid-19](https://www.journals.elsevier.com/journal-of-critical-care/covid-19) (accessed 30 Apr 2020).
12
13
14 54 Anesthesia & Analgesia. Call for Papers: Coronavirus Disease 2019 (COVID-19).
15 <https://journals.lww.com/anesthesia-analgesia/Pages/CFPCOVID19.aspx> (accessed
16 30 Apr 2020).
17
18
19
20 55 National Health Service Health Research Authority. COVID-19 research - Health
21 Research Authority. <https://www.hra.nhs.uk/covid-19-research/> (accessed 30 Apr
22 2020).
23
24
25
26 56 World Health Organization. COVID-19: Global literature on coronavirus disease.
27 <https://search.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/>
28 (accessed 30 Apr 2020).
29
30
31
32
33 57 Majumder MS, Mandl KD. Early in the epidemic: impact of preprints on global
34 discourse about COVID-19 transmissibility. *Lancet Glob Heal* 2020.
35
36
37 58 Pradhan P, Pandey AK, Mishra A, *et al*. Uncanny similarity of unique inserts in the
38 2019-nCoV spike protein to HIV-1 gp120 and Gag. *BioRxiv* 2020.
39
40
41 59 Liu DWC. Science Denial and the Science Classroom. *Cbe-Life Sci Educ*
42 2012;**11**:129–34. doi:10.1187/cbe.12-03-0029
43
44
45 60 Altmetric – Uncanny similarity of unique inserts in the 2019-nCoV spike protein to
46 HIV-1 gp120 and Gag. <https://www.altmetric.com/details/74957328> (accessed 30 Apr
47 2020).
48
49
50
51 61 Reisi M, Javadzade SH, Heydarabadi AB, *et al*. The relationship between functional
52 health literacy and health promoting behaviors among older adults. *J Educ Health*
53 *Promot* 2014;**3**:119. doi:10.4103/2277-9531.145925
54
55
56
57 62 Geboers B, Reijneveld SA, Jansen CJM, *et al*. Health Literacy Is Associated With
58 Health Behaviors and Social Factors Among Older Adults: Results from the LifeLines
59
60

- 1
2
3 Cohort Study. *J Health Commun* 2016;**21**:45–53.
4
5 doi:10.1080/10810730.2016.1201174
6
7 63 Husson O, Mols F, Fransen MP, *et al.* Low subjective health literacy is associated
8 with adverse health behaviors and worse health-related quality of life among
9 colorectal cancer survivors: Results from the profiles registry. *Psychooncology*
10 2015;**24**:478–86. doi:10.1002/pon.3678
11
12
13
14
15 64 Chesser AK, Keene Woods N, Smothers K, *et al.* Health Literacy and Older Adults.
16 *Gerontol Geriatr Med* 2016;**2**:233372141663049. doi:10.1177/2333721416630492
17
18
19 65 Bay JL, Vickers MH, Mora HA, *et al.* Adolescents as agents of healthful change
20 through scientific literacy development: A school-university partnership program in
21 New Zealand. *Int J STEM Educ* 2017;**4**. doi:10.1186/s40594-017-0077-0
22
23
24
25 66 Barel-ben David Y, Garty ES, Baram-tsabari A. Can scientists fill the science
26 journalism void ? Online public engagement with science stories authored by
27 scientists. 2020;:1–15.
28
29
30
31
32 67 Lazer BDMJ, Baum MA, Benkler Y, *et al.* The science of fake news. 2018.
33
34
35 68 Longo DR. Understanding health information, communication, and information
36 seeking of patients and consumers: a comprehensive and integrated model. *Heal*
37 *Expect* 2005;**8**:189–94.
38
39
40
41 69 Keshvari M, Yamani N, Adibi P, *et al.* Health journalism: Health reporting status and
42 challenges. *Iran J Nurs Midwifery Res* 2018;**23**:14.
43
44
45 70 Schwitzer G. How do US journalists cover treatments, tests, products, and
46 procedures? An evaluation of 500 stories. *PLoS Med* 2008;**5**.
47
48
49 71 Larsson A, Oxman AD, Carling C, *et al.* Medical messages in the media—barriers and
50 solutions to improving medical journalism. *Heal Expect* 2003;**6**:323–31.
51
52
53 72 Cattani M. Global coalition to accelerate COVID-19 clinical research in resource-
54 limited settings. *Lancet* 2020.
55
56
57 73 ST. George's University of London. 3 April: 2020 Covid-19 response — our role in
58 tackling the pandemic. <https://www.sgul.ac.uk/news/alerts/bulletins/3-april-2020>
59
60

- (accessed 30 Apr 2020).
- 74 Saey Tina Hesman. Repurposed drugs may help scientists fight the new coronavirus. 2020. doi:10.1101/2020.01.28.922922V2
- 75 Kowitt SD, Schmidt AM, Hannan A, *et al.* Awareness and trust of the FDA and CDC: Results from a national sample of US adults and adolescents. *PLoS One* 2017;**12**.
- 76 Bish A, Yardley L, Nicoll A, *et al.* Factors associated with uptake of vaccination against pandemic influenza: a systematic review. *Vaccine* 2011;**29**:6472–84.
- 77 Whetten K, Leserman J, Whetten R, *et al.* Exploring lack of trust in care providers and the government as a barrier to health service use. *Am J Public Health* 2006;**96**:716–21.
- 78 Quinn SC, Parmer J, Freimuth VS, *et al.* Exploring communication, trust in government, and vaccination intention later in the 2009 H1N1 pandemic: results of a national survey. *Biosecurity bioterrorism biodefense Strateg Pract Sci* 2013;**11**:96–106.
- 79 Sadah SA, Shahbazi M, Wiley MT, *et al.* Demographic-based content analysis of web-based health-related social media. *J Med Internet Res* 2016;**18**:e148.
- 80 Sadah SA, Shahbazi M, Wiley MT, *et al.* A study of the demographics of web-based health-related social media users. *J Med Internet Res* 2015;**17**:e194.
- 81 World Health Organization. Myth busters. <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/advice-for-public/myth-busters> (accessed 30 Apr 2020).
- 82 Smith D. Coronavirus: medical experts denounce Trump’s theory of ‘disinfectant injection’ | World news | The Guardian. 2020.<https://www.theguardian.com/world/2020/apr/23/trump-coronavirus-treatment-disinfectant> (accessed 30 Apr 2020).
- 83 Zhao Y, Zhang J. Consumer health information seeking in social media: a literature review. *Health Info Libr J* 2017;**34**:268–83. doi:10.1111/hir.12192

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Table 1. Website demographic and background information

| Type | Total (n,%) | Treatment (n,%) | Prevention (n,%) | Treatment and Prevention (n,%) |
|------------------------------|--------------|-----------------|------------------|--------------------------------|
| Academic Centre | 10 (3.12%) | 1 (0.31%) | 4 (1.25%) | 5 (1.56%) |
| Charity/NGO | 12 (3.74%) | 1 (0.31%) | 9 (2.8%) | 2 (0.62%) |
| Encyclopaedia | 5 (1.56%) | 0 (0%) | 1 (0.31%) | 4 (1.25%) |
| Government/Health Department | 87 (27.10%) | 1 (0.31%) | 65 (20.25%) | 21 (6.54%) |
| Hospital | 7 (2.18%) | 0 (0%) | 5 (1.56%) | 2 (0.62%) |
| Industry | 30 (9.35%) | 8 (2.49%) | 10 (3.12%) | 12 (3.74%) |
| Military | 1 (0.31%) | 0 (0%) | 1 (0.31%) | 0 (0%) |
| News Service | 163 (50.78%) | 34 (10.59%) | 102 (31.78%) | 27 (8.41%) |
| Patient group | 1 (0.10%) | 1 (0.31%) | 0 (0%) | 0 (0%) |
| Professional society | 4 (1.25%) | 0 (0%) | 4 (1.25%) | 0 (0%) |
| Research Centre | 1 (0.31%) | 0 (0%) | 1 (0.31%) | 0 (0%) |
| Total | 321 | 46 (14.33%) | 202 (62.93%) | 73 (22.74%) |

Table 2. Overall quality of information of all sources of information

| Indicator/ (Mean, SD) | Academic centre | Charity/N GO | Encyclop aedia | Governm ent/Healt h Departme nt | Hospital | Industry | Military | News Service | Patient group | Professio nal society | Research Centre | P Value |
|-----------------------------|--------------------|-----------------|-------------------|--|----------|----------|----------|-----------------|------------------|-----------------------------|--------------------|---------|
|-----------------------------|--------------------|-----------------|-------------------|--|----------|----------|----------|-----------------|------------------|-----------------------------|--------------------|---------|

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

| | | | | | | | | | | | | |
|---------------------|------------------|-----------------|-----------------|-----------------|-----------------|------------------|-----------|------------------|-----------|----------------|-----------|--------|
| EQIP Content | 7.70 (2.50) | 6.75 (3.33) | 10.80 (3.11) | 8.11 (2.49) | 7.14 (2.19) | 7.13 (2.60) | 5.00 (0) | 6.22 (2.11) | 10.00 (0) | 5.50 (3) | 5.00 (0) | <0.001 |
| EQIP Identification | 2.90 (1.20) | 3.08 (0.90) | 4.80 (0.45) | 3.44 (1.03) | 2.71 (1.38) | 3.4 (1.13) | 1.00 (0) | 3.62 (0.73) | 3.00 (0) | 4.00 (0) | 4.00 (0) | 0.003 |
| EQIP Structure | 7.90 (1.85) | 7.67 (1.30) | 8.60 (1.67) | 7.34 (1.45) | 7.43 (0.98) | 6.97 (1.83) | 9.00 (0) | 7.22 (1.39) | 10.00 (0) | 7.25 (0.5) | 5.00 (0) | 0.08 |
| EQIP Total | 18.50 (3.66) | 17.50 (4.32) | 24.20 (3.56) | 18.9 (3.79) | 17.29 (3.50) | 17.5 (4.48) | 15.00 (0) | 17.06 (3.19) | 23.00 (0) | 16.75 (3.4) | 14.00 (0) | <0.001 |
| JAMA Total | 2.50 (0.97) | 2.50 (1.00) | 3.40 (0.55) | 2.16 (0.86) | 2.14 (1.57) | 2.73 (1.23) | 1.00 (0) | 2.98 (0.85) | 3.00 (0) | 3.50 (0.58) | 3.00 (0) | <0.001 |
| DISCERN Reliability | 27.20 (6.78) | 26.25 (6.51) | 35.60 (4.77) | 27.47 (5.96) | 29.86 (5.58) | 26.6 (7.46) | 23.00 (0) | 26.31 (6.3) | 27.00 (0) | 29.50 (4.2) | 26.00 (0) | 0.128 |
| DISCERN Treatment | 13.00 (6.70) | 9.42 (2.39) | 16.00 (9.30) | 9.02 (3.14) | 8.71 (1.89) | 13.33 (6.39) | 8.00 (0) | 11.72 (6.22) | 13.00 (0) | 8.50 (1) | 17.00 (0) | 0.001 |
| DISCERN Total | 40.20 (10.38) | 35.67 (7.67) | 51.60 (12.3) | 36.49 (7.50) | 38.57 (5.47) | 39.93 (10.45) | 31.00 (0) | 38.04 (10.44) | 40.00 (0) | 38.00 (5.1) | 43.00 (0) | 0.167 |

Table 3. Overall quality of information of all websites subsets

| Indicator/(Mean, SD) | Overall | Treatment | Prevention | Treatment and Prevention | P Value |
|----------------------|---------|-----------|------------|--------------------------|---------|
|----------------------|---------|-----------|------------|--------------------------|---------|

| | | | | | |
|---------------------|--------------|---------------|--------------|---------------|--------|
| EQIP Content | 6.97 (2.52) | 6.26 (1.81) | 6.55 (2.30) | 8.58 (2.84) | <0.001 |
| EQIP Identification | 3.50 (0.93) | 3.87 (0.72) | 3.32 (0.97) | 3.78 (0.80) | <0.001 |
| EQIP Structure | 7.30 (1.47) | 6.76 (1.46) | 7.25 (1.46) | 7.79 (1.37) | <0.001 |
| EQIP Total | 17.78 (3.71) | 16.89 (2.84) | 17.12 (3.45) | 20.15 (3.95) | <0.001 |
| JAMA Total | 2.69 (0.98) | 3.13 (0.72) | 2.53 (1.05) | 2.85 (0.84) | 0.001 |
| DISCERN Reliability | 26.93 (6.35) | 26.98 (6.92) | 26.04 (5.72) | 29.37 (7.04) | <0.001 |
| DISCERN Treatment | 11.07 (5.60) | 18.09 (6.04) | 8.60 (2.45) | 13.47 (6.73) | <0.001 |
| DISCERN Total | 38.00 (9.61) | 45.07 (11.67) | 34.64 (6.52) | 42.84 (10.93) | <0.001 |

Table 4. Comparison between Government and News Services

| Indicator | Global (USA inclusive) (n=250) | USA (n=121) |
|-----------|--------------------------------|-------------|
|-----------|--------------------------------|-------------|

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

| | Government Mean Score | Government Mean Rank | News Mean Score | News Mean Rank | P Value | Government Mean Score | Government Mean Rank | News Mean Score | News Mean Rank | P Value |
|---------------------|-----------------------|----------------------|-----------------|----------------|---------|-----------------------|----------------------|-----------------|----------------|---------|
| EQIP Content | 8.11 | 161.34 | 6.22 | 106.37 | <0.001 | 7.66 | 75.80 | 6.17 | 54.22 | 0.002 |
| EQIP Identification | 3.44 | 118.28 | 3.62 | 129.35 | 0.207 | 3.34 | 50.29 | 3.78 | 65.90 | 0.011 |
| EQIP Structure | 7.34 | 129.90 | 7.22 | 123.15 | 0.464 | 7.55 | 67.54 | 7.08 | 58.01 | 0.148 |
| EQIP Total | 18.90 | 151.52 | 17.06 | 111.61 | <0.001 | 18.55 | 71.21 | 17.04 | 56.33 | 0.029 |
| JAMA Total | 2.16 | 85.72 | 2.98 | 146.73 | <0.001 | 2.03 | 34.28 | 3.17 | 73.23 | <0.001 |
| DISCERN Reliability | 27.47 | 137.15 | 26.31 | 119.28 | 0.062 | 26.53 | 60.26 | 26.66 | 61.34 | 0.876 |
| DISCERN Treatment | 9.02 | 110.95 | 11.72 | 133.27 | 0.001 | 8.84 | 47.99 | 12.59 | 66.96 | 0.001 |

| | | | | | | | | | | |
|---------------|-------|--------|-------|--------|-------|-------|-------|-------|-------|-------|
| DISCERN Total | 36.49 | 105.32 | 38.04 | 136.27 | 0.963 | 35.37 | 54.72 | 39.25 | 63.87 | 0.182 |
|---------------|-------|--------|-------|--------|-------|-------|-------|-------|-------|-------|

Table 5. Top 5 websites based on EQIP and DISCERN scores

| URL | Country | Treatment Prevention | or | Total EQIP | Total JAMA | Total DISCERN |
|---|--------------------------|-------------------------|----|------------|------------|---------------|
| Top Scoring EQIP Sites | | | | | | |
| https://www.gov.je/health/coronavirus/Pages/index.aspx | Channel Islands (Jersey) | Both | | 29 | 3 | 49 |
| https://en.wikipedia.org/wiki/2019%E2%80%9320_coronavirus_pandemic | USA | Both | | 28 | 3 | 61 |
| https://www.health.nsw.gov.au/Infectious/alerts/Pages/coronavirus-faqs.aspx | Australia | Both | | 28 | 3 | 46 |
| https://www.ageuk.org.uk/information-advice/coronavirus/coronavirus/# | UK | Both | | 27 | 3 | 48 |
| https://www.wikihow.com/Prevent-Coronavirus | USA | Prevention only | | 27 | 4 | 46 |
| Top Scoring DISCERN Sites | | | | | | |
| https://www.sciencenews.org/article/coronavirus-covid19-repurposed-treatments-drugs | USA | Treatment only | | 22 | 4 | 75 |
| https://www.vox.com/science-and-health/2020/3/4/21154590/coronavirus-vaccine-treatment-covid-19-drug-cure | USA | Both | | 22 | 4 | 74 |

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

| | | | | | |
|---|-----|----------------|----|---|----|
| https://en.wikipedia.org/wiki/Coronavirus_disease_2019 | USA | Both | 25 | 3 | 68 |
| https://www.bloomberg.com/news/articles/2020-03-25/hydroxychloroquine-no-better-than-regular-covid-19-care-in-study | USA | Treatment only | 21 | 3 | 65 |
| https://www.theverge.com/2020/2/4/21122327/coronavirus-experimental-medication-treatment-wuhan-china-gilead-hiv | USA | Treatment only | 18 | 4 | 64 |

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1. Popular Search Terms

99x123mm (300 x 300 DPI)




Figure 2. Workflow of Webscraping and Exclusion

70x55mm (300 x 300 DPI)




Figure 3. Country of origin of websites

132x79mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 4. Scores by top contributing countries
63x94mm (300 x 300 DPI)




Figure 5. High-score distribution

60x94mm (300 x 300 DPI)

| Item | | Overall number of websites (n, %) | High-scoring websites (n, %) | Low-scoring websites (n, %) | OR |
|---|-----|-----------------------------------|------------------------------|-----------------------------|--------|
| Modified EQIP Content Data | | | | | |
| 1. Initial definition of which subjects will be | Yes | 274 (85.36%) | 71 (95.95%) | 203 (82.19%) | 5.102 |
| | No | 47 (14.64%) | 3 (4.05%) | 44 (17.81%) | |
| 2. Coverage of the previously defined | Yes | 273 (85.05%) | 71 (95.95%) | 202 (81.78%) | 3.509 |
| | No | 48 (14.95%) | 3 (4.05%) | 45 (18.22%) | |
| 3. Description of the medical | Yes | 251 (78.19%) | 73 (98.65%) | 178 (72.06%) | 5.882 |
| | No | 70 (21.81%) | 1 (1.35%) | 69 (27.94%) | |
| 4. Definition of the purpose of the | Yes | 216 (67.29%) | 67 (90.54%) | 149 (60.32%) | 27.778 |
| | No | 105 (32.71%) | 7 (9.46%) | 98 (39.68%) | |
| 5. Description of treatment alternatives | Yes | 82 (25.55%) | 40 (54.05%) | 42 (17%) | 6.250 |
| | No | 239 (74.45%) | 34 (45.95%) | 205 (83%) | |
| 6. Description of the sequence of the | Yes | 51 (15.89%) | 26 (35.14%) | 25 (10.12%) | 4.785 |
| | No | 270 (84.11%) | 48 (64.86%) | 222 (89.88%) | |
| 7. Description of the qualitative benefits for | Yes | 114 (35.51%) | 46 (62.16%) | 68 (27.53%) | 4.310 |
| | No | 207 (64.49%) | 28 (37.84%) | 179 (72.47%) | |
| 8. Description of the quantitative benefits to | Yes | 9 (2.8%) | 3 (4.05%) | 6 (2.43%) | 1.695 |
| | No | 312 (97.2%) | 71 (95.95%) | 241 (97.57%) | |
| 9. Description of the qualitative risks and | Yes | 49 (15.26%) | 25 (33.78%) | 24 (9.72%) | 4.717 |
| | No | 272 (84.74%) | 49 (66.22%) | 223 (90.28%) | |
| 10. Description of the quantitative risks and | Yes | 3 (0.93%) | 3 (4.05%) | 0 (0%) | - |
| | No | 318 (99.07%) | 71 (95.95%) | 247 (100%) | |
| 11. Addressing quality-of-life issues | Yes | 137 (42.68%) | 58 (78.38%) | 79 (31.98%) | 7.634 |
| | No | 184 (57.32%) | 16 (21.62%) | 168 (68.02%) | |
| 12. Description of how complications are | Yes | 35 (10.9%) | 20 (27.03%) | 15 (6.07%) | 5.682 |
| | No | 286 (89.1%) | 54 (72.97%) | 232 (93.93%) | |
| 13. Description of the precautions that the | Yes | 265 (82.55%) | 70 (94.59%) | 195 (78.95%) | 4.651 |
| | No | 56 (17.45%) | 4 (5.41%) | 52 (21.05%) | |
| 14. Mention of alert signs that the patient | Yes | 212 (66.04%) | 66 (89.19%) | 146 (59.11%) | 5.682 |
| | No | 109 (33.96%) | 8 (10.81%) | 101 (40.89%) | |
| 15. Addressing medical intervention costs and | Yes | 68 (21.18%) | 31 (41.89%) | 37 (14.98%) | 3.968 |
| | No | 253 (78.82%) | 43 (58.11%) | 210 (85.02%) | |
| 16. Specific contact details for hospital | Yes | 10 (3.12%) | 3 (4.05%) | 7 (2.83%) | - |
| | No | 311 (96.88%) | 71 (95.95%) | 240 (97.17%) | |

| | | | | | |
|---|-----|--------------|-------------|--------------|-------|
| 17. Specific details of other sources of reliable | Yes | 185 (57.63%) | 62 (83.78%) | 123 (49.8%) | 5.181 |
| | No | 136 (42.37%) | 12 (16.22%) | 124 (50.2%) | |
| 18. Coverage of all relevant issues for the | Yes | 4 (1.25%) | 4 (5.41%) | 0 (0%) | - |
| | No | 317 (98.75%) | 70 (94.59%) | 247 (100%) | |
| Modified EQIP Identification Data | | | | | |
| 19. Date of issue or revision | Yes | 280 (87.23%) | 69 (93.24%) | 211 (85.43%) | 2.347 |
| | No | 41 (12.77%) | 5 (6.76%) | 36 (14.57%) | |
| 20. Logo of the issuing body | Yes | 317 (98.75%) | 74 (100%) | 243 (98.38%) | - |
| | No | 4 (1.25%) | 0 (0%) | 4 (1.62%) | |
| 21. Names of the persons or entities that | Yes | 254 (79.13%) | 61 (82.43%) | 193 (78.14%) | 1.312 |
| | No | 67 (20.87%) | 13 (17.57%) | 54 (21.86%) | |
| 22. Names of the persons or entities that | Yes | 210 (65.42%) | 62 (83.78%) | 148 (59.92%) | 3.448 |
| | No | 111 (34.58%) | 12 (16.22%) | 99 (40.08%) | |
| 23. Short bibliography of the evidence-based data | Yes | 60 (18.69%) | 31 (41.89%) | 29 (11.74%) | 5.376 |
| | No | 261 (81.31%) | 43 (58.11%) | 218 (88.26%) | |
| 24. Statement about whether and how | Yes | 3 (0.93%) | 1 (1.35%) | 2 (0.81%) | 1.675 |
| | No | 318 (99.07%) | 73 (98.65%) | 245 (99.19%) | |
| Modified EQIP Structure Data | | | | | |
| 25. Use of everyday language and | Yes | 3 (0.93%) | 72 (97.3%) | 229 (92.71%) | 2.825 |
| | No | 318 (99.07%) | 2 (5.41%) | 18 (25.35%) | |
| 26. Use of generic names for all medications or | Yes | 88 (27.41%) | 35 (47.3%) | 53 (21.46%) | 1.838 |
| | No | 233 (44.05%) | 39 (35.14%) | 194 (46.41%) | |
| 27. Use of short sentences (<15 words on | Yes | 296 (92.21%) | 72 (97.3%) | 224 (90.69%) | 3.690 |
| | No | 25 (9.47%) | 2 (2.99%) | 23 (11.68%) | |
| 28. Personal address to the reader | Yes | 239 (74.45%) | 65 (87.84%) | 174 (70.45%) | 3.021 |
| | No | 82 (21.03%) | 9 (10.98%) | 73 (23.7%) | |
| 29. Respectful tone | Yes | 308 (95.95%) | 73 (98.65%) | 235 (95.14%) | 3.717 |
| | No | 13 (4.22%) | 1 (1.35%) | 12 (5.13%) | |
| 30. Clear information (no ambiguities or | Yes | 295 (91.9%) | 73 (98.65%) | 222 (89.88%) | 8.197 |
| | No | 26 (31.71%) | 1 (3.33%) | 25 (48.08%) | |
| 31. Balanced information on risks and benefits | Yes | 56 (17.45%) | 29 (39.19%) | 27 (10.93%) | 5.208 |
| | No | 265 (47.58%) | 45 (37.82%) | 220 (50.23%) | |
| 32. Presentation of information in a logical | Yes | 292 (90.97%) | 74 (100%) | 218 (88.26%) | - |
| | No | 29 (9.12%) | 0 (0%) | 29 (11.84%) | |

| | | | | | |
|---|-----|--------------|-------------|--------------|--------|
| 33. Satisfactory design and layout (excluding | Yes | 289 (90.03%) | 73 (98.65%) | 216 (87.45%) | 10.417 |
| | No | 32 (22.38%) | 1 (2.33%) | 31 (31%) | |
| 34. Clear and relevant figures or graphs (NA if | Yes | 111 (34.58%) | 42 (56.76%) | 69 (27.94%) | 12.987 |
| | No | 210 (75.27%) | 32 (65.31%) | 178 (77.39%) | |
| 35. Inclusion of a named space for the reader's | Yes | 69 (21.5%) | 17 (22.97%) | 52 (21.05%) | 1.119 |
| | No | 252 (100%) | 57 (100%) | 195 (100%) | |
| 36. Inclusion of a printed consent form contrary to | Yes | 0 (0%) | 0 (0%) | 0 (0%) | - |
| | No | 321 (100%) | 74 (100%) | 247 (100%) | |

*Some data is omitted due to odds ratio and confidence interval being infinite values

For peer review only

| 95% CI | P Value |
|------------------|---------|
| | |
| 1.560 - 26.316 | 0.002 |
| 0.483 - 166.667 | 0.300 |
| 3.215 - 10.870 | <0.001 |
| 4.695 - 1000.000 | <0.001 |
| 2.725 - 16.949 | <0.001 |
| 2.427 - 9.434 | <0.001 |
| 2.416 - 7.752 | <0.001 |
| 0.267 - 8.197 | 0.436 |
| 2.370 - 9.434 | <0.001 |
| - | 0.012 |
| 4.032 - 15.152 | <0.001 |
| 2.584 - 12.821 | <0.001 |
| 1.621 - 18.519 | 0.001 |
| 2.571 - 14.286 | <0.001 |
| 2.137 - 7.407 | <0.001 |
| - | 0.228 |

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

| | |
|-----------------|--------|
| 2.604 - 11.111 | <0.001 |
| - | 0.003 |
| | |
| 0.870 - 8.000 | 0.110 |
| - | 0.577 |
| 0.652 - 2.801 | 0.515 |
| 1.727 - 7.407 | <0.001 |
| 1.727 - 7.407 | <0.001 |
| 1.727 - 7.407 | 0.546 |
| | |
| 0.650 - 25.64 | 0.181 |
| 0.561 - 7.143 | 0.309 |
| 0.875 - 33.333 | 0.082 |
| 1.401 - 7.299 | 0.002 |
| 0.533 - 166.667 | 0.312 |
| 1.294 - 333.333 | 0.013 |
| 2.703 - 10.101 | <0.001 |
| - | 0.001 |

For peer review only

| | |
|-----------------|--------|
| 1.675 - 500.000 | 0.003 |
| 3.086 - 111.111 | <0.001 |
| 0.561 - 2.151 | 0.748 |
| - | - |

For peer review only

| Item | | Overall number of websites (n, %) | High-scoring websites (n, %) | Low-scoring websites (n,%) |
|---|-----|-----------------------------------|------------------------------|----------------------------|
| JAMA Benchmark | | | | |
| 1. Authorship: Authors and contributors, their affiliations, | Yes | 183 (57.01%) | 74 (100%) | 109 (44.13%) |
| | No | 138 (42.99%) | 0 (0%) | 138 (55.87%) |
| 2. Attribution: References and sources for all content should | Yes | 118 (36.76%) | 74 (100%) | 44 (17.81%) |
| | No | 203 (63.24%) | 0 (0%) | 203 (82.19%) |
| 3. Disclosure: Web site "ownership", sponsorship, funding arrangements or | Yes | 287 (89.41%) | 74 (100%) | 213 (86.23%) |
| | No | 34 (10.59%) | 0 (0%) | 34 (13.77%) |
| 4. Currency: Dates that content was posted and updated | Yes | 276 (85.98%) | 74 (100%) | 202 (81.78%) |
| | No | 45 (14.02%) | 0 (0%) | 45 (18.22%) |

*Some data is omitted due to odds ratio and confidence interval being inf

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

| OR | 95% CI | P Value |
|---------------|--------|---------|
| - | - | <0.001 |
| - | - | <0.001 |
| - | - | <0.001 |
| - | - | <0.001 |
| finite values | | |

| Item | Score | Overall number of websites (n, %) | High-scoring websites (n,%) | Low-scoring websites (n,%) |
|--|-------|-----------------------------------|-----------------------------|----------------------------|
| DISCERN Reliability | | | | |
| 1. Are the aims clear? | 1 | 6 (1.87%) | 0 (0%) | 6 (2.45%) |
| | 2 | 16 (4.98%) | 2 (2.63%) | 14 (5.71%) |
| | 3 | 39 (12.15%) | 9 (11.84%) | 30 (12.24%) |
| | 4 | 51 (15.89%) | 6 (7.89%) | 45 (18.37%) |
| | 5 | 209 (65.11%) | 59 (77.63%) | 150 (61.22%) |
| 2. Does it achieve its aims | 1 | 7 (2.18%) | 0 (0%) | 7 (2.86%) |
| | 2 | 18 (5.61%) | 4 (5.26%) | 14 (5.71%) |
| | 3 | 45 (14.02%) | 10 (13.16%) | 35 (14.29%) |
| | 4 | 57 (17.76%) | 8 (10.53%) | 49 (20%) |
| | 5 | 194 (60.44%) | 54 (71.05%) | 140 (57.14%) |
| 3. Is it relevant? | 1 | 4 (1.25%) | 0 (0%) | 4 (1.63%) |
| | 2 | 17 (5.3%) | 3 (3.95%) | 14 (5.71%) |
| | 3 | 42 (13.08%) | 14 (18.42%) | 28 (11.43%) |
| | 4 | 64 (19.94%) | 3 (3.95%) | 61 (24.9%) |
| | 5 | 194 (60.44%) | 56 (73.68%) | 138 (56.33%) |
| 4. Is it clear what sources of information were used to compile the publication (other than the author or producer)? | 1 | 68 (21.18%) | 3 (3.95%) | 65 (26.53%) |
| | 2 | 67 (20.87%) | 3 (3.95%) | 64 (26.12%) |
| | 3 | 72 (22.43%) | 14 (18.42%) | 58 (23.67%) |
| | 4 | 48 (14.95%) | 15 (19.74%) | 33 (13.47%) |
| | 5 | 66 (20.56%) | 41 (53.95%) | 25 (10.2%) |
| 5. Is it clear when the information used or reported in the publication was produced? | 1 | 83 (25.86%) | 2 (2.63%) | 81 (33.06%) |
| | 2 | 78 (24.3%) | 12 (15.79%) | 66 (26.94%) |
| | 3 | 88 (27.41%) | 28 (36.84%) | 60 (24.49%) |
| | 4 | 36 (11.21%) | 11 (14.47%) | 25 (10.2%) |
| | 5 | 36 (11.21%) | 23 (30.26%) | 13 (5.31%) |
| 6. Is it balanced and unbiased? | 1 | 24 (7.48%) | 4 (5.26%) | 20 (8.16%) |
| | 2 | 65 (20.25%) | 16 (21.05%) | 49 (20%) |
| | 3 | 146 (45.48%) | 33 (43.42%) | 113 (46.12%) |
| | 4 | 69 (21.5%) | 14 (18.42%) | 55 (22.45%) |
| | 5 | 17 (5.3%) | 9 (11.84%) | 8 (3.27%) |
| | 1 | 77 (23.99%) | 4 (5.26%) | 73 (29.8%) |

| | | | | |
|--|---|--------------|-------------|--------------|
| 7. Does it provide details of additional sources of support and information? | 2 | 64 (19.94%) | 15 (19.74%) | 49 (20%) |
| | 3 | 62 (19.31%) | 19 (25%) | 43 (17.55%) |
| | 4 | 58 (18.07%) | 17 (22.37%) | 41 (16.73%) |
| | 5 | 60 (18.69%) | 21 (27.63%) | 39 (15.92%) |
| 8. Does it refer to areas of uncertainty? | 1 | 99 (30.84%) | 14 (18.42%) | 85 (34.69%) |
| | 2 | 61 (19%) | 15 (19.74%) | 46 (18.78%) |
| | 3 | 75 (23.36%) | 24 (31.58%) | 51 (20.82%) |
| | 4 | 44 (13.71%) | 10 (13.16%) | 34 (13.88%) |
| | 5 | 42 (13.08%) | 13 (17.11%) | 29 (11.84%) |
| DISCERN Quality and Overall rating | | | | |
| 9. Does it describe how each treatment works? | 1 | 250 (77.88%) | 52 (68.42%) | 198 (80.82%) |
| | 2 | 24 (7.48%) | 8 (10.53%) | 16 (6.53%) |
| | 3 | 18 (5.61%) | 4 (5.26%) | 14 (5.71%) |
| | 4 | 13 (4.05%) | 6 (7.89%) | 7 (2.86%) |
| | 5 | 16 (4.98%) | 6 (7.89%) | 10 (4.08%) |
| 10. Does it describe the benefits of each treatment? | 1 | 247 (76.95%) | 52 (68.42%) | 195 (79.59%) |
| | 2 | 20 (6.23%) | 6 (7.89%) | 14 (5.71%) |
| | 3 | 26 (8.1%) | 6 (7.89%) | 20 (8.16%) |
| | 4 | 20 (6.23%) | 7 (9.21%) | 13 (5.31%) |
| | 5 | 8 (2.49%) | 5 (6.58%) | 3 (1.22%) |
| 11. Does it describe the risks of each treatment? | 1 | 281 (87.54%) | 60 (78.95%) | 221 (90.2%) |
| | 2 | 18 (5.61%) | 6 (7.89%) | 12 (4.9%) |
| | 3 | 17 (5.3%) | 7 (9.21%) | 10 (4.08%) |
| | 4 | 3 (0.93%) | 1 (1.32%) | 2 (0.82%) |
| | 5 | 2 (0.62%) | 2 (2.63%) | 0 (0%) |
| 12. Does it describe what would happen if no treatment is used? | 1 | 283 (88.16%) | 61 (80.26%) | 222 (90.61%) |
| | 2 | 15 (4.67%) | 6 (7.89%) | 9 (3.67%) |
| | 3 | 13 (4.05%) | 5 (6.58%) | 8 (3.27%) |
| | 4 | 7 (2.18%) | 2 (2.63%) | 5 (2.04%) |
| | 5 | 3 (0.93%) | 2 (2.63%) | 1 (0.41%) |
| 13. Does it describe how the treatment choices affect overall quality of life? | 1 | 289 (90.03%) | 62 (81.58%) | 227 (92.65%) |
| | 2 | 13 (4.05%) | 5 (6.58%) | 8 (3.27%) |
| | 3 | 14 (4.36%) | 8 (10.53%) | 6 (2.45%) |
| | 4 | 2 (0.62%) | 0 (0%) | 2 (0.82%) |

| | | | | |
|--|---|--------------|-------------|--------------|
| | 5 | 3 (0.93%) | 1 (1.32%) | 2 (0.82%) |
| 14. Is it clear that there may be more than one possible treatment choice? | 1 | 240 (74.77%) | 52 (68.42%) | 188 (76.73%) |
| | 2 | 18 (5.61%) | 5 (6.58%) | 13 (5.31%) |
| | 3 | 24 (7.48%) | 6 (7.89%) | 18 (7.35%) |
| | 4 | 10 (3.12%) | 2 (2.63%) | 8 (3.27%) |
| | 5 | 29 (9.03%) | 11 (14.47%) | 18 (7.35%) |
| 15. Does it provide support for shared decision-making? | 1 | 262 (81.62%) | 59 (77.63%) | 203 (82.86%) |
| | 2 | 13 (4.05%) | 7 (9.21%) | 6 (2.45%) |
| | 3 | 35 (10.9%) | 4 (5.26%) | 31 (12.65%) |
| | 4 | 3 (0.93%) | 2 (2.63%) | 1 (0.41%) |
| | 5 | 8 (2.49%) | 4 (5.26%) | 4 (1.63%) |
| 16. Based on the answers to all of the above questions, rate the overall quality of the publication as a source of information about | 1 | 241 (75.08%) | 52 (68.42%) | 189 (77.14%) |
| | 2 | 48 (14.95%) | 12 (15.79%) | 36 (14.69%) |
| | 3 | 25 (7.79%) | 8 (10.53%) | 17 (6.94%) |
| | 4 | 7 (2.18%) | 4 (5.26%) | 3 (1.22%) |
| | 5 | 0 (0%) | 0 (0%) | 0 (0%) |

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

| P Value |
|---------|
| |
| 0.321 |
| 0.246 |
| 0.032 |
| 0.019 |
| 0.007 |
| <0.001 |
| |

For peer review only

| | |
|----|--------|
| 1 | |
| 2 | |
| 3 | 0.093 |
| 4 | |
| 5 | |
| 6 | |
| 7 | |
| 8 | <0.001 |
| 9 | |
| 10 | |
| 11 | |
| 12 | |
| 13 | |
| 14 | |
| 15 | 0.005 |
| 16 | |
| 17 | |
| 18 | |
| 19 | |
| 20 | |
| 21 | <0.001 |
| 22 | |
| 23 | |
| 24 | |
| 25 | |
| 26 | |
| 27 | 0.016 |
| 28 | |
| 29 | |
| 30 | |
| 31 | |
| 32 | |
| 33 | <0.001 |
| 34 | |
| 35 | |
| 36 | |
| 37 | |
| 38 | |
| 39 | <0.001 |
| 40 | |
| 41 | |

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

| |
|--------|
| |
| <0.001 |
| <0.001 |
| <0.001 |

For peer review only


| URL | Country | Original search term | Texas, USA March | Texas, USA July | London, UK July | Toronto, C |
|---|-----------|------------------------------------|------------------|-----------------|-----------------|------------|
| Top Scoring EQIP Sites | | | | | | |
| https://www.gov.ie/health | UK | What is self isolation coronavirus | Page 4 | None | None | No |
| https://en.wikipedia.org/ | USA | Coronavirus | Page 1 | None | None | No |
| https://www.health.nsw.gov.au/ | Australia | Covid 19 | Page 10 | Page 4 | None | No |
| https://www.ageuk.org.uk/ | UK | Stop getting coronavirus | Page 6 | Page 4 | Page 2 | No |
| https://www.wikihow.co | USA | Stop getting coronavirus | Page 10 | None | None | No |
| Top Scoring DISCERN Sites | | | | | | |
| https://www.sciencenews.org/ | USA | How to treat coronavirus | Page 10 | None | None | No |
| https://www.vox.com/science | USA | Drugs for coronavirus | Page 3 | None | None | No |
| https://en.wikipedia.org/ | USA | Covid 19 | Page 1 | Page 1 | Page 1 | No |
| https://www.kineta.org/ | USA | Drugs for coronavirus | Page 1 | None | None | No |
| https://www.bloomberg.com | USA | Drugs for coronavirus | Page 32 | None | None | No |
| https://www.theverge.co | | | | | | |

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

| Canada July | Sydney, Australia July | URL Changes |
|-------------|------------------------|-------------|
| None | None | Same |
| None | None | Changed |
| None | Page 1 | Same |
| None | None | Same |
| None | None | Same |
| None | None | Same |
| None | None | Same |
| None | None | Same |
| None | Page 9 | Same |
| None | None | Same |
| None | None | Same |


For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




238x141mm (150 x 150 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



163x191mm (150 x 150 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



333x154mm (150 x 150 DPI)



PRISMA 2009 Checklist

| Section/topic | # | Checklist item | Reported on page # |
|------------------------------------|----|---|--------------------|
| TITLE | | | |
| Title | 1 | Identify the report as a systematic review, meta-analysis, or both. | 2 |
| ABSTRACT | | | |
| Structured summary | 2 | Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number. | 3 |
| INTRODUCTION | | | |
| Rationale | 3 | Describe the rationale for the review in the context of what is already known. | 4-7 |
| Objectives | 4 | Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS). | 4-7 |
| METHODS | | | |
| Protocol and registration | 5 | Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number. | 7-8 |
| Eligibility criteria | 6 | Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale. | 7-9 |
| Information sources | 7 | Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched. | 7-9 |
| Search | 8 | Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated. | 7-9 |
| Study selection | 9 | State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis). | 6-9 |
| Data collection process | 10 | Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators. | 8-12 |
| Data items | 11 | List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made. | 8-12 |
| Risk of bias in individual studies | 12 | Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis. | 12 |
| Summary measures | 13 | State the principal summary measures (e.g., risk ratio, difference in means). | 8-12 |
| Synthesis of results | 14 | Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I ²) for each meta-analysis. | 12 |



PRISMA 2009 Checklist

Page 1 of 2

| Section/topic | # | Checklist item | Reported on page # |
|-------------------------------|----|--|--------------------|
| Risk of bias across studies | 15 | Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies). | N/A |
| Additional analyses | 16 | Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified. | N/A |
| RESULTS | | | |
| Study selection | 17 | Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram. | 12, Figure 2 |
| Study characteristics | 18 | For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations. | 12-13 |
| Risk of bias within studies | 19 | Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12). | 15 |
| Results of individual studies | 20 | For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot. | N/A |
| Synthesis of results | 21 | Present results of each meta-analysis done, including confidence intervals and measures of consistency. | N/A |
| Risk of bias across studies | 22 | Present results of any assessment of risk of bias across studies (see Item 15). | N/A |
| Additional analysis | 23 | Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]). | 10-14 |
| DISCUSSION | | | |
| Summary of evidence | 24 | Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers). | 16-24 |
| Limitations | 25 | Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias). | 24-25 |
| Conclusions | 26 | Provide a general interpretation of the results in the context of other evidence, and implications for future research. | 24 |
| FUNDING | | | |
| Funding | 27 | Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review. | 2 |

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit: www.prisma-statement.org.

BMJ Open

COVID-19 prevention and treatment information on the Internet: a systematic analysis and quality assessment

| | |
|---------------------------------|--|
| Journal: | <i>BMJ Open</i> |
| Manuscript ID | bmjopen-2020-040487.R2 |
| Article Type: | Original research |
| Date Submitted by the Author: | 31-Aug-2020 |
| Complete List of Authors: | Fan, Ka Siu; St George's University Hospitals NHS Foundation Trust, Ghani, Shahi; St George's University Hospitals NHS Foundation Trust Machairas, Nikolaos ; Royal Free Hospital, Department of HPB Surgery and Liver Transplant Lenti, Lorenzo; St George's University Hospitals NHS Foundation Trust Fan, Ka Hay; Imperial College London Richardson, Daniel; St George's University Hospitals NHS Foundation Trust Scott, Aneya; St George's University Hospitals NHS Foundation Trust Raptis, Dimitri; Royal Free Hospital, Department of HPB Surgery and Liver Transplant |
| Primary Subject Heading: | Health informatics |
| Secondary Subject Heading: | Infectious diseases, Patient-centred medicine, Public health |
| Keywords: | World Wide Web technology < BIOTECHNOLOGY & BIOINFORMATICS, Health informatics < BIOTECHNOLOGY & BIOINFORMATICS, JOURNALISM (see Medical Journalism) |
| | |

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 **COVID-19 prevention and treatment information on the Internet: a systematic analysis**
4
5 **and quality assessment**
6

7 Ka Siu Fan, BSc*¹, Shahi Abdul Ghani, MSc, DHMSA*¹, Nikolaos Machairas, MD, PhD²,
8 Lorenzo Lenti, BSc¹, Ka Hay Fan³, Daniel Richardson, BSc¹, Aneya Scott, MChem¹, Dimitri
9 Aristotle Raptis MD, MSc, PhD²
10
11
12

13 *Ka Siu Fan and Shahi Abdul Ghani contributed equally to this paper.

- 14
15
16 1. St. Georges University of London, UK
17
18 2. Department of HPB Surgery and Liver Transplant, Royal Free Hospital, London, UK
19
20 3. Imperial College London, UK
21
22

23
24 **Corresponding author:**
25

26 Dr Dimitri Aristotle Raptis MD, MSc, PhD
27
28 Department of HPB Surgery and Liver Transplant
29
30 Royal Free Hospital, London, UK
31
32 Dimitri.Raptis@NHS.net
33
34
35
36

37 **Conflict of interest:** The authors have no conflicts of interests or funding sources to disclose
38
39
40

41 **Acknowledgements:** None
42
43
44

45 **Statement of Author Contribution:**
46

47 Study conception and design: DAR, NM, SAG, KSF
48
49 Acquisition of data: SAG, KSF, LL, KHF, DR, AS
50
51 Analysis and interpretation of data: KSF, SAG, NM, DAR
52
53 Drafting of manuscript: KSF, SAG, NM, KHF
54
55 Critical revision: KSF, SAG, NM, DAR
56
57
58
59

60 **Word count:** 6297

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Keywords: Coronavirus, Internet, Patient Education Handout, Public Health Informatics,
Search Engine

For peer review only

Abstract

Objective: To evaluate the quality of information regarding the prevention and treatment of COVID-19 available to the general public from all countries.

Design: Systematic analysis using the 'Ensuring Quality Information for Patients' (EQIP) tool (score 0-36), JAMA benchmark (score 0-4) and the DISCERN tool (score 16-80) to analyse websites containing information targeted at the general public.

Data Sources: Twelve popular search-terms, including 'Coronavirus', 'COVID 19', 'Wuhan virus', 'How to treat coronavirus' and 'COVID 19 Prevention' were identified by 'Google AdWords' and 'Google Trends'. Unique links from the first 10 pages for each search-term were identified and evaluated on its quality of information.

Eligibility Criteria for selecting studies: All websites written in the English language, and provides information on prevention or treatment of COVID-19 intended for the general public were considered eligible. Any websites intended for professionals, or specific isolated populations, such as students from one particular school, were excluded, as well as websites with only video content, marketing content, daily caseload update or news dashboard pages with no health information.

Results: Of the 1275 identified websites, 321 (25%) were eligible for analysis. The overall EQIP, JAMA and DISCERN scores were 17.8, 2.7 and 38.0. Websites originated from 34 countries, with the majority from the USA (55%). News Services (50%) and Government/Health Departments (27%) were the most common sources of information and their information quality varied significantly. Majority of websites discuss prevention alone despite popular search trends of COVID-19 treatment. Websites discussing both prevention and treatment (n=73, 23%) score significantly higher across all tools ($P<0.001$).

Conclusion: This comprehensive assessment of online COVID-19 information using EQIP, JAMA and DISCERN tools indicate that most websites were inadequate. This necessitates improvements in online resources to facilitate public health measures during the pandemic.

Strengths and limitations of this study

- Over 1200 websites were identified by using 12 search-terms to improve the representativeness of returned COVID-19 websites.
- A comprehensive analysis can be achieved using a combination of modified 'Ensuring Quality Information for Patients' (EQIP) tool, JAMA benchmark and the DISCERN tool, all of which are respected and validated health information assessment tools.
- Representativeness of search results of the Google search engine may be influenced by geographical factors and may differ when performed elsewhere.
- Video-based health content was not within our scope and may provide a more comprehensive analysis of all online health information on COVID-19.
- This study provides a snapshot of online health information as information on the Internet is constantly changing.

Review only

Introduction

With the increasing popularity of the Internet, both the accessibility and availability of health information grew drastically and has now become a primary source of information for many.[1,2] It is known that health information-seeking behaviour also applies to the use of online resources and is ever more important during the current Coronavirus disease 2019 (COVID-19) pandemic.[3] Information on such a widely-discussed topic will inevitably be vast and vary in production quality, potentially adversely affecting patient awareness and health-seeking behaviour.[4] Many of these resources read by the public may be unreliable or produced from non-peer-reviewed sources and affect behaviours such as recognition of symptoms, taking appropriate preventative precautions or seeking timely treatment.[3,5,6] Furthermore, inaccurate online information may contradict healthcare professionals and potentially compromise the trusting relationship with patients, worsening outcomes.[7]

Since the declaration of COVID-19 as a pandemic on 12th March 2020, its prevalence and mortality have continued to rise[8–10] and lead to the introduction of various measures such as social distancing, quarantine procedures and lockdown protocols.[11] As evidenced by previous outbreaks, effective public education and public health intervention rely on access to health information[12,13], which is now primarily delivered through the Internet. Many countries have since introduced lockdown and quarantine protocols as their mainstay preventative measures[14] but public health continues to be threatened by certain populations.[15] Due to both the novelty and rapid developments of COVID-19, there is a significant barrier against the critical appraisal of online resources and, hence, necessitates a quantitative evaluation of the popular information sources available to the wider public.

Many instruments have been developed to evaluate patient information and may also be applied to online COVID-19 information.[16] The modified Ensuring Quality of Information for Patients (EQIP) tool is a reproducible modality used in previous studies to evaluate the reliability and quality of all information types, providing a robust assessment of quality,

1
2
3 readability and design aspects of any written information[17–19]. Previously, our group
4 evaluated online information using the modified EQIP tool in a variety of conditions and
5 procedures including bariatric surgery[20], Dupuytren's disease[21], carpal tunnel disease[22],
6 breast augmentation[23], liposuction[17] and liver transplantation[24]. The Minervation
7 validation instrument (LIDA)[25], Flesch Reading Ease (FRE) Score and the Flesch-Kincaid
8 Grade (FKG) have also been used to evaluate the quality of online health information.[26]
9 However, they are not considered appropriate here as only readability and the website design
10 are assessed, both of which are adequately covered by EQIP.[27] Tools such as the Journal
11 of American Medical Association (JAMA) benchmark and the DISCERN tool (no acronym)
12 have also been used to evaluate online health information and their combinational use can
13 provide a more comprehensive evaluation.[19,28,29] The Internet has become an ever-
14 important source of information and can determine health-seeking behaviour, which ultimately
15 affects the progression of COVID-19. Hence, our study aims to assess the quality of
16 information of top indexed websites that discuss information, prevention, or treatment of
17 COVID-19 using the modified EQIP tool, JAMA benchmark and DISCERN tool.
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36

37 **Methods**

38 **Eligibility criteria, information sources and data selection**

39 On 27th March 2020, 12 search-terms and phrases were queried on the most used search
40 engine, Google[30–32], to obtain a database of websites. Only Google was used as previous
41 studies have shown that the use of multiple search engines will only provide duplicate results.
42 To increase the number of results, more search-terms were used: 'Coronavirus', 'COVID 19',
43 'Stop getting Coronavirus', 'Corona Virus', 'How to treat coronavirus', 'Coronavirus safety tips',
44 'Drugs for coronavirus', 'What is self isolation coronavirus', 'China virus', 'Wuhan virus',
45 'Coronavirus Medicine' and 'COVID 19 prevention'. These were commonly searched phrases
46 identified using the 'Google Adwords Keyword Planner'[33]. Google AdWords allows the input
47 of a term (in this case coronavirus) which then provides popular related keyword suggestions.
48 The most popular search-terms were 'Coronavirus', followed by 'COVID' and 'Corona Virus'
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 and their respective search popularity peaked in mid- and late-March 2020 respectively.
4
5 **Figure 1** summarises the most popular search trends. Only the first 10 pages of unique
6
7 websites were identified and recorded as previous work suggests patients tend to stay within
8
9 the first 100 returned webpages[18,24]. Various search-terms and their relative popularity
10
11 were also collected directly from Google Trends[34] for further comparative analysis.
12
13

14
15 All websites written in the English language and providing information on prevention or
16
17 treatment of COVID-19 intended for the general public or COVID-19 patients were considered
18
19 eligible for inclusion. Any subsidiary pages or subdirectories of a website that contained
20
21 information for the public and were easily accessible were also assessed. Websites or articles
22
23 intended for professionals or specific population subsets, such as students alone, were
24
25 excluded. Weblinks to purely video content, marketing content, daily caseload update or news
26
27 dashboard pages with no educational purposes were excluded. The creation of the website
28
29 database, eligibility assessment, website assessment and statistical analysis was performed
30
31 between March and April 2020.
32
33

34 35 36 **Website Scraping**

37
38 A website scraping tool was developed to identify and record all unique websites from the first
39
40 10 pages of Google results. The tool utilises custom PHP to make HTTP requests to the
41
42 search engine to mimic the requests made by the public. The queries were made from a server
43
44 located in Texas, USA but no preferences were made to limit searches by geographical region.
45
46 The tool makes repeated requests, logs the first 10 pages of unique URLs and outputs the
47
48 dataset after excluding all duplicate links within each search-term. A minority of websites were
49
50 restricted by General Data Protection Regulation (GDPR) and were accessed through the use
51
52 of virtual private networks (VPN) as any websites that could reasonably be accessed by the
53
54 general public were included.
55
56
57
58
59

60 **Data entry**

1
2
3 Six assessors, (KSF, SAG, KHF, LL, AS and DR), all of whom fluent in English, independently
4 assessed the websites between 30 March and 13 April 2020. The evaluation included 36 EQIP
5 items and four items on JAMA benchmark, all assessed through 'Yes, No or N/A' questions.
6
7 DISCERN tool adds a further 16 items to assess reliability and quality of treatment information
8 using scales of 1 to 5. Assessors also recorded the country of origin, and type of source:
9 Academic Centre, Charity/Non-Governmental Organisation, Encyclopaedia,
10 Government/Health Department, Hospital, Industry, News Service, Patient Group,
11 Practitioner, and Professional Society. Organisations that primarily serve patients, such as
12 Patient.info, is considered a 'Patient Group' whereas non-governmental organisations that
13 oversee a broader demographic, like Red Cross and World Health Organization (WHO), are
14 classified as 'Charity/Non-Governmental Organisation'. News service includes both primary
15 and secondary news articles that are not written for professionals. 'Practitioner' considers the
16 for-profit webpages of individual medical practitioners, whereas 'Industry' considers any for-
17 profit organisation within the medical industry. 'Academic Centres' consider all sources from
18 academic institutions, while 'Professional Society' refer to non-profit groups of healthcare
19 professionals. Qualitative information about preventative methods and treatment was also
20 recorded. After the initial round of data entry, each website was verified on a second-round
21 between 14 April and 21 April by a verifier with previous experience performing data entry for
22 the evaluation of patient health information.
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44

45 **EQIP Tool**

46
47 The Ensuring Quality Information for Patients (EQIP) tool consists of 20 items, acting as a
48 checklist for criteria such as quality of written work, design and coherence.[35] More recently,
49 modifications were made to the EQIP tool, expanding the criteria to 36 items[36]. This serves
50 to satisfy both the guidelines of British Medical Association (BMA)[37] and International Patient
51 Decision Aids Standards (IPDAS) collaboration[38] on the ideal patient information and the
52 modified EQIP tool have been utilised in a variety of specialities previously.[17–19] A decision
53 was made to use the modified EQIP tool as the inclusion of 'partly yes' in the original EQIP
54
55
56
57
58
59
60

1
2
3 introduces subjectivity into the responses and has been shown to lower its reliability.[24,35]
4
5 36 items across three domains were included: Content (items 1-18), Identification (items 19-
6
7 24) and Structure (items 25-36). Similar to previous uses, 'Yes/No' binary questions reduce
8
9 assessor subjectivity in partial answers. 'N/A' option was also included if items were not
10
11 relevant for the type of source. The Content domain assesses whether an adequate amount
12
13 of information is included in an article, ranging from a description of the medical problem itself
14
15 (items 1-3,11,14) to the details of its management and complications (items 4-11).
16
17 Identification domain assesses how well a website displays its production details, including
18
19 date of issue, author, finance sources and bibliography (items 19-24). Structure domain
20
21 evaluates the readability of a website and how well it accommodates its audience, such as
22
23 delivering information through short, non-contradictory statements arranged in a logical layout
24
25 (items 25-36). As COVID-19 is an emergent disease, certain items are tailored to
26
27 accommodate for the limited evidence: describing treatment (item 3) include articles that
28
29 address the lack of proven treatment, and alert signs (item 14) include recognised COVID-19
30
31 symptoms such as fever, cough and changes in taste or smell. A cut-off point of 75th percentile
32
33 was set for EQIP score to discriminate between high-scoring from low-scoring websites as
34
35 was done in previous studies.
36
37
38
39
40
41

42 **JAMA Benchmark**

43
44 Critical appraisals of Internet resources are also assessed by one of the earliest core
45
46 standards identified by JAMA in 1997.[39] This checklist was proposed by Silberg *et al.* to
47
48 assist the appraisal and evaluation of the credibility of unregulated Internet resources and
49
50 have been used in various studies previously[40,41]. This is evaluated by four items:
51
52 Authorship, Attribution, Disclosure and Currency: Authorship requires identification of authors,
53
54 their credentials and affiliations; Attribution requires appropriate citations on written
55
56 information; Disclosure requires transparency of the website owner and conflicts of interests;
57
58
59
60

1
2
3 Currency requires a clear indication of the date of publication and updates. Similarly, the
4
5 'Yes/No' criterion is implemented to reduce the subjectivity of partial answers.
6
7
8

9 **DISCERN Tool**

10
11 The DISCERN evaluation tool was first developed in 1998 at Oxford to judge the quality of
12
13 information regarding treatment choices.[42] This tool has been validated and used across
14
15 various specialities to assess treatment information.[29,40,43] This consisted of 16 items to
16
17 assess both the reliability and level of detail on treatments as well as the overall quality of the
18
19 information. The reliability section (items 1-8) evaluates the ability of a website to achieve its
20
21 aims while remaining unbiased and providing its sources of information. Quality section (items
22
23 9-15) evaluates the content specifically for describing the rationale, methods and alternatives
24
25 to the current management of a disease. Criteria for treatment section was adjusted to
26
27 accommodate the treatment uncertainty and items are considered fulfilled as long as the
28
29 website discusses the relevant information with regards to potential drugs or interventions
30
31 such as assisted ventilation. A score between 1 and 5 can be assigned to each item, with 1
32
33 being 'No', 3 being 'Partial' and 5 being 'Yes'. To improve assessment accuracy, overall quality
34
35 of information will be scored in proportion to the mean scores calculated from the answers to
36
37 items 1-15, with 1 being the lowest and 5 being the highest.
38
39
40
41
42

43 **Additional Items**

44
45 Additional items were included to further assess the websites, including whether a website
46
47 discussed prevention methods, current treatments and the role of empirical evidence in the
48
49 prevention or treatment for COVID-19. Data collected were in the form of 'Yes/No' to reduce
50
51 the ambiguity of partial answers. Additionally, details provided by the website on these items
52
53 were recorded if the item scores 'Yes'. Websites were further analysed by whether their
54
55 purpose is prevention, treatment, or both.
56
57
58
59
60

Statistical Analysis

1
2
3 The dataset consisted of both continuous and categorical variables, which are reported as the
4 mean, median and interquartile range (IQR) as well as numbers and percentages respectively.
5
6 High-scoring websites are identified as those with scores above the 75th percentile for all three
7
8 tools. Kruskal-Wallis tests were used for the analysis of continuous variables where
9
10 appropriate and intraclass correlation coefficient (ICC) was calculated to identify the
11
12 correlation between website analysis test methods. Fisher's or χ^2 tests were used to analyse
13
14 proportions where appropriate. Inter-rater reliability of each assessor was evaluated using
15
16 Bland-Altman plots. All P values were two-tailed and considered significant when $P < 0.05$. R
17
18 version 3.3.2 (R Core Team, GNU GPL v2 License), R Studio version 1.0.44 (RStudio, Inc.
19
20 GNU Affero General Public License v3, Boston, MA, 2016) and their respective graphical user
21
22 interface (GUI) rBiostatistics.com (rBiostatistics.com, London, Switzerland, 2017)[44] was
23
24 used to perform the statistical analysis.
25
26
27
28
29

30 **Patient and Public Involvement**

31
32 There was no patient or public involvement in the conception, design or data collection of the
33
34 study or the production of the manuscript.
35
36
37
38
39
40

41 **Results**

42 **Gathering of websites with information on COVID-19, its prevention and its** 43 **management**

44
45 A database of websites was gathered from the first 10 pages of unique URLs returned using
46
47 the 12 search-terms. The final dataset included 1275 URLs. After filtering out duplicate results
48
49 and websites that failed to meet our inclusion criteria, 321 remained eligible for analysis. The
50
51 workflow of dataset creation is shown in **Figure 2**. The list of websites was obtained on a
52
53 single day, 27th March 2020, and website evaluation was completed within two weeks.
54
55
56
57
58
59

60 **Website demographics and search trends**

1
2
3 COVID-19-specific searches regarding treatment and masks were significantly more popular
4 (P<0.001) than prevention and peaked in mid-March and early-April respectively. The returned
5 websites originated from 34 different countries (**Figure 3 and 4**): the USA produced the most
6 websites (n=178), followed by the United Kingdom (n=52), Australia (n=18) and Canada
7 (n=18). However, no statistically significant differences were observed between the four
8 countries across all tools. The source of information and website category is shown in **Table**
9
10
11
12
13
14
15
16 **1. News Services** were the most common source of information (n=163), followed by Health
17 Departments/Government (n=87).
18
19

20
21
22 Forty-six websites (14.3%) described treatment methods alone, 202 websites (62.9%)
23 mentioned treatment methods alone and 73 websites (22.7%) discussed both. Of the
24 prevention websites, 205 (63.9%) described social isolation, 169 (52.7%) physical distancing,
25 157 (48.9%) advised staying home and 136 (42.4%) described the benefits of disinfecting or
26 cleaning surfaces. Of those that discussed treatment, 55 (17.1%) described the use of antiviral
27 medications, 31 (9.7%) described hydroxychloroquine or chloroquine and 26 (8.1%) described
28 the use of non-steroidal anti-inflammatory drugs such as paracetamol and ibuprofen. Only 31
29 (9.7%) websites discussed the use of oxygen, ventilation or fluids as a possible treatment
30 method.
31
32
33
34
35
36
37
38
39
40
41
42

43 **Overall performance**

44
45 The mean total score for EQIP, JAMA and DISCERN are 17.78, 2.69 and 38.00 respectively,
46 with a respective 75th percentile high-score cut-offs of 21, 4 and 43. No website achieved the
47 maximum score for EQIP Content (out of 18) or Structure (out of 6) domain but one website
48 did attain the maximum for EQIP Identification (out of 12). Seventy-four websites fulfilled all
49 four JAMA criteria. Four websites achieved the maximum for DISCERN Reliability (out of 40)
50 but none scored fully in DISCERN Treatment (out of 40). 74 high-scoring websites were
51 identified for EQIP and JAMA and 76 for DISCERN tool. The mean scores of high- and low-
52 scoring websites for each tool and domain are as follows: EQIP Content (9.99 vs 6.07;
53
54
55
56
57
58
59
60

1
2
3 P<0.001), EQIP Identification (4.03 vs 3.34; P<0.001), EQIP Structure (8.45 vs 6.96;
4 P<0.001), Total EQIP (22.46 vs 16.37; P<0.001), Total JAMA (4.00 vs 2.30; P<0.001),
5 DISCERN Reliability (31.72 vs 25.44; P<0.001), DISCERN Treatment (13.49 vs 10.31;
6 P=0.002) and Total DISCERN (45.21 vs 35.76; P<0.001).
7
8
9
10

11
12
13 All tools and subsequent domains, except DISCERN Reliability and Total DISCERN scores,
14 varied significantly between websites of different sources, notably with the Encyclopaedia
15 (n=5) cohort holding the highest score across all domains. All tools and domains varied
16 between website cohorts, with websites that discussed both Prevention and Treatment scoring
17 above the mean values. **Table 2** and **Table 3** summarises the variation of information quality
18 with the source of information and website category respectively. A detailed breakdown of the
19 performance of each tool is displayed in **Supplementary Table 1, 2 and 3**.
20
21
22
23
24
25
26
27
28
29

30 **Subset analysis of Government/Health Department and News Services**

31
32 Collectively, 250 (77.9%) of all web links were either Government/Health Departments and
33 News Services websites, of which 121 (37.7%) were based in the USA. Globally, there is
34 significant variation between Government/Health Departments and News Services in EQIP
35 Content (mean 8.11 vs 6.22; P<0.001), Total EQIP (mean 18.90 vs 17.06; P<0.001), Total
36 JAMA (mean 2.16 vs 2.98; P<0.001) and DISCERN Treatment (mean 9.02 vs 11.72;
37 P=0.001). Variations in US websites were similar except for EQIP structure (P=0.148). The
38 US-based cohort scored lower in Total EQIP than the global cohort but USA News Services
39 specifically scored higher in Total JAMA (3.17 vs 2.98) and Total DISCERN (39.25 vs 38.04).
40
41
42
43
44
45
46
47
48
49
50 Breakdowns of comparison between the cohorts are provided in **Table 4**.
51

52 **High-scoring websites**

53
54 Sixteen websites scored above 75th percentile across all three evaluation tools, 13 were from
55 the USA, 2 from the UK and 1 from Canada. Most were from News Services (n=10), followed
56 by industry (n=4), Encyclopaedia (n=1) and Government/Health Departments (n=1). The top
57
58
59
60

1
2
3 5 websites with the highest Total EQIP and Total DISCERN scores are shown in **Table 5** with
4 their respective breakdowns. Top JAMA websites were not shown as there were 74 that
5 scored the full four points.
6
7
8

9 10 11 **Intraclass correlation between tools**

12 Intraclass correlation (ICC) between the 3 analysis tools is provided in **Supplementary Figure**

13 **1**. The ICC between all three tools was moderate to high at 0.48 (95% CI 0.37-0.56).

14 Furthermore, as the JAMA benchmark only offers four scoring variations, the Kruskal-Wallis
15 analysis is used to correlate JAMA with EQIP and DISCERN. The results are shown in

16 **Supplementary Figure 2** and demonstrate statistically significant moderate-high correlation
17 for both JAMA-EQIP and JAMA-DISCERN.
18
19
20
21
22
23
24
25
26
27

28 **Inter-rater reliability**

29 The biases of each tool and assessor are within 95% CI interval limits. The Bland-Altman plots
30 and individual degree of bias have been provided in **Supplementary Figure 3**. The mean
31 degree of bias and 95% confidence intervals for each assessor is identified. Mean bias for
32 EQIP, JAMA and DISCERN were -0.36, +0.29 and +0.51 respectively. Bias for each assessor,
33 within each tool, was minimal and falls within their respective 95% CI.
34
35
36
37
38
39
40
41
42

43 **Discussion**

44 To our knowledge, this is the first study to evaluate the content intended for the public seeking
45 information for preventing or treating of COVID-19. Our search-terms included various
46 synonyms of COVID-19 and “open” search-terms to capture the majority of materials related
47 to our study. While no tools are validated to assess information specifically during pandemics;
48 this study used a combination of EQIP, JAMA and DISCERN. The combined scope and
49 efficacy of these tools enable a comprehensive evaluation of all the important aspects for a
50 layperson seeking health information from articles; namely readability, coherence, design and
51 quality of information.
52
53
54
55
56
57
58
59
60

Evaluation of the websites

We determined the quality of information to be low, as indicated by the low 75th percentile cut-offs for EQIP and DISCERN, at 21 and 43 respectively, or 58.3% and 53.8% of their respective full scores. Abundant COVID-19 content is being produced, as evident in **Figure 1**, with the majority being excluded due to its nature rather than inter-term duplications. Most frequently excluded websites were either caseload updates or general news articles lacking information on prevention and treatment.

Websites generally scored poorly, with an EQIP mean and median of 18 (IQR 15-20). Despite fewer marks allocated to Structure, websites generally outperform the Content domain (7.30 vs 6.97), suggesting information quality is less adequate than usability. The indicators assessing referencing quality, such as JAMA benchmark and DISCERN Reliability, scored similarly at 2.69 (67.3% of maximum) and 26.93 (67.3% of maximum) respectively but scored lower in the EQIP Identification domain 3.50 (58.3% of maximum), likely due to more items (i.e. whether patients were involved in the material's production). Generally, high-scoring websites performed better in the Content domain, with odds ratios (OR) between 3-7. The OR was significantly higher for item 4 (defining the purpose of interventions) (OR 27.78; 95% CI 4.695-1000; $P < 0.001$), suggesting that high-scoring websites provided greater reasoning behind preventative and treatment measures. While high-scoring websites scored significantly higher across 23 of the 36 EQIP items, quantitative benefits (item 8) is a notable exception where both cohorts performed poorly (4.1% vs 2.4%; OR 1.695; 95% CI 0.267-8.197; $P = 0.436$), significantly lower than available literature.[18,23,24] This likely reflects the general lack of COVID-19 knowledge compared to previously explored diseases and treatments. High-scoring websites similarly performed better in Identification (OR ranged between 1.312 and 5.376), with the inclusion of bibliography (item 23) differing most (41.89% vs 11.74%; OR 5.376; 95% CI 1.727-7.407; $P < 0.001$) as the majority of websites lacked bibliographies, potentially due to subpar production quality in a high turnover topic. Structure

1
2
3 revealed both high- and low-scoring websites to provide clear information (item 30; 98.65% vs
4 89.88%; OR 8.197; 95% CI 1.294-333.3; P=0.013). High scoring websites provided poor
5 benefit-risk balancing (item 31; 39.19% vs 10.93%; OR 5.208; 95% CI 2.703-10.101;
6 P<0.001), as did most other websites assessed (17.5% overall), comparable to existing
7 studies ranging 11% to 44%. As shown in **Figure 5**, EQIP scores were relatively
8 homogeneous, ranging from 6 to 29, with the majority between 14-22. Overall performance
9 agreed with available literature that online health information is inadequate, as median EQIP
10 scores ranged between 15-19 and IQR ranged 12-20 and 16-22.[18,20,22,23,45]
11 Furthermore, scores for describing intervention sequence (item 6) and quantitative risks (item
12 10) were much lower (15.9% and 0.9% respectively) when compared against the study on
13 gallstone disease (27% and 21% respectively) or liver transplantation (66% and 53%
14 respectively). This likely reflects the prioritisation of discussing prevention and treatment
15 method efficacy over treatment sequences and risks. Item 23 also scored poorly, both in itself
16 and against literature: only 18.7% of websites provided a short bibliography whereas studies
17 ranged from 19% in liver transplantation to 47% in orthognathic surgery. Interestingly, COVID-
18 19 websites scored well in dating (item 19; 87.2%) compared literature, likely reflecting the
19 demanding and time-sensitive nature to understand how the COVID-19 pandemic affects
20 individuals. Unsurprisingly, encyclopaedias (n= 5) scored the highest in content (10.80),
21 identification (4.80) domains and overall EQIP (24.20), holding the highest proportion of
22 websites discussing both prevention and treatment (n=4; 80%). Encyclopaedias' high scores
23 are attained through their endeavours to provide neutral summaries which meet the majority
24 of the EQIP criterion.[46] Nonetheless, while overall EQIP scores do not differ substantially
25 from existing literature, it is important to recognise that the quality of information is significantly
26 influenced by the rapid turnover of information, a phenomenon not present in previous studies.
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56 JAMA benchmark scores, unlike EQIP and DISCERN, were more consistent as only four
57 points are available. Hence, high-scoring websites often fulfilled all four JAMA criteria whereas
58 the majority of other entries scored two or three. Low-scoring websites scored significantly
59
60

1
2
3 lower ($P<0.001$) in Authorship and Attribution, with only 44.13% and 17.81% fulfilling the
4 criteria, reflecting congruence with the findings from EQIP regarding bibliography inclusion.
5 Contrarily, website ownership and funding assessment, under Disclosure (86.23%), and
6 assessments of publishing and updating dates, under Currency (81.78%), varied to a lesser
7 degree, albeit still scoring significantly lower ($P<0.001$). Comparative to the related EQIP
8 sections, Disclosure and Currency likely scored better by assessing attributes independent to
9 the content itself. Professional societies ($n=4$; 3.50), closely followed by encyclopaedias ($n=5$;
10 3.40), scored the highest overall, whereas the mean JAMA scores were only 2.69 and four
11 websites scoring zero. This is likely attributable to the lack of additional assessment criteria
12 by the JAMA benchmark as it was developed during the infancy of web-based resources.
13 Regardless, the tool is still effective at identifying high-quality content as high-scoring websites
14 scored significantly better across each item ($P<0.001$).

15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
DISCERN's mean score of 38.0 across 16 items averaged 2.38 out of five per item. The
DISCERN handbook details a rating of one when the information does not provide the
appropriate information, three where it addresses it partially and five for a complete and
adequate inclusion. Based on these guidelines, the majority of websites meet the listed criteria
to a minimal extent. Similar to EQIP, DISCERN scores vary significantly, ranging from 19 to
75, with the majority distributed between 25 to 47. Of the 16 items, 12 presented statistically
significant differences between high- and low-scoring websites. Interestingly, the Reliability
section provided the greatest difference in scoring, seen between item 4, clear display of
information sources (mean 4.16 vs 2.55; $P=0.019$), and item 5, a clear indication of where
sources were used (mean 3.54 vs 2.28; $P=0.007$). This corroborates with results from EQIP
and JAMA assessments in highlighting the inadequacies of informative material production.

Quality of treatment information section scores varied less, albeit all with statistically significant
differences. The greatest differences were in item 9, describing how each treatment works
(1.76 vs 1.43; $P=0.005$) and item 10, detailing treatment benefits (1.78 vs 1.43; $P<0.001$).

1
2
3 Despite accommodating the treatment uncertainty during the assessment, almost all items
4 evaluating treatment scored poorly, including high-scoring websites, and may be reflective of
5 its lower journalistic priority or demand as the majority of websites were tailored towards
6 discussing prevention. As a whole, DISCERN scores specifically addressing treatment options
7 were poor, scoring 45.07 (SD 11.68) for websites that only discuss treatment as well as 42.84
8 (SD 10.93) for websites that discuss both prevention and treatment. These scores are also
9 lower than those of other DISCERN studies, which have mean scores between 45.8 and 56.1,
10 with SD between 8.76 and 13.6.[47–49] While the majority of DISCERN scores were low,
11 websites scored similarly in the Reliability section. The mean scores for items 1, 2 and 3 were
12 the highest of all indicators, averaging 4.37, 4.29 and 4.33, whereas the items in treatment
13 section scored between 1 and 2, with a maximum mean score of 1.66 in Item 14. The treatment
14 section of DISCERN shows much more variation, with prevention alone (8.60; n=202) scoring
15 lowest, treatment alone (18.09; n=46) scoring highest and websites discussing both (13.47;
16 n=73) in between. This suggests that many websites do not include treatment information and,
17 of those that do, websites tend to avoid discussion rather than provide the limited information
18 available.

19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39 In short, all three tools utilised are validated based on international recommendations and
40 provides a comprehensive assessment of online information: EQIP delivers an all-rounded
41 evaluation of health information, DISCERN excels at scrutinising treatment and JAMA
42 benchmark assesses all of a website's content as a whole. Additionally, as design alone is
43 known to improve the perception of information credibility[50], the higher emphasis on quality
44 of content in EQIP and DISCERN will likely prevent well-presented and user-friendly websites
45 with poor content from attaining high scores over poorly-presented websites with good
46 content. Altogether the tools suggest that the majority of COVID-19 websites are generally of
47 poor quality and that quality fluctuates highly. This may subsequently impair the ability of the
48 public to filter out websites of low validity and reliability and, hence, increase their risk of unsafe
49 health behaviours during the pandemic. Through the use of these tools, the same standards
50
51
52
53
54
55
56
57
58
59
60

1
2
3 can be held across different sources of information to produce higher quality educational
4 material to improve both education and awareness.
5
6
7
8

9 **Reasons for poor quality information**

10
11 Most sources scored poorly due to several possible reasons. Firstly, as COVID-19 was only
12 identified in early December 2019[51], and recognised as a pandemic in March 2020[52], the
13 general lack of information to produce patient information prevents accurate and reliable
14 conclusions to be drawn. While research efforts have since gained traction, production of
15 research, reviewing and publication is a lengthy process comparative to the rapid spread of
16 COVID-19. Journals have since implemented fast-tracking of COVID-19 research.[53–55]
17
18 Similarly, Governments and Health Departments have also cooperated to support and fast-
19 track COVID-19 studies.[56] The combined efforts have facilitated the publication of over
20 5,000 COVID-19 articles in the WHO database alone.[57] It is also important to note the role
21 of preprint servers during the pandemic as they are accessible to the public. While improving
22 accessibility helps facilitate peer-reviewing; non-peer-reviewed articles can potentially be
23 used, or cherry-picked, by non-professionals which can adversely affect public
24 understanding.[58–61]
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40

41 Health literacy also plays a crucial role in how COVID-19 information influences health
42 behaviour. The associations between health literacy and health behaviour are well
43 documented: low literacy is common among older adults engaging in poor health behaviour
44 (P<0.005) ranging from lifestyles, such as physical activity, dietary habits and obesity, to social
45 factors, such as loneliness and social isolation.[62–64] The effects of primary preventative
46 measures, such as social distancing, self-isolation and other hygiene recommendations, may
47 become impaired by the abundance of poorly written and incorrect information online. In
48 particular, the elderly, most vulnerable population, suffer from even higher risks due to their
49 lower health literacy.[65] Although health literacy, and by extension, health behaviours, can
50 be improved through education[66], effective dissemination of credible information is critical
51
52
53
54
55
56
57
58
59
60

1
2
3 during the pandemic. The public, and journalists, need to exercise caution when accessing
4 research and pre-prints during this period as inadequate health literacy may lead to
5 counterproductive effects. Similarly, mass production of online information greatly increases
6 the difficulty in distinguishing reliable information from the sea of misinformation, and hence,
7 a greater emphasis must be placed on authors and journalists to deliver unbiased, credible
8 and accurate information to the public.[67,68]
9
10
11
12
13
14
15
16
17

18 Upon publication, articles are reviewed and summarised by journalists who bridge the
19 knowledge gap between scientists and the wider public. This allows efficient dissemination of
20 critical research to those who lack the scientific background to critically appraise and evaluate
21 research. Notably, while 52% (n=169) of websites were 'News Services', only 12 (7.1%) were
22 considered high-scoring, reflecting that very few provide a comprehensive account of COVID-
23 19 information, possibly explained by the difficulty in matching the pace of COVID-19 research
24 and technical inadequacies in delivering accurate and concise scientific information. As health
25 information-seeking behaviour of the public will likely be based on news services[69], the
26 highly variable and generally poor content is problematic.
27
28
29
30
31
32
33
34
35
36
37
38

39 Previous studies have identified that many health journalists lack the training required to
40 accurately disseminate health news, leading to potentially harmful health effects.[70,71] The
41 low scores across all tools indicate overall inadequacy of both reliability and accuracy. A
42 survey of medical journalists across 37 countries highlighted the 3 most common barriers
43 against quality content: lack of time, space and knowledge.[72] While journalism stresses the
44 ability to summarise content quickly and concisely, experienced journalists often report the
45 lack of knowledge as a barrier. The lack of expert knowledge in a rapidly progressing scientific
46 field can impact the quality of conveyed information significantly. Furthermore, journalists
47 reported difficulty in finding experts to explain the jargon, further impacting quality. This
48 presents a large barrier towards disseminating quality COVID-19 information as the redirected
49 efforts of many countries and institutions' scientists into research reduces availability to assist
50
51
52
53
54
55
56
57
58
59
60

1
2
3 with medical journalism.[73,74] Expertise in a relevant academic background likely helps
4 improve the content, as indicated by the highest-scoring entry, whose author holds a PhD in
5 molecular genetics which scored 22 in EQIP, 4 in JAMA and 74 in DISCERN.[75] In short, our
6 findings highlight the importance of addressing health outcomes through health literacy of both
7 the public and authors.
8
9
10
11
12

13
14
15 Our analysis identified the majority of websites as sources from Governments or health
16 departments across various states of the USA, many of which have based information and
17 advice from the Centers for Disease Control and Prevention (CDC). As both the nature and
18 purpose of these sources vary, the visiting population and demographics would also vary due
19 to differences in information-seeking behaviours. A recent study has identified a deficit of
20 awareness and trust in information originating from the Government such as those of the CDC,
21 revealing that while up to 83.6% of American adults are aware of the CDC, only 64.6% trust
22 this source.[76] American adolescents were, however, less aware of the CDC (55.8%), but
23 were more trusting of their information (72.2%). As previously established, trust in a
24 Government is predictive of health outcomes as it affects behaviours such as service usage
25 and vaccination rates.[77–79] Similarly, as access and usage of online health information vary
26 between different demographics, it is paramount that we create and provide targeted and
27 effective educational material for public use.[80,81]
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44

45 A comparison between the global Government/Health Department and News Services
46 websites revealed significant differences between EQIP Content, Total EQIP, Total and
47 DISCERN Treatment. The EQIP Content scores reflect differences in where information is
48 obtained, with Government/Health Departments using primary research whereas journalists
49 tend to utilise secondary research. However, News Services scored higher in DISCERN
50 Treatment, potentially due to the Government's reluctance to prematurely disclose treatment
51 information at early stages of discovery, whereas journalists may freely report results of all
52 potential studies. Interestingly, the majority of USA Government websites had some form of
53
54
55
56
57
58
59
60

1
2
3 copy-pasted information from the Centre for Disease Control and Prevention (CDC), likely with
4 the aim of maintaining consistency and centralisation information sources. In contrast, the
5 majority of other sources rewrite information based on a variety of sources. American sources
6 display a similar pattern of variation but the EQIP Identification scores of Government/Health
7 Departments show statistically significant differences and scores lower than News Services
8 (mean 3.34 vs 3.78; $P=0.011$). The verbatim use of CDC information on these Government
9 websites may have neglected the importance of clarity, transparency and critical appraisal of
10 literature and focused on disseminating information instead.
11
12
13
14
15
16
17
18
19
20
21

22 **Is the current information online adequate?**

23
24 Google Trends identified the search popularity of treatment to have increased rapidly,
25 outgrowing prevention searches since early-March. This suggests that initial demands for
26 preventative information have been sufficiently met and interests now shift towards treatment.
27
28 The 275 websites addressing prevention scored below the mean EQIP (17.12 vs 17.78;
29 $P<0.001$), JAMA (2.53 vs 2.69; $P=0.001$) and DISCERN scores (34.64 vs 38.00; $P<0.001$),
30 showing that quality of preventative information remains subpar across all indicators. Similarly,
31 treatment websites demonstrated their efficacy in sourcing, over discussing information, as
32 they excelled in Identification (3.87 vs 3.50; $P<0.001$) but scored poorly and below the mean
33 in EQIP (16.89 vs 17.78; $P<0.001$). This is also reflected by its above-average JAMA (3.13 vs
34 2.69; $P=0.001$) and DISCERN (45.07 vs 38.00; $P<0.001$) scores. Contrarily, the 73 websites
35 that discussed both prevention and treatment of COVID-19 consistently scored higher than
36 the mean across all indicators: EQIP (20.15 vs 17.78; $P<0.001$), JAMA (2.85 vs 2.69; $P=0.001$)
37 and DISCERN (42.84 vs 38.00; $P<0.001$). These websites explored multiple aspects of the
38 virus, and likely utilises a variety of sources, thus producing higher quality articles through a
39 better understanding of the topic. To combat increasingly dangerous COVID-19 myths, such
40 as injection of disinfectants as treatment, continued maintenance and improvement to online
41 available resources is paramount.[82,83]
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Limitations

Although our utilised search engine, 'Google', is the most commonly used, it is not wholly representative as searches are often affected by the location of the requesting server and previous Internet usage. While querying from every country is not practical, the server used in the study was not used to conduct any other COVID-19-related searches, thus impact should be minimised. A further search was conducted on 10th July 2020 on the top 10 scoring EQIP and DISCERN websites through VPN servers in Texas, London, Toronto and Sydney. Only three of the websites were found within the first 10 pages of results using the same search-terms on the original server, with London and Sydney each returning two of the results, Toronto returning none (**Supplementary Table 4**) and a remaining URL redirecting to another page. The search also confirms differences in results between the location of the search, however, all three results from the Texas server were covered by London and Sydney. As websites can be updated or removed any time, our results are representative only at the time of the search, demonstrated by the distinct lack of the original websites in our second search in July. Similarly, search-terms obtained using 'Google Adwords Keyword Planner' and 'Google Trends', may not truly be indicative of search patterns of the wider public. Hence, 12 different variations of 'COVID-19' names and phrases potentially used by patients were utilised as search-terms. While social media is increasingly used to share health information, our study focused on search engines because previous studies have identified a lack of trust in social media information and which acts as a barrier against public engagement.[84] Similarly, while video-based information constitutes a valuable source of information, no tools have been validated in assessing video-based information, particularly for COVID-19, to the best of our knowledge. Forced inclusion of video content would likely yield inaccurately low scores across current tools as videos typically do not include as much written information. Another limitation is the exclusion of non-English language websites, especially reducing the representation of publicly available information given the international nature of the pandemic. A minority of URLs, particularly of News Services, regularly update their content or redirect visitors, potentially affecting the second round of evaluation and subsequent statistical analysis.

1
2
3 Additionally, modified EQIP tool, JAMA benchmark and DISCERN tool were limited as they
4 were not designed to specifically assess the highly variable information produced during
5 pandemics. However, the EQIP tool was designed to assess any type of patient information
6 and demonstrated high inter-rater reliability.[17] Similarly, JAMA benchmark was designed to
7 evaluate website reliability alone and DISCERN examines both reliability and content
8 accuracy, thus, the combinational use of tools enhances the accuracy and objective
9 assessment of these websites.
10
11
12
13
14
15
16
17
18
19

20 **Conclusion**

21
22 In short, the abundance of Internet resources providing COVID-19 information is exemplified
23 by the numerous identified websites during our search. The information available to the public
24 may affect their health decisions, which, subsequently, affects the efficacy and outcome of
25 public health measures implemented by health departments. As effective treatments and
26 vaccine research is underway, COVID-19 is primarily addressed with preventative measures,
27 hence necessitating a critical review of the quality and nature of the information accessible to
28 the public. Our results demonstrated that the websites were chiefly produced by News
29 Services and Government/Health Departments but were nonetheless of low quality. While the
30 majority of websites addressed prevention, and likely met the information needs of the public
31 as reflected by search trends, there is a relative deficit in websites that discuss treatment
32 methods. A minority of websites discussed both prevention methods and treatment and were
33 generally good resources but the majority of websites were also of inadequate quality. Thus,
34 there is a need for higher quality online COVID-19 resources to facilitate public education and
35 enable better cooperation and outcomes of public health measures.
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Contributorship statement

Study conception and design: DAR, NM, SAG, KSF

Acquisition of data: SAG, KSF, LL, KHF, DR, AS

Analysis and interpretation of data: KSF, SAG, NM, DAR

Drafting of manuscript: KSF, SAG, NM, KHF

Critical revision: KSF, SAG, NM, DAR

Competing interests

Authors have declared that no competing interests exist.

Funding

Authors received no specific funding for this work.

Data sharing statement

All relevant data are within this manuscript and supplementary files.

Figures and Supplementary Figures

Figure 1. Popular search terms used in COVID-19 and their relative popularity throughout the pandemic provided by Google Trends

Figure 2. Workflow of webscraping and exclusion: initial 1275 websites returned were filtered for duplicates and assessed for eligibility to include 321 websites in the final dataset

Figure 3. Country of origin of websites in descending order of the number of websites contributed

Figure 4. Scores by top contributing countries (USA, UK, Canada and Australia) for EQIP tool, JAMA benchmark and DISCERN tool

Figure 5. High-score distribution of the final dataset compared against low-scoring websites for EQIP tool, JAMA benchmark and DISCERN tool

1
2
3 **Supplementary Figure 1.** Intraclass correlation plot demonstrating correlation between EQIP
4 tool, JAMA benchmark and DISCERN tool
5

6
7 **Supplementary Figure 2.** Kruskal-Wallis box-plot of score distributions of JAMA benchmark
8 against EQIP tool and DISCERN tool
9

10
11 **Supplementary Figure 3.** Bland-Altman Plot demonstrating assessor variations within each
12 of the three tools and against other assessors
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

- 1
2
3 undergoing surgery with perioperative SARS-CoV-2 infection: an international cohort
4 study. *Lancet* 2020;**396**:27–38. doi:10.1016/S0140-6736(20)31182-X
5
6
7
8 11 World Health Organization. COVID-19 Strategy Update. 2020.
9
10 [https://www.who.int/docs/default-source/coronaviruse/covid-strategy-update-](https://www.who.int/docs/default-source/coronaviruse/covid-strategy-update-14april2020.pdf?sfvrsn=29da3ba0_19)
11 [14april2020.pdf?sfvrsn=29da3ba0_19](https://www.who.int/docs/default-source/coronaviruse/covid-strategy-update-14april2020.pdf?sfvrsn=29da3ba0_19) (accessed 30 Apr 2020).
12
13
14 12 Feldmann H. Ebola — A Growing Threat? *N Engl J Med* 2014;**371**:1375–8.
15
16 doi:10.1056/NEJMp1405314
17
18 13 Odlum M, Yoon S. Health Information Needs and Health Seeking Behavior During the
19
20 2014-2016 Ebola Outbreak: A Twitter Content Analysis. *PLoS Curr* 2018;**10**.
21
22 doi:10.1371/currents.outbreaks.fa814fb2bec36e29b718ab6af66124fa
23
24
25 14 Gilbert D. Which countries are under lockdown - and is it working?
26
27 2020.[https://www.telegraph.co.uk/news/2020/04/16/countries-in-lockdown-denmark-](https://www.telegraph.co.uk/news/2020/04/16/countries-in-lockdown-denmark-germany/)
28 [germany/](https://www.telegraph.co.uk/news/2020/04/16/countries-in-lockdown-denmark-germany/) (accessed 30 Apr 2020).
29
30
31 15 British Broadcasting Company. Coronavirus lockdown protest: What's behind the US
32
33 demonstrations? - BBC News. 2020.[https://www.bbc.co.uk/news/world-us-canada-](https://www.bbc.co.uk/news/world-us-canada-52359100)
34 [52359100](https://www.bbc.co.uk/news/world-us-canada-52359100) (accessed 30 Apr 2020).
35
36
37 16 Elwyn G, O'Connor A, Stacey D, *et al*. Developing a quality criteria framework for
38
39 patient decision aids: online international Delphi consensus process. *Bmj-British Med*
40 *J* 2006;**333**:417–9. doi:10.1136/bmj.38926.629329.AE
41
42
43 17 Zuk G, Palma AF, Eylert G, *et al*. Systematic Review of Quality of Patient Information
44
45 on Liposuction in the Internet. *Plast Reconstr Surgery-Global Open* 2016;**4**.
46
47 doi:10.1097/gox.0000000000000798
48
49
50 18 Raptis DA, Sinanyan M, Ghani S, *et al*. Quality assessment of patient information on
51
52 the management of gallstone disease in the internet – A systematic analysis using the
53
54 modified ensuring quality information for patients tool. *HPB* 2019;**21**:1632–40.
55
56 doi:10.1016/j.hpb.2019.03.355
57
58 19 McCool ME, Wahl J, Schlecht I, *et al*. Evaluating written patient information for
59
60 eczema in German: Comparing the reliability of two instruments, DISCERN and EQIP.

- 1
2
3 *PLoS One* 2015;**10**. doi:10.1371/journal.pone.0139895
4
5 20 Vetter D, Ruhwinkel H, Raptis DA, *et al*. Quality Assessment of Information on
6
7 Bariatric Surgery Websites. *Obes Surg* 2018;:1–8.
8
9 21 Zuk G, Reinisch KB, Raptis DA, *et al*. Dupuytren Disease: Is There Enough
10
11 Comprehensive Patient Information on the Internet? *Interact J Med Res* 2017;**6**:e7.
12
13 doi:10.2196/ijmr.7822
14
15 22 Frueh FS, Palma AF, Raptis DA, *et al*. Carpal tunnel syndrome: Analysis of online
16
17 patient information with the EQIP tool. *Chir Main* 2015;**34**:113–21.
18
19 doi:10.1016/j.main.2015.04.003
20
21 23 Palma AF, Zuk G, Raptis DA, *et al*. Quality of information for women seeking breast
22
23 augmentation in the Internet. *J Plast Surg Hand Surg* 2016;**50**:262–71.
24
25 doi:10.3109/2000656X.2016.1154469
26
27 24 Melloul E, Raptis DA, Oberkofler CE, *et al*. Donor information for living donor liver
28
29 transplantation: Where can comprehensive information be found? *Liver Transplant*
30
31 2012;**18**:892–900. doi:10.1002/lt.23442
32
33 25 Minervation. The LIDA Instrument Minervation validation instrument for health care
34
35 web sites Full Version (1.2) containing instructions. 2007.
36
37 www.minervation.com/validation (accessed 30 Apr 2020).
38
39 26 Coughler C, M Burke S, Cardy JO. Analysis of the quality of online resources for
40
41 parents of children who are late to talk. *Autism Dev Lang Impair*
42
43 2020;**5**:239694152091794. doi:10.1177/2396941520917940
44
45 27 Kher A, Johnson S, Griffith R. Readability assessment of online patient education
46
47 material on congestive heart failure. *Adv Prev Med* 2017;**2017**.
48
49 28 Corcelles R, Daigle CR, Talamas HR, *et al*. Assessment of the quality of Internet
50
51 information on sleeve gastrectomy. *Surg Obes Relat Dis* 2015;**11**:539–44.
52
53 doi:10.1016/j.soard.2014.08.014
54
55 29 Sobota A, Ozakinci G. The quality and readability of online consumer information
56
57 about gynecologic cancer. *Int J Gynecol Cancer* 2015;**25**:537–41.
58
59
60

- 1
2
3 doi:10.1097/IGC.0000000000000362
4
5 30 The eBusiness. Top 15 Best Search Engines | February 2020.
6
7 <http://www.ebizmba.com/articles/search-engines> (accessed 30 Apr 2020).
8
9 31 Search Engine Watch. Google Hits the Billion Monthly Unique Visitors Mark.
10
11 2011;**2020**.[https://www.searchenginewatch.com/2011/06/23/google-hits-the-billion-](https://www.searchenginewatch.com/2011/06/23/google-hits-the-billion-monthly-unique-visitors-mark/)
12
13 [monthly-unique-visitors-mark/](https://www.searchenginewatch.com/2011/06/23/google-hits-the-billion-monthly-unique-visitors-mark/)
14
15 32 Google. <https://www.google.com/> (accessed 30 Apr 2020).
16
17 33 Google. Google Ads - Get More Customers With Easy Online Advertising.
18
19 https://ads.google.com/intl/en_GB/home/ (accessed 30 Apr 2020).
20
21 34 Google. Google Trends. <https://trends.google.com/trends>
22
23 35 Moul B, Franck LS, Brady H. Ensuring quality information for patients: development
24
25 and preliminary validation of a new instrument to improve the quality of written health
26
27 care information. *Health Expect* 2004;**7**:165–75. doi:10.1111/j.1369-
28
29 7625.2004.00273.x
30
31 36 Charvet-Berard AI, Chopard P, Perneger T V. Measuring quality of patient information
32
33 documents with an expanded EQIP scale. *Patient Educ Couns* 2008;**70**:407–11.
34
35 doi:10.1016/j.pec.2007.11.018
36
37 37 British Medical Association. BMA Patient Information Awards, .
38
39 2018;**2018**.<https://www.bma.org.uk/library/patient-information-awards>
40
41 38 International Patient Decision Aid Standards Collaboration. IPDAS Collaboration
42
43 Background Document. 2005;**2018**.http://ipdas.ohri.ca/IPDAS_Background.pdf
44
45 39 Silberg WM, Lundberg GD, Musacchio RA. Assessing, controlling, and assuring the
46
47 quality of medical information on the Internet: Caveant lector et viewer—Let the
48
49 reader and viewer beware. *JAMA* 1997;**277**:1244–5.
50
51 40 Janssen S, Fahlbusch FB, Kaesmann L, *et al*. Radiotherapy for prostate cancer:
52
53 DISCERN quality assessment of patient-oriented websites in 2018. *Bmc Urol*
54
55 2019;**19**. doi:10.1186/s12894-019-0474-4
56
57 41 Borgmann H, Wölm J-H, Vallo S, *et al*. Prostate Cancer on the Web—Expedient Tool
58
59
60

- 1
2
3 for Patients' Decision-Making? *J Cancer Educ* 2017;**32**:135–40.
4
5
6 42 Charnock D, Shepperd S, Needham G, *et al*. DISCERN: an instrument for judging the
7 quality of written consumer health information on treatment choices. 1998.
8
9
10 43 Nghiem AZ, Mahmoud Y, Som R. Evaluating the quality of internet information for
11 breast cancer. *Breast* 2016;**25**:34–7. doi:10.1016/j.breast.2015.10.001
12
13
14 44 Raptis DA. rBiostatistics.com (alpha version) | rBiostatistics.com.
15
16 <https://www.rbiostatistics.com/> (accessed 30 Apr 2020).
17
18 45 Karamitros GA, Kitsos NA. Clefts of the lip and palate: is the Internet a trustworthy
19 source of information for patients? *Int J Oral Maxillofac Surg* 2018;**47**:1114–20.
20
21
22 doi:10.1016/j.ijom.2018.03.003
23
24 46 Sanger L. Wikipedia Policy.
25
26 2001.[http://en.wikipedia.org/w/index.php?title=Wikipedia_policy&direction=next&oldid](http://en.wikipedia.org/w/index.php?title=Wikipedia_policy&direction=next&oldid=68263)
27
28 [=68263](http://en.wikipedia.org/w/index.php?title=Wikipedia_policy&direction=next&oldid=68263) (accessed 10 Jul 2020).
29
30
31 47 Som R, Gunawardana NP. Internet chemotherapy information is of good quality:
32 Assessment with the DISCERN tool. *Br J Cancer* 2012;**107**:403.
33
34
35 doi:10.1038/bjc.2012.223
36
37 48 Kaicker J, Debono VB, Dang W, *et al*. Assessment of the quality and variability of
38 health information on chronic pain websites using the DISCERN instrument. *BMC*
39
40
41 *Med* 2010;**8**:59. doi:10.1186/1741-7015-8-59
42
43
44 49 Jaffe J, Tonick S, Angell N. Quality of Web-Based Information on Epidural
45 Anesthesia. *Obstet Gynecol* 2014;**123**:115S.
46
47
48 doi:10.1097/01.aog.0000447063.32706.46
49
50
51 50 Sbaffi L, Rowley J. Trust and Credibility in Web-Based Health Information: A Review
52 and Agenda for Future Research. *J Med Internet Res* 2017;**19**. doi:10.2196/jmir.7579
53
54
55 51 World Health Organization. WHO | Novel Coronavirus – China.
56 2020.<https://www.who.int/csr/don/12-january-2020-novel-coronavirus-china/en/>
57
58 (accessed 30 Apr 2020).
59
60
52 World Health Organization. Statement on the second meeting of the International

- 1
2
3 Health Regulations (2005) Emergency Committee regarding the outbreak of novel
4 coronavirus (2019-nCoV). 2020.[https://www.who.int/news-room/detail/30-01-2020-](https://www.who.int/news-room/detail/30-01-2020-statement-on-the-second-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-(2019-ncov))
5
6
7
8
9
10
11
12 statement-on-the-second-meeting-of-the-international-health-regulations-(2005)-
13
14 emergency-committee-regarding-the-outbreak-of-novel-coronavirus-(2019-ncov)
15 (accessed 30 Apr 2020).
- 16 53 COVID-19 Updates. <https://plos.org/covid-19/> (accessed 30 Apr 2020).
- 17 54 Elsevier. COVID-19 Update - Elsevier. [https://www.journals.elsevier.com/journal-of-](https://www.journals.elsevier.com/journal-of-critical-care/covid-19)
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
- Health Regulations (2005) Emergency Committee regarding the outbreak of novel coronavirus (2019-nCoV). 2020.[https://www.who.int/news-room/detail/30-01-2020-statement-on-the-second-meeting-of-the-international-health-regulations-\(2005\)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-\(2019-ncov\)](https://www.who.int/news-room/detail/30-01-2020-statement-on-the-second-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-(2019-ncov)) (accessed 30 Apr 2020).
- 53 COVID-19 Updates. <https://plos.org/covid-19/> (accessed 30 Apr 2020).
- 54 Elsevier. COVID-19 Update - Elsevier. <https://www.journals.elsevier.com/journal-of-critical-care/covid-19> (accessed 30 Apr 2020).
- 55 Anesthesia & Analgesia. Call for Papers: Coronavirus Disease 2019 (COVID-19). <https://journals.lww.com/anesthesia-analgesia/Pages/CFPCOVID19.aspx> (accessed 30 Apr 2020).
- 56 National Health Service Health Research Authority. COVID-19 research - Health Research Authority. <https://www.hra.nhs.uk/covid-19-research/> (accessed 30 Apr 2020).
- 57 World Health Organization. COVID-19: Global literature on coronavirus disease. <https://search.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/> (accessed 30 Apr 2020).
- 58 Majumder MS, Mandl KD. Early in the epidemic: impact of preprints on global discourse about COVID-19 transmissibility. *Lancet Glob Heal* 2020.
- 59 Pradhan P, Pandey AK, Mishra A, *et al*. Uncanny similarity of unique inserts in the 2019-nCoV spike protein to HIV-1 gp120 and Gag. *BioRxiv* 2020.
- 60 Liu DWC. Science Denial and the Science Classroom. *Cbe-Life Sci Educ* 2012;**11**:129–34. doi:10.1187/cbe.12-03-0029
- 61 Altmetric – Uncanny similarity of unique inserts in the 2019-nCoV spike protein to HIV-1 gp120 and Gag. <https://www.altmetric.com/details/74957328> (accessed 30 Apr 2020).
- 62 Reisi M, Javadzade SH, Heydarabadi AB, *et al*. The relationship between functional health literacy and health promoting behaviors among older adults. *J Educ Health*

- 1
2
3 *Promot* 2014;**3**:119. doi:10.4103/2277-9531.145925
4
5 63 Geboers B, Reijneveld SA, Jansen CJM, *et al.* Health Literacy Is Associated With
6 Health Behaviors and Social Factors Among Older Adults: Results from the LifeLines
7 Cohort Study. *J Health Commun* 2016;**21**:45–53.
8
9 doi:10.1080/10810730.2016.1201174
10
11
12
13 64 Husson O, Mols F, Fransen MP, *et al.* Low subjective health literacy is associated
14 with adverse health behaviors and worse health-related quality of life among
15 colorectal cancer survivors: Results from the profiles registry. *Psychooncology*
16 2015;**24**:478–86. doi:10.1002/pon.3678
17
18
19
20
21
22 65 Chesser AK, Keene Woods N, Smothers K, *et al.* Health Literacy and Older Adults.
23 *Gerontol Geriatr Med* 2016;**2**:233372141663049. doi:10.1177/2333721416630492
24
25
26 66 Bay JL, Vickers MH, Mora HA, *et al.* Adolescents as agents of healthful change
27 through scientific literacy development: A school-university partnership program in
28 New Zealand. *Int J STEM Educ* 2017;**4**. doi:10.1186/s40594-017-0077-0
29
30
31
32
33 67 Barel-ben David Y, Garty ES, Baram-tsabari A. Can scientists fill the science
34 journalism void ? Online public engagement with science stories authored by
35 scientists. 2020;**1**–15.
36
37
38
39 68 Lazer BDMJ, Baum MA, Benkler Y, *et al.* The science of fake news. 2018.
40
41 69 Longo DR. Understanding health information, communication, and information
42 seeking of patients and consumers: a comprehensive and integrated model. *Heal*
43 *Expect* 2005;**8**:189–94.
44
45
46
47 70 Keshvari M, Yamani N, Adibi P, *et al.* Health journalism: Health reporting status and
48 challenges. *Iran J Nurs Midwifery Res* 2018;**23**:14.
49
50
51 71 Schwitzer G. How do US journalists cover treatments, tests, products, and
52 procedures? An evaluation of 500 stories. *PLoS Med* 2008;**5**.
53
54
55 72 Larsson A, Oxman AD, Carling C, *et al.* Medical messages in the media—barriers and
56 solutions to improving medical journalism. *Heal Expect* 2003;**6**:323–31.
57
58
59 73 Cattani M. Global coalition to accelerate COVID-19 clinical research in resource-

- 1
2
3 limited settings. *Lancet* 2020.
4
- 5 74 ST. George's University of London. 3 April: 2020 Covid-19 response — our role in
6 tackling the pandemic. <https://www.sgul.ac.uk/news/alerts/bulletins/3-april-2020>
7 (accessed 30 Apr 2020).
8
9
- 10
11 75 Saey Tina Hesman. Repurposed drugs may help scientists fight the new coronavirus.
12 2020. doi:10.1101/2020.01.28.922922V2
13
14
- 15 76 Kowitt SD, Schmidt AM, Hannan A, *et al.* Awareness and trust of the FDA and CDC:
16 Results from a national sample of US adults and adolescents. *PLoS One* 2017;**12**.
17
18
- 19 77 Bish A, Yardley L, Nicoll A, *et al.* Factors associated with uptake of vaccination
20 against pandemic influenza: a systematic review. *Vaccine* 2011;**29**:6472–84.
21
22
- 23 78 Whetten K, Leserman J, Whetten R, *et al.* Exploring lack of trust in care providers and
24 the government as a barrier to health service use. *Am J Public Health* 2006;**96**:716–
25 21.
26
27
- 28 79 Quinn SC, Parmer J, Freimuth VS, *et al.* Exploring communication, trust in
29 government, and vaccination intention later in the 2009 H1N1 pandemic: results of a
30 national survey. *Biosecurity bioterrorism biodefense Strateg Pract Sci* 2013;**11**:96–
31 106.
32
33
- 34 80 Sadah SA, Shahbazi M, Wiley MT, *et al.* Demographic-based content analysis of web-
35 based health-related social media. *J Med Internet Res* 2016;**18**:e148.
36
37
- 38 81 Sadah SA, Shahbazi M, Wiley MT, *et al.* A study of the demographics of web-based
39 health-related social media users. *J Med Internet Res* 2015;**17**:e194.
40
41
- 42 82 World Health Organization. Myth busters.
43 [https://www.who.int/emergencies/diseases/novel-coronavirus-2019/advice-for-](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/advice-for-public/myth-busters)
44 public/myth-busters (accessed 30 Apr 2020).
45
46
- 47 83 Smith D. Coronavirus: medical experts denounce Trump's theory of 'disinfectant
48 injection' | World news | The Guardian.
49 2020.[https://www.theguardian.com/world/2020/apr/23/trump-coronavirus-treatment-](https://www.theguardian.com/world/2020/apr/23/trump-coronavirus-treatment-disinfectant)
50 disinfectant (accessed 30 Apr 2020).
51
52
53
54
55
56
57
58
59
60

- 1
2
3 84 Zhao Y, Zhang J. Consumer health information seeking in social media: a literature
4 review. *Health Info Libr J* 2017;**34**:268–83. doi:10.1111/hir.12192
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Table 1. Website demographic and background information

| Type | Total (n,%) | Treatment (n,%) | Prevention (n,%) | Prevention and Treatment (n,%) |
|------------------------------|--------------|-----------------|------------------|--------------------------------|
| Academic Centre | 10 (3.12%) | 1 (0.31%) | 4 (1.25%) | 5 (1.56%) |
| Charity/NGO | 12 (3.74%) | 1 (0.31%) | 9 (2.8%) | 2 (0.62%) |
| Encyclopaedia | 5 (1.56%) | 0 (0%) | 1 (0.31%) | 4 (1.25%) |
| Government/Health Department | 87 (27.10%) | 1 (0.31%) | 65 (20.25%) | 21 (6.54%) |
| Hospital | 7 (2.18%) | 0 (0%) | 5 (1.56%) | 2 (0.62%) |
| Industry | 30 (9.35%) | 8 (2.49%) | 10 (3.12%) | 12 (3.74%) |
| Military | 1 (0.31%) | 0 (0%) | 1 (0.31%) | 0 (0%) |
| News Service | 163 (50.78%) | 34 (10.59%) | 102 (31.78%) | 27 (8.41%) |
| Patient group | 1 (0.10%) | 1 (0.31%) | 0 (0%) | 0 (0%) |
| Professional society | 4 (1.25%) | 0 (0%) | 4 (1.25%) | 0 (0%) |
| Research Centre | 1 (0.31%) | 0 (0%) | 1 (0.31%) | 0 (0%) |
| Total | 321 | 46 (14.33%) | 202 (62.93%) | 73 (22.74%) |

Table 2. Overall quality of information of all sources of information

| Indicator/ (Mean, SD) | Academic centre | Charity/N GO | Encyclop aedia | Governm ent/Healt h Departme nt | Hospital | Industry | Military | News Service | Patient group | Professio nal society | Research Centre | P Value |
|-----------------------------|--------------------|-----------------|-------------------|--|----------|----------|----------|-----------------|------------------|-----------------------------|--------------------|---------|
|-----------------------------|--------------------|-----------------|-------------------|--|----------|----------|----------|-----------------|------------------|-----------------------------|--------------------|---------|

| | | | | | | | | | | | | |
|---------------------|------------------|-----------------|-----------------|-----------------|-----------------|------------------|-----------|------------------|-----------|----------------|-----------|--------|
| EQIP Content | 7.70 (2.50) | 6.75 (3.33) | 10.80 (3.11) | 8.11 (2.49) | 7.14 (2.19) | 7.13 (2.60) | 5.00 (0) | 6.22 (2.11) | 10.00 (0) | 5.50 (3) | 5.00 (0) | <0.001 |
| EQIP Identification | 2.90 (1.20) | 3.08 (0.90) | 4.80 (0.45) | 3.44 (1.03) | 2.71 (1.38) | 3.4 (1.13) | 1.00 (0) | 3.62 (0.73) | 3.00 (0) | 4.00 (0) | 4.00 (0) | 0.003 |
| EQIP Structure | 7.90 (1.85) | 7.67 (1.30) | 8.60 (1.67) | 7.34 (1.45) | 7.43 (0.98) | 6.97 (1.83) | 9.00 (0) | 7.22 (1.39) | 10.00 (0) | 7.25 (0.5) | 5.00 (0) | 0.08 |
| EQIP Total | 18.50 (3.66) | 17.50 (4.32) | 24.20 (3.56) | 18.9 (3.79) | 17.29 (3.50) | 17.5 (4.48) | 15.00 (0) | 17.06 (3.19) | 23.00 (0) | 16.75 (3.4) | 14.00 (0) | <0.001 |
| JAMA Total | 2.50 (0.97) | 2.50 (1.00) | 3.40 (0.55) | 2.16 (0.86) | 2.14 (1.57) | 2.73 (1.23) | 1.00 (0) | 2.98 (0.85) | 3.00 (0) | 3.50 (0.58) | 3.00 (0) | <0.001 |
| DISCERN Reliability | 27.20 (6.78) | 26.25 (6.51) | 35.60 (4.77) | 27.47 (5.96) | 29.86 (5.58) | 26.6 (7.46) | 23.00 (0) | 26.31 (6.3) | 27.00 (0) | 29.50 (4.2) | 26.00 (0) | 0.128 |
| DISCERN Treatment | 13.00 (6.70) | 9.42 (2.39) | 16.00 (9.30) | 9.02 (3.14) | 8.71 (1.89) | 13.33 (6.39) | 8.00 (0) | 11.72 (6.22) | 13.00 (0) | 8.50 (1) | 17.00 (0) | 0.001 |
| DISCERN Total | 40.20 (10.38) | 35.67 (7.67) | 51.60 (12.3) | 36.49 (7.50) | 38.57 (5.47) | 39.93 (10.45) | 31.00 (0) | 38.04 (10.44) | 40.00 (0) | 38.00 (5.1) | 43.00 (0) | 0.167 |

Table 3. Overall quality of information of all websites subsets

| Indicator/(Mean, SD) | Overall | Treatment | Prevention | Prevention Treatment and | P Value |
|----------------------|---------|-----------|------------|--------------------------|---------|
|----------------------|---------|-----------|------------|--------------------------|---------|

| | | | | | |
|---------------------|--------------|---------------|--------------|---------------|--------|
| EQIP Content | 6.97 (2.52) | 6.26 (1.81) | 6.55 (2.30) | 8.58 (2.84) | <0.001 |
| EQIP Identification | 3.50 (0.93) | 3.87 (0.72) | 3.32 (0.97) | 3.78 (0.80) | <0.001 |
| EQIP Structure | 7.30 (1.47) | 6.76 (1.46) | 7.25 (1.46) | 7.79 (1.37) | <0.001 |
| EQIP Total | 17.78 (3.71) | 16.89 (2.84) | 17.12 (3.45) | 20.15 (3.95) | <0.001 |
| JAMA Total | 2.69 (0.98) | 3.13 (0.72) | 2.53 (1.05) | 2.85 (0.84) | 0.001 |
| DISCERN Reliability | 26.93 (6.35) | 26.98 (6.92) | 26.04 (5.72) | 29.37 (7.04) | <0.001 |
| DISCERN Treatment | 11.07 (5.60) | 18.09 (6.04) | 8.60 (2.45) | 13.47 (6.73) | <0.001 |
| DISCERN Total | 38.00 (9.61) | 45.07 (11.67) | 34.64 (6.52) | 42.84 (10.93) | <0.001 |

Table 4. Comparison between Government and News Services

| Indicator | Global (USA inclusive) (n=250) | USA (n=121) |
|-----------|--------------------------------|-------------|
|-----------|--------------------------------|-------------|

| | Government Mean Score | Government Mean Rank | News Mean Score | News Mean Rank | P Value | Government Mean Score | Government Mean Rank | News Mean Score | News Mean Rank | P Value |
|---------------------|-----------------------|----------------------|-----------------|----------------|---------|-----------------------|----------------------|-----------------|----------------|---------|
| EQIP Content | 8.11 | 161.34 | 6.22 | 106.37 | <0.001 | 7.66 | 75.80 | 6.17 | 54.22 | 0.002 |
| EQIP Identification | 3.44 | 118.28 | 3.62 | 129.35 | 0.207 | 3.34 | 50.29 | 3.78 | 65.90 | 0.011 |
| EQIP Structure | 7.34 | 129.90 | 7.22 | 123.15 | 0.464 | 7.55 | 67.54 | 7.08 | 58.01 | 0.148 |
| EQIP Total | 18.90 | 151.52 | 17.06 | 111.61 | <0.001 | 18.55 | 71.21 | 17.04 | 56.33 | 0.029 |
| JAMA Total | 2.16 | 85.72 | 2.98 | 146.73 | <0.001 | 2.03 | 34.28 | 3.17 | 73.23 | <0.001 |
| DISCERN Reliability | 27.47 | 137.15 | 26.31 | 119.28 | 0.062 | 26.53 | 60.26 | 26.66 | 61.34 | 0.876 |
| DISCERN Treatment | 9.02 | 110.95 | 11.72 | 133.27 | 0.001 | 8.84 | 47.99 | 12.59 | 66.96 | 0.001 |

| | | | | | | | | | | |
|---------------|-------|--------|-------|--------|-------|-------|-------|-------|-------|-------|
| DISCERN Total | 36.49 | 105.32 | 38.04 | 136.27 | 0.963 | 35.37 | 54.72 | 39.25 | 63.87 | 0.182 |
|---------------|-------|--------|-------|--------|-------|-------|-------|-------|-------|-------|

Table 5. Top 5 websites based on EQIP and DISCERN scores

| URL | Country | Treatment Prevention | or | Total EQIP | Total JAMA | Total DISCERN |
|---|--------------------------|-------------------------|----|------------|------------|---------------|
| Top Scoring EQIP Sites | | | | | | |
| https://www.gov.je/health/coronavirus/Pages/index.aspx | Channel Islands (Jersey) | Both | | 29 | 3 | 49 |
| https://en.wikipedia.org/wiki/2019%E2%80%932020_coronavirus_pandemic | USA | Both | | 28 | 3 | 61 |
| https://www.health.nsw.gov.au/Infectious/alerts/Pages/coronavirus-faqs.aspx | Australia | Both | | 28 | 3 | 46 |
| https://www.ageuk.org.uk/information-advice/coronavirus/coronavirus/# | UK | Both | | 27 | 3 | 48 |
| https://www.wikihow.com/Prevent-Coronavirus | USA | Prevention only | | 27 | 4 | 46 |
| Top Scoring DISCERN Sites | | | | | | |
| https://www.sciencenews.org/article/coronavirus-covid19-repurposed-treatments-drugs | USA | Treatment only | | 22 | 4 | 75 |
| https://www.vox.com/science-and-health/2020/3/4/21154590/coronavirus-vaccine-treatment-covid-19-drug-cure | USA | Both | | 22 | 4 | 74 |

| | | | | | |
|---|-----|----------------|----|---|----|
| https://en.wikipedia.org/wiki/Coronavirus_disease_2019 | USA | Both | 25 | 3 | 68 |
| https://www.bloomberg.com/news/articles/2020-03-25/hydroxychloroquine-no-better-than-regular-covid-19-care-in-study | USA | Treatment only | 21 | 3 | 65 |
| https://www.theverge.com/2020/2/4/21122327/coronavirus-experimental-medication-treatment-wuhan-china-gilead-hiv | USA | Treatment only | 18 | 4 | 64 |

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1. Popular Search Terms
99x123mm (300 x 300 DPI)




Figure 2. Workflow of Webscraping and Exclusion

70x55mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 3. Country of origin of websites

132x79mm (300 x 300 DPI)




Figure 4. Scores by top contributing countries

63x94mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 5. High-score distribution
60x94mm (300 x 300 DPI)

| Item | | Overall number of websites (n, %) | High-scoring websites (n, %) | Low-scoring websites (n, %) | OR |
|---|-----|-----------------------------------|------------------------------|-----------------------------|--------|
| Modified EQIP Content Data | | | | | |
| 1. Initial definition of which subjects will be | Yes | 274 (85.36%) | 71 (95.95%) | 203 (82.19%) | 5.102 |
| | No | 47 (14.64%) | 3 (4.05%) | 44 (17.81%) | |
| 2. Coverage of the previously defined | Yes | 273 (85.05%) | 71 (95.95%) | 202 (81.78%) | 3.509 |
| | No | 48 (14.95%) | 3 (4.05%) | 45 (18.22%) | |
| 3. Description of the medical | Yes | 251 (78.19%) | 73 (98.65%) | 178 (72.06%) | 5.882 |
| | No | 70 (21.81%) | 1 (1.35%) | 69 (27.94%) | |
| 4. Definition of the purpose of the | Yes | 216 (67.29%) | 67 (90.54%) | 149 (60.32%) | 27.778 |
| | No | 105 (32.71%) | 7 (9.46%) | 98 (39.68%) | |
| 5. Description of treatment alternatives | Yes | 82 (25.55%) | 40 (54.05%) | 42 (17%) | 6.250 |
| | No | 239 (74.45%) | 34 (45.95%) | 205 (83%) | |
| 6. Description of the sequence of the | Yes | 51 (15.89%) | 26 (35.14%) | 25 (10.12%) | 4.785 |
| | No | 270 (84.11%) | 48 (64.86%) | 222 (89.88%) | |
| 7. Description of the qualitative benefits for | Yes | 114 (35.51%) | 46 (62.16%) | 68 (27.53%) | 4.310 |
| | No | 207 (64.49%) | 28 (37.84%) | 179 (72.47%) | |
| 8. Description of the quantitative benefits to | Yes | 9 (2.8%) | 3 (4.05%) | 6 (2.43%) | 1.695 |
| | No | 312 (97.2%) | 71 (95.95%) | 241 (97.57%) | |
| 9. Description of the qualitative risks and | Yes | 49 (15.26%) | 25 (33.78%) | 24 (9.72%) | 4.717 |
| | No | 272 (84.74%) | 49 (66.22%) | 223 (90.28%) | |
| 10. Description of the quantitative risks and | Yes | 3 (0.93%) | 3 (4.05%) | 0 (0%) | - |
| | No | 318 (99.07%) | 71 (95.95%) | 247 (100%) | |
| 11. Addressing quality-of-life issues | Yes | 137 (42.68%) | 58 (78.38%) | 79 (31.98%) | 7.634 |
| | No | 184 (57.32%) | 16 (21.62%) | 168 (68.02%) | |
| 12. Description of how complications are | Yes | 35 (10.9%) | 20 (27.03%) | 15 (6.07%) | 5.682 |
| | No | 286 (89.1%) | 54 (72.97%) | 232 (93.93%) | |
| 13. Description of the precautions that the | Yes | 265 (82.55%) | 70 (94.59%) | 195 (78.95%) | 4.651 |
| | No | 56 (17.45%) | 4 (5.41%) | 52 (21.05%) | |
| 14. Mention of alert signs that the patient | Yes | 212 (66.04%) | 66 (89.19%) | 146 (59.11%) | 5.682 |
| | No | 109 (33.96%) | 8 (10.81%) | 101 (40.89%) | |
| 15. Addressing medical intervention costs and | Yes | 68 (21.18%) | 31 (41.89%) | 37 (14.98%) | 3.968 |
| | No | 253 (78.82%) | 43 (58.11%) | 210 (85.02%) | |
| 16. Specific contact details for hospital | Yes | 10 (3.12%) | 3 (4.05%) | 7 (2.83%) | - |
| | No | 311 (96.88%) | 71 (95.95%) | 240 (97.17%) | |

| | | | | | |
|---|-----|--------------|-------------|--------------|-------|
| 17. Specific details of other sources of reliable | Yes | 185 (57.63%) | 62 (83.78%) | 123 (49.8%) | 5.181 |
| | No | 136 (42.37%) | 12 (16.22%) | 124 (50.2%) | |
| 18. Coverage of all relevant issues for the | Yes | 4 (1.25%) | 4 (5.41%) | 0 (0%) | - |
| | No | 317 (98.75%) | 70 (94.59%) | 247 (100%) | |
| Modified EQIP Identification Data | | | | | |
| 19. Date of issue or revision | Yes | 280 (87.23%) | 69 (93.24%) | 211 (85.43%) | 2.347 |
| | No | 41 (12.77%) | 5 (6.76%) | 36 (14.57%) | |
| 20. Logo of the issuing body | Yes | 317 (98.75%) | 74 (100%) | 243 (98.38%) | - |
| | No | 4 (1.25%) | 0 (0%) | 4 (1.62%) | |
| 21. Names of the persons or entities that | Yes | 254 (79.13%) | 61 (82.43%) | 193 (78.14%) | 1.312 |
| | No | 67 (20.87%) | 13 (17.57%) | 54 (21.86%) | |
| 22. Names of the persons or entities that | Yes | 210 (65.42%) | 62 (83.78%) | 148 (59.92%) | 3.448 |
| | No | 111 (34.58%) | 12 (16.22%) | 99 (40.08%) | |
| 23. Short bibliography of the evidence-based data | Yes | 60 (18.69%) | 31 (41.89%) | 29 (11.74%) | 5.376 |
| | No | 261 (81.31%) | 43 (58.11%) | 218 (88.26%) | |
| 24. Statement about whether and how | Yes | 3 (0.93%) | 1 (1.35%) | 2 (0.81%) | 1.675 |
| | No | 318 (99.07%) | 73 (98.65%) | 245 (99.19%) | |
| Modified EQIP Structure Data | | | | | |
| 25. Use of everyday language and | Yes | 3 (0.93%) | 72 (97.3%) | 229 (92.71%) | 2.825 |
| | No | 318 (99.07%) | 2 (5.41%) | 18 (25.35%) | |
| 26. Use of generic names for all medications or | Yes | 88 (27.41%) | 35 (47.3%) | 53 (21.46%) | 1.838 |
| | No | 233 (44.05%) | 39 (35.14%) | 194 (46.41%) | |
| 27. Use of short sentences (<15 words on | Yes | 296 (92.21%) | 72 (97.3%) | 224 (90.69%) | 3.690 |
| | No | 25 (9.47%) | 2 (2.99%) | 23 (11.68%) | |
| 28. Personal address to the reader | Yes | 239 (74.45%) | 65 (87.84%) | 174 (70.45%) | 3.021 |
| | No | 82 (21.03%) | 9 (10.98%) | 73 (23.7%) | |
| 29. Respectful tone | Yes | 308 (95.95%) | 73 (98.65%) | 235 (95.14%) | 3.717 |
| | No | 13 (4.22%) | 1 (1.35%) | 12 (5.13%) | |
| 30. Clear information (no ambiguities or | Yes | 295 (91.9%) | 73 (98.65%) | 222 (89.88%) | 8.197 |
| | No | 26 (31.71%) | 1 (3.33%) | 25 (48.08%) | |
| 31. Balanced information on risks and benefits | Yes | 56 (17.45%) | 29 (39.19%) | 27 (10.93%) | 5.208 |
| | No | 265 (47.58%) | 45 (37.82%) | 220 (50.23%) | |
| 32. Presentation of information in a logical | Yes | 292 (90.97%) | 74 (100%) | 218 (88.26%) | - |
| | No | 29 (9.12%) | 0 (0%) | 29 (11.84%) | |

| | | | | | |
|---|-----|--------------|-------------|--------------|--------|
| 33. Satisfactory design and layout (excluding | Yes | 289 (90.03%) | 73 (98.65%) | 216 (87.45%) | 10.417 |
| | No | 32 (22.38%) | 1 (2.33%) | 31 (31%) | |
| 34. Clear and relevant figures or graphs (NA if | Yes | 111 (34.58%) | 42 (56.76%) | 69 (27.94%) | 12.987 |
| | No | 210 (75.27%) | 32 (65.31%) | 178 (77.39%) | |
| 35. Inclusion of a named space for the reader's | Yes | 69 (21.5%) | 17 (22.97%) | 52 (21.05%) | 1.119 |
| | No | 252 (100%) | 57 (100%) | 195 (100%) | |
| 36. Inclusion of a printed consent form contrary to | Yes | 0 (0%) | 0 (0%) | 0 (0%) | - |
| | No | 321 (100%) | 74 (100%) | 247 (100%) | |

*Some data is omitted due to odds ratio and confidence interval being infinite values

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

| 95% CI | P Value |
|------------------|---------|
| | |
| 1.560 - 26.316 | 0.002 |
| 0.483 - 166.667 | 0.300 |
| 3.215 - 10.870 | <0.001 |
| 4.695 - 1000.000 | <0.001 |
| 2.725 - 16.949 | <0.001 |
| 2.427 - 9.434 | <0.001 |
| 2.416 - 7.752 | <0.001 |
| 0.267 - 8.197 | 0.436 |
| 2.370 - 9.434 | <0.001 |
| - | 0.012 |
| 4.032 - 15.152 | <0.001 |
| 2.584 - 12.821 | <0.001 |
| 1.621 - 18.519 | 0.001 |
| 2.571 - 14.286 | <0.001 |
| 2.137 - 7.407 | <0.001 |
| - | 0.228 |

For peer review only

| | |
|-----------------|--------|
| 2.604 - 11.111 | <0.001 |
| - | 0.003 |
| | |
| 0.870 - 8.000 | 0.110 |
| - | 0.577 |
| 0.652 - 2.801 | 0.515 |
| 1.727 - 7.407 | <0.001 |
| 1.727 - 7.407 | <0.001 |
| 1.727 - 7.407 | 0.546 |
| | |
| 0.650 - 25.64 | 0.181 |
| 0.561 - 7.143 | 0.309 |
| 0.875 - 33.333 | 0.082 |
| 1.401 - 7.299 | 0.002 |
| 0.533 - 166.667 | 0.312 |
| 1.294 - 333.333 | 0.013 |
| 2.703 - 10.101 | <0.001 |
| - | 0.001 |

| | |
|-----------------|--------|
| 1.675 - 500.000 | 0.003 |
| 3.086 - 111.111 | <0.001 |
| 0.561 - 2.151 | 0.748 |
| - | - |

For peer review only

| Item | | Overall number of websites (n, %) | High-scoring websites (n, %) | Low-scoring websites (n,%) |
|---|-----|-----------------------------------|------------------------------|----------------------------|
| JAMA Benchmark | | | | |
| 1. Authorship: Authors and contributors, their affiliations, | Yes | 183 (57.01%) | 74 (100%) | 109 (44.13%) |
| | No | 138 (42.99%) | 0 (0%) | 138 (55.87%) |
| 2. Attribution: References and sources for all content should | Yes | 118 (36.76%) | 74 (100%) | 44 (17.81%) |
| | No | 203 (63.24%) | 0 (0%) | 203 (82.19%) |
| 3. Disclosure: Web site "ownership", sponsorship, funding arrangements or | Yes | 287 (89.41%) | 74 (100%) | 213 (86.23%) |
| | No | 34 (10.59%) | 0 (0%) | 34 (13.77%) |
| 4. Currency: Dates that content was posted and updated | Yes | 276 (85.98%) | 74 (100%) | 202 (81.78%) |
| | No | 45 (14.02%) | 0 (0%) | 45 (18.22%) |

*Some data is omitted due to odds ratio and confidence interval being inf

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

| OR | 95% CI | P Value |
|---------------|--------|---------|
| | | |
| - | - | <0.001 |
| - | - | <0.001 |
| - | - | <0.001 |
| - | - | <0.001 |
| finite values | | |

For peer review only

| Item | Score | Overall number of websites (n, %) | High-scoring websites (n,%) | Low-scoring websites (n,%) |
|--|-------|--------------------------------------|-----------------------------|----------------------------|
| DISCERN Reliability | | | | |
| 1. Are the aims clear? | 1 | 6 (1.87%) | 0 (0%) | 6 (2.45%) |
| | 2 | 16 (4.98%) | 2 (2.63%) | 14 (5.71%) |
| | 3 | 39 (12.15%) | 9 (11.84%) | 30 (12.24%) |
| | 4 | 51 (15.89%) | 6 (7.89%) | 45 (18.37%) |
| | 5 | 209 (65.11%) | 59 (77.63%) | 150 (61.22%) |
| 2. Does it achieve its aims | 1 | 7 (2.18%) | 0 (0%) | 7 (2.86%) |
| | 2 | 18 (5.61%) | 4 (5.26%) | 14 (5.71%) |
| | 3 | 45 (14.02%) | 10 (13.16%) | 35 (14.29%) |
| | 4 | 57 (17.76%) | 8 (10.53%) | 49 (20%) |
| | 5 | 194 (60.44%) | 54 (71.05%) | 140 (57.14%) |
| 3. Is it relevant? | 1 | 4 (1.25%) | 0 (0%) | 4 (1.63%) |
| | 2 | 17 (5.3%) | 3 (3.95%) | 14 (5.71%) |
| | 3 | 42 (13.08%) | 14 (18.42%) | 28 (11.43%) |
| | 4 | 64 (19.94%) | 3 (3.95%) | 61 (24.9%) |
| | 5 | 194 (60.44%) | 56 (73.68%) | 138 (56.33%) |
| 4. Is it clear what sources of information were used to compile the publication (other than the author or producer)? | 1 | 68 (21.18%) | 3 (3.95%) | 65 (26.53%) |
| | 2 | 67 (20.87%) | 3 (3.95%) | 64 (26.12%) |
| | 3 | 72 (22.43%) | 14 (18.42%) | 58 (23.67%) |
| | 4 | 48 (14.95%) | 15 (19.74%) | 33 (13.47%) |
| | 5 | 66 (20.56%) | 41 (53.95%) | 25 (10.2%) |
| 5. Is it clear when the information used or reported in the publication was produced? | 1 | 83 (25.86%) | 2 (2.63%) | 81 (33.06%) |
| | 2 | 78 (24.3%) | 12 (15.79%) | 66 (26.94%) |
| | 3 | 88 (27.41%) | 28 (36.84%) | 60 (24.49%) |
| | 4 | 36 (11.21%) | 11 (14.47%) | 25 (10.2%) |
| | 5 | 36 (11.21%) | 23 (30.26%) | 13 (5.31%) |
| 6. Is it balanced and unbiased? | 1 | 24 (7.48%) | 4 (5.26%) | 20 (8.16%) |
| | 2 | 65 (20.25%) | 16 (21.05%) | 49 (20%) |
| | 3 | 146 (45.48%) | 33 (43.42%) | 113 (46.12%) |
| | 4 | 69 (21.5%) | 14 (18.42%) | 55 (22.45%) |
| | 5 | 17 (5.3%) | 9 (11.84%) | 8 (3.27%) |
| | 1 | 77 (23.99%) | 4 (5.26%) | 73 (29.8%) |

| | | | | |
|--|---|--------------|-------------|--------------|
| 7. Does it provide details of additional sources of support and information? | 2 | 64 (19.94%) | 15 (19.74%) | 49 (20%) |
| | 3 | 62 (19.31%) | 19 (25%) | 43 (17.55%) |
| | 4 | 58 (18.07%) | 17 (22.37%) | 41 (16.73%) |
| | 5 | 60 (18.69%) | 21 (27.63%) | 39 (15.92%) |
| 8. Does it refer to areas of uncertainty? | 1 | 99 (30.84%) | 14 (18.42%) | 85 (34.69%) |
| | 2 | 61 (19%) | 15 (19.74%) | 46 (18.78%) |
| | 3 | 75 (23.36%) | 24 (31.58%) | 51 (20.82%) |
| | 4 | 44 (13.71%) | 10 (13.16%) | 34 (13.88%) |
| | 5 | 42 (13.08%) | 13 (17.11%) | 29 (11.84%) |
| DISCERN Quality and Overall rating | | | | |
| 9. Does it describe how each treatment works? | 1 | 250 (77.88%) | 52 (68.42%) | 198 (80.82%) |
| | 2 | 24 (7.48%) | 8 (10.53%) | 16 (6.53%) |
| | 3 | 18 (5.61%) | 4 (5.26%) | 14 (5.71%) |
| | 4 | 13 (4.05%) | 6 (7.89%) | 7 (2.86%) |
| | 5 | 16 (4.98%) | 6 (7.89%) | 10 (4.08%) |
| 10. Does it describe the benefits of each treatment? | 1 | 247 (76.95%) | 52 (68.42%) | 195 (79.59%) |
| | 2 | 20 (6.23%) | 6 (7.89%) | 14 (5.71%) |
| | 3 | 26 (8.1%) | 6 (7.89%) | 20 (8.16%) |
| | 4 | 20 (6.23%) | 7 (9.21%) | 13 (5.31%) |
| | 5 | 8 (2.49%) | 5 (6.58%) | 3 (1.22%) |
| 11. Does it describe the risks of each treatment? | 1 | 281 (87.54%) | 60 (78.95%) | 221 (90.2%) |
| | 2 | 18 (5.61%) | 6 (7.89%) | 12 (4.9%) |
| | 3 | 17 (5.3%) | 7 (9.21%) | 10 (4.08%) |
| | 4 | 3 (0.93%) | 1 (1.32%) | 2 (0.82%) |
| | 5 | 2 (0.62%) | 2 (2.63%) | 0 (0%) |
| 12. Does it describe what would happen if no treatment is used? | 1 | 283 (88.16%) | 61 (80.26%) | 222 (90.61%) |
| | 2 | 15 (4.67%) | 6 (7.89%) | 9 (3.67%) |
| | 3 | 13 (4.05%) | 5 (6.58%) | 8 (3.27%) |
| | 4 | 7 (2.18%) | 2 (2.63%) | 5 (2.04%) |
| | 5 | 3 (0.93%) | 2 (2.63%) | 1 (0.41%) |
| 13. Does it describe how the treatment choices affect overall quality of life? | 1 | 289 (90.03%) | 62 (81.58%) | 227 (92.65%) |
| | 2 | 13 (4.05%) | 5 (6.58%) | 8 (3.27%) |
| | 3 | 14 (4.36%) | 8 (10.53%) | 6 (2.45%) |
| | 4 | 2 (0.62%) | 0 (0%) | 2 (0.82%) |

| | | | | |
|--|---|--------------|-------------|--------------|
| | 5 | 3 (0.93%) | 1 (1.32%) | 2 (0.82%) |
| 14. Is it clear that there may be more than one possible treatment choice? | 1 | 240 (74.77%) | 52 (68.42%) | 188 (76.73%) |
| | 2 | 18 (5.61%) | 5 (6.58%) | 13 (5.31%) |
| | 3 | 24 (7.48%) | 6 (7.89%) | 18 (7.35%) |
| | 4 | 10 (3.12%) | 2 (2.63%) | 8 (3.27%) |
| | 5 | 29 (9.03%) | 11 (14.47%) | 18 (7.35%) |
| 15. Does it provide support for shared decision-making? | 1 | 262 (81.62%) | 59 (77.63%) | 203 (82.86%) |
| | 2 | 13 (4.05%) | 7 (9.21%) | 6 (2.45%) |
| | 3 | 35 (10.9%) | 4 (5.26%) | 31 (12.65%) |
| | 4 | 3 (0.93%) | 2 (2.63%) | 1 (0.41%) |
| | 5 | 8 (2.49%) | 4 (5.26%) | 4 (1.63%) |
| 16. Based on the answers to all of the above questions, rate the overall quality of the publication as a source of information about | 1 | 241 (75.08%) | 52 (68.42%) | 189 (77.14%) |
| | 2 | 48 (14.95%) | 12 (15.79%) | 36 (14.69%) |
| | 3 | 25 (7.79%) | 8 (10.53%) | 17 (6.94%) |
| | 4 | 7 (2.18%) | 4 (5.26%) | 3 (1.22%) |
| | 5 | 0 (0%) | 0 (0%) | 0 (0%) |

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

| P Value |
|---------|
| 0.321 |
| 0.246 |
| 0.032 |
| 0.019 |
| 0.007 |
| <0.001 |
| |

For peer review only

| | |
|----|--------|
| 1 | |
| 2 | |
| 3 | 0.093 |
| 4 | |
| 5 | |
| 6 | |
| 7 | |
| 8 | <0.001 |
| 9 | |
| 10 | |
| 11 | |
| 12 | |
| 13 | |
| 14 | |
| 15 | 0.005 |
| 16 | |
| 17 | |
| 18 | |
| 19 | |
| 20 | |
| 21 | <0.001 |
| 22 | |
| 23 | |
| 24 | |
| 25 | |
| 26 | |
| 27 | 0.016 |
| 28 | |
| 29 | |
| 30 | |
| 31 | |
| 32 | |
| 33 | <0.001 |
| 34 | |
| 35 | |
| 36 | |
| 37 | |
| 38 | |
| 39 | <0.001 |
| 40 | |
| 41 | |

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

| |
|--------|
| |
| <0.001 |
| <0.001 |
| <0.001 |


For peer review only

| URL | Country | Original search term | Texas, USA March | Texas, USA July | London, UK July | Toronto, C |
|---|-----------|------------------------------------|------------------|-----------------|-----------------|------------|
| Top Scoring EQIP Sites | | | | | | |
| https://www.gov.ie/health/https://en.wikipedia.org/ | UK | What is self isolation coronavirus | Page 4 | None | None | No |
| https://www.kinedia.org/ | USA | Coronavirus | Page 1 | None | None | No |
| https://www.health.nsw.gov.au/ | Australia | Covid 19 | Page 10 | Page 4 | None | No |
| https://www.ageuk.org.uk/ | UK | Stop getting coronavirus | Page 6 | Page 4 | Page 2 | No |
| https://www.wikihow.co | USA | Stop getting coronavirus | Page 10 | None | None | No |
| Top Scoring DISCERN Sites | | | | | | |
| https://www.sciencenews.org/ | USA | How to treat coronavirus | Page 10 | None | None | No |
| https://www.vox.com/science/ | USA | Drugs for coronavirus | Page 3 | None | None | No |
| https://en.wikipedia.org/ | USA | Covid 19 | Page 1 | Page 1 | Page 1 | No |
| https://www.kinedia.org/ | USA | Drugs for coronavirus | Page 1 | None | None | No |
| https://www.bloomberg.com/ | USA | Drugs for coronavirus | Page 32 | None | None | No |
| https://www.theverge.co | | | | | | |

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46


| Canada July | Sydney, Australia July | URL Changes |
|--------------------|-------------------------------|--------------------|
| ine | None | Same |
| ine | None | Changed |
| ine | Page 1 | Same |
| ine | None | Same |
| ine | None | Same |
| ine | None | Same |
| ine | None | Same |
| ine | Page 9 | Same |
| ine | None | Same |
| ine | None | Same |

For peer review only




238x141mm (150 x 150 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



163x191mm (150 x 150 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



333x154mm (150 x 150 DPI)



PRISMA 2009 Checklist

| Section/topic | # | Checklist item | Reported on page # |
|------------------------------------|----|---|--------------------|
| TITLE | | | |
| Title | 1 | Identify the report as a systematic review, meta-analysis, or both. | 2 |
| ABSTRACT | | | |
| Structured summary | 2 | Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number. | 3 |
| INTRODUCTION | | | |
| Rationale | 3 | Describe the rationale for the review in the context of what is already known. | 4-7 |
| Objectives | 4 | Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS). | 4-7 |
| METHODS | | | |
| Protocol and registration | 5 | Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number. | 7-8 |
| Eligibility criteria | 6 | Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale. | 7-9 |
| Information sources | 7 | Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched. | 7-9 |
| Search | 8 | Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated. | 7-9 |
| Study selection | 9 | State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis). | 6-9 |
| Data collection process | 10 | Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators. | 8-12 |
| Data items | 11 | List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made. | 8-12 |
| Risk of bias in individual studies | 12 | Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis. | 12 |
| Summary measures | 13 | State the principal summary measures (e.g., risk ratio, difference in means). | 8-12 |
| Synthesis of results | 14 | Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I ²) for each meta-analysis. | 12 |



PRISMA 2009 Checklist

Page 1 of 2

| Section/topic | # | Checklist item | Reported on page # |
|-------------------------------|----|--|--------------------|
| Risk of bias across studies | 15 | Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies). | N/A |
| Additional analyses | 16 | Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified. | N/A |
| RESULTS | | | |
| Study selection | 17 | Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram. | 12, Figure 2 |
| Study characteristics | 18 | For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations. | 12-13 |
| Risk of bias within studies | 19 | Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12). | 15 |
| Results of individual studies | 20 | For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot. | N/A |
| Synthesis of results | 21 | Present results of each meta-analysis done, including confidence intervals and measures of consistency. | N/A |
| Risk of bias across studies | 22 | Present results of any assessment of risk of bias across studies (see Item 15). | N/A |
| Additional analysis | 23 | Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]). | 10-14 |
| DISCUSSION | | | |
| Summary of evidence | 24 | Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers). | 16-24 |
| Limitations | 25 | Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias). | 24-25 |
| Conclusions | 26 | Provide a general interpretation of the results in the context of other evidence, and implications for future research. | 24 |
| FUNDING | | | |
| Funding | 27 | Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review. | 2 |

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit: www.prisma-statement.org.

Page 2 of 2

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>